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Immune responses are a complex network of interactions between proteins in different cellular 
processes with multiple layers of regulation. In the present study, we explored the role of some 
regulators of the ubiquitination and proteasome systems in cell death and innate immune 
signalling pathways in macrophages. Initial studies focused on a form of regulated cell death 
termed necroptosis, a type of cell death mediated by the receptor-interacting protein kinases 
(RIP). RIP kinases are known to interact with E3 ubiquitin ligases Pellino proteins. Pellino 1 has 
recently been described to target RIP kinases and regulate necroptosis. Firstly, the roles of the 
E3 ubiquitin ligases Pellino 2 and Pellino 3 were studied. The findings demonstrated that neither 
of them regulates necroptosis induced by innate immunity triggers. Studies next characterised 
the role of TLR signalling pathways in the activation of hypoxia-inducible factor 1α (HIF-1α), a 
critical target of the ubiquitin/proteasome system. Interestingly, these studies revealed that 
some of the TLRs promote a faster migration form of HIF-1α of approximately 40kDa. The 
upregulation of the latter was mediated by the TLR adaptor protein TRIF. The role of proteasome 
and lysosome mediators on processing of full length 110kDa HIF-1α to this smaller form was also 
assessed. As part of these experimental approaches, an intriguing discovery was made showing 
that treatment of macrophages with the proteasome inhibitor MG132 induced high levels of the 
anti-inflammatory cytokine IL10. This effect was dependent on P38 MAPK pathway activation 
and phosphorylation of the transcription factor CREB. Similar results were seen with proteasome 
inhibitor Bortezomib which is used clinically in the treatment of multiple myeloma. This effect is 
interesting considering that IL10 is a growth factor for myeloma cells and some patients treated 
with Bortezomib develop a refractory response to treatment and progression of disease. Overall, 
the present research provides novel insights into the roles of some regulators of the ubiquitin 
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1.1 The mammalian immune system 
 
Immune systems are protective mechanisms present across species and manifest as basic 
enzymes in unicellular organisms, or phagocytosis, antimicrobial peptides and the complement 
system in plants and invertebrates, up to more sophisticated defences in vertebrates (Beck and 
Habicht, 1996; Litman, Cannon and Dishaw, 2005). The mammalian immune system is a complex 
ensemble of tissues, cells and processes responsible for defending an organism from infections 
agents. It is also the centre of homeostatic regulation keeping control over defective or 
malignant cells. There are several layers of protection in many species, including physical 
barriers which limit the entrance of bacteria and viruses to an organism, and then there are two 
more complex responses known as innate and adaptive immune systems (Litman, Cannon and 
Dishaw, 2005; Medzhitov, 2007; Kurosaki, Kometani and Ise, 2015). If a pathogen breaks the 
physical barriers (skin, internal epithelial layers or mucosal layers), the innate immune system 
provides a non-specific immediate response (Litman, Cannon and Dishaw, 2005). The adaptive 
immune system acts as a second layer of response providing a more specific pathogen 
recognition and a long-term protection in the form of an immunological memory (Restifo and 
Gattinoni, 2013; Kurosaki, Kometani and Ise, 2015). An adequate immunological response 
through both innate and adaptive immunity depends on an initial accurate distinction between 
self and non-self molecules (also known as antigens). Being the first line of response, the innate 
immune system has evolved to recognize a broad set of molecules that are conserved across 
microorganisms and also contains specific receptors for signals of damage, injury or stress in 
cells (Matzinger, 2002; Medzhitov, 2007). These receptors, called pattern recognition receptors 
(PRRs), can identify pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs) (Medzhitov, 2007; Kumar, Kawai and Akira, 2011). The innate and 
adaptive responses interact in many ways. Adaptive response relies on soluble signals and on 
the phagocytosis and antigen presentation function of the innate response to initiate antigen 
specific clonal expansion in T and B lymphocytes (Iwasaki and Medzhitov, 2010). The adaptive 
response is sophisticated and highly specific; however, the innate response and its initial 
response and recognition of potential harmful signals is essential to trigger a proper immune 
response. Considering its crucial role, it is a highly regulated and widely complex system, and as 
part of this thesis some of those layers of regulation and interaction will be explored. For 




1.1.1 Pattern Recognition Receptors 
There are different types of PRRs. The best known and well characterized PRRs are Nucleotide-
binding oligomerization-like receptors (NLRs), RIG-I-like receptors (RLRs), cytosolic DNA-sensing 
receptors and Toll-like receptors (TLRs) (Kumar, Kawai and Akira, 2011; O’Neill, Golenbock and 
Bowie, 2013; Paludan and Bowie, 2013). NLRs are characterized by containing a C-terminal 
leucine rich repeat (LRR) domain that recognize microbial PAMPs or endogenous molecules, and 
a nucleotide-binding oligomerization (NACHT) domain required for activation of downstream 
signalling (Kumar, Kawai and Akira, 2011). Up to 23 human and 34 murine members of NLRs 
family have been described, with the NOD and inflammasome subgroups being the best-studied 
(Kumar, Kawai and Akira, 2011). The inflammasomes have been widely explored in the last years 
and are characterized as requiring a two-signal activation process. A first signal inducing the 
expression of Pro-Caspase 1, Pro-IL1β and Pro-IL18, and a second signal mediating 
inflammasome assembly and processing of these proteins (Palazon-Riquelme and Lopez-
Castejon, 2018). Meanwhile, the RIG-I like receptors family consist of three members, RIG-I 
(Retinoic acid inducible gene 1), Mda-5 (Melanoma differentiation associated factor 5) and LGP2 
(Laboratory of genetics and physiology 2). Their main characteristic is the DExD/H box RNA 
helicase domain which allows the identification of intracellular PAMPs in viral RNA (Kumar, 
Kawai and Akira, 2011). Finally, TLRs are the core of innate immune signalling and key regulators 
of the adaptive immune response (Manicassamy and Pulendran, 2009; Iwasaki and Medzhitov, 
2010). They are the most relevant of the PRRs in the present study. 
1.1.1.1 Toll-like receptors (TLRs). 
TLRs are transmembrane glycoproteins similar in structure to Toll proteins, an important 
receptor in Drosophila embryogenesis. Ten genes in humans and 13 in mice have been identified 
for TLRs (name TLR1–13) (Akira and Takeda, 2004; Sato et al., 2009; O’Neill, Golenbock and 
Bowie, 2013). TLRs can be found in the plasma membrane or inside endosomes, and each of 
them recognizes a specific PAMP or DAMP depending on their subcellular location (Table 1.1 
and Figure 1.1). The functional heterodimers formed by TLR2/TLR1 and TLR2/TLR6, as well as 
TLR4, TLR5 and TLR11 are usually located on the cell membrane while TLR3, TLR7/TLR8, TLR9 
and TLR13 are present inside endosomes (Akira and Takeda, 2004; Kumar, Kawai and Akira, 
2011; O’Neill, Golenbock and Bowie, 2013). The main function of these receptors is to induce 
pro-inflammatory molecules but their role in cellular proliferation, survival, tissue repair and 
modulation of adaptive response have also been described (Iwasaki and Medzhitov, 2010; Li, 









Ligand Ligand Origin 
TLR1  Lipopeptides 
Soluble factors 
Bacteria and Mycobacteria 
Neisseria meningitidis 
TLR2 Heat-shock protein 60 
(HSP60), HSP70 and 
HSP96 
High-mobility group 




















Leptospira interrogans and 
Porphyromonas gingivalis 
Fungi 
TLR3 Double-stranded RNA 
(dsRNA), mRNA 
Double-stranded RNA Viruses 
TLR4 HSP22, HSP60, 
HSP70, 
HSP96 
HMGB1β-defensin 2  















Respiratory syncytial virus and 
mouse mammary tumor virus 
Trypanosoma cruzi 
Plant product 
TLR5  Flagellin Gram-positive or Gram-
negative bacteria 
TLR6  Diacyl lipopeptides 
Lipoteichoic acid 
Phenol-soluble modulin  
Zymosan 





Group B streptococcus 
TLR7 Endogenous RNA Single-stranded RNA (ssRNA) Viruses 
TLR8 Endogenous RNA ssRNA Viruses 
TLR9 Endogenous DNA Unmethylated CpG motifs 
Hemozoin 
Bacteria and viruses 
Plasmodium 
TLR10 Unknown Unknown  
TLR11  Profilin Uropathogenic bacteria 
TLR12  Profilin Uropathogenic bacteria 
TLR13  Bacterial ribosomal RNA Toxoplasma gondii 
 
Table 1.1 Toll-like receptors (TLRs) and their DAMPs and PAMPs ligands. DAMPs: Damage 
associated molecular pattern molecules; PAMPs: Pathogen-associated molecular patterns. 




Considering their essential role in regulating the immune system, activation of TLRs signalling 
have also important roles in controlling tumor growth, progression and immune evasion (Huang 
et al., 2005; Sato et al., 2009; Multhoff, Molls and Radons, 2012). 
The structural conformation of TLRs is defined by extracellular leucine rich repeats 
(LRRs) domain arranged in a horseshoe-like structure, which recognize PAMPs or DAMPs, a 
transmembrane domain and an intracellular Toll/Interleukin-1 receptor (TIR) domain (Akira and 
Takeda, 2004; O’Neill, Golenbock and Bowie, 2013). In mammals, TIR domain mediates TLR 
downstream signalling by recruiting four possible signalling adaptor proteins; Myeloid 
differentiation primary-response protein 88 (MyD88), TIR-domain-containing adaptor protein 
inducing IFNβ (TRIF), TRIF-related adaptor molecule (TRAM), and MYD88-adaptor-like protein 
(MAL) (also known as TIR-domain-containing adaptor protein (TIRAP)) (Figure 1.1) (Akira and 
Takeda, 2004). These adaptors activate different patterns of gene expression depending on the 
TLRs that are being stimulated. MYD88 initiates the signalling cascade of most TLRs, except for 
TLR3 which depends exclusively on TRIF mediated activation. TLR5, TLR7/TLR8, TLR9, TLR11 and 
TLR13 all signal through MYD88 only, while TLR2/TLR1 - TLR2/TLR6 and TLR4 have been reported 
to use MAL and MYD88-dependent pathways. TLR4 can also be activated in a MYD88-
independent way by interaction of the adaptors TRIF and TRAM (Akira and Takeda, 2004; O’Neill, 
Golenbock and Bowie, 2013). These adaptor proteins act as scaffolds for downstream signalling. 
Activation of MYD88 by TLRs recruits and phosphorylates IL-1R-associated kinases 
(IRAK) 1, 2, 4 which in turn recruit and activates TAB2 and TNF- receptor-associated factor 6 
(TRAF6). TRAF6 is an E3 ubiquitin ligase that interacts with the transforming growth factor-β 
(TGF-β) activated kinase (TAK1) complex containing TAK1 and TAK1-binding proteins (1 to 4) 
(O’Neill, Golenbock and Bowie, 2013). The activated TAK1 complex will mediate the signalling 
through the IB kinase (IKK) complex, and the Mitogen Activated Protein Kinase (MAPK) such as 
P38 and c-Jun N-Terminal kinase (JNK) (Wang et al., 2001). The IKK complex consists of two 
catalytic subunits known as IKK-α and IKK-β and a regulatory subunit, Nuclear Factor Kappa B 
Essential Modifier (NEMO). This complex phosphorylates the inhibitory IκB proteins which in 
their unphosphorylated states retain the Nuclear factor kappa-B (NF-B) in an inactive form in 
the cytoplasm (Akira and Takeda, 2004). The phosphorylation of the IκB proteins target them 
for polyubiquitination and further proteasomal degradation, releasing NF-κB and allowing its 
translocation to the nucleus where it will activate a plethora of genes (Medzhitov, 2007). A 
similar mechanism of activation is used by TLR2/TLR1, TLR2/TLR6 and TLR4 with the additional 
initial interaction of the adaptor MAL with MYD88 that also leads to NF-B and MAPKs activation 





Figure 1.1 TLR signalling pathways.  
From the 13 TLRs described in mice, TLR5, TLR11, and the heterodimers TLR2–TLR1 or TLR2–
TLR6 are in the cell surface, whereas TLR3, TLR7–TLR8, TLR9 and TLR13 localize in endosomes. 
TLR4 is localized in the plasma membrane and it is later endocytosed. The signalling cascade 
initiated by TLRs begins with the ligand-induced dimerization of receptors and it is followed by 
the recruitment of adaptors proteins to the receptors TIR domains. Four TIR domain-containing 
adaptor proteins have been identified: MYD88, MAL, TRIF and TRAM. Cooperation and 
interaction between the TIR domains of the receptor and the adaptor proteins triggers a 
signalling cascade which includes IRAKs and TRAFs proteins. These proteins will in turn activate 
the corresponding transcription factor in a MAPKs, IKK or TBK1/IKKε-dependent way. NF-B, IRF, 
CREB and AP1 are some of the transcription factors induced by TLRs engagement. TLR signalling 
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ultimately leads to production of pro-inflammatory cytokines and type I interferon (IFN). dsRNA, 
double- stranded RNA; IKK, inhibitor of NF-κB kinase; IRAKs, IL-1R-associated kinases; LPS, 
lipopolysaccharide; MAL, MYD88-adaptor-like protein; MAPKs, mitogen-activated protein 
kinases; MYD88, myeloid differentiation primary-response protein 88; MKK, MAP kinase kinase; 
RIP1, receptor-interacting protein 1; rRNA, ribosomal RNA; ssRNA, single-stranded RNA; TAB, 
TAK1-binding protein; TAK, TGFβ-activated kinase; TIR, Toll–IL-1-resistence; TBK1, TANK-binding 
kinase 1; TRAFs, TNF receptor-associated factors; TRAM, TRIF-related adaptor molecule; TRIF, 




The activation of MYD88-independent pathways, characteristic of TLR3 and also 
possible with TLR4, is known to induce type 1 Interferons (IFNs) (Kumar, Kawai and Akira, 2011). 
TRIF, the adaptor mediating this type of signalling, recruits and activates the kinases TBK1 and 
IKKε through TRAF3 (Fitzgerald et al., 2003; Saha and Cheng, 2006). Another player in this 
signalling pathway is the receptor interacting protein 1 (RIP1) which links TRIF signalling to NF-
κB activation by interacting with TRAF6 (Sato et al., 2003; Meylan et al., 2004). Meanwhile, TLR4 
requires the additional interaction with the adaptor TRAM to initiate its TRIF-dependent cascade 
of activation that will ultimately lead to the production of type 1 IFNs (Lee and Barton, 2014). 
All the TLR signalling pathways result in the secretion of pro-inflammatory or anti-inflammatory 
cytokines and chemokines, direct soluble effectors of the different types of immune response. 
1.1.1.2 TNFα and TNFR1 signalling 
Tumor necrosis factor α (TNFα) is one of the proinflammatory cytokines induced as a primary 
response to bacterial or viral challenge by TLR signalling (Parameswaran and Patial, 2010). TNFα 
is produced by monocytes/macrophages, activated NK and T cells, endothelial cells and 
fibroblasts as a transmembrane 26 kDa protein which will later be cleaved by a metalloprotease 
into a 17 kDa soluble TNFα (Sedger and McDermott, 2014). Transmembrane and soluble TNF 
can bind to two receptor molecules: the death-domain-containing TNFR1 or TNFR2. The binding 
of TNFα to its receptor TNFR1 has the potential to trigger the production of more 
proinflammatory cytokines but it can also influence cellular process like proliferation, 
differentiation or programmed cell death (Sedger and McDermott, 2014). Activation of TNFR1 
receptor attracts TNF-R1 associated death domain protein (TRADD) proteins, FAS associated 
death domain protein (FADD), TRAF2 and RIP1 to the intracellular portion of this receptor (Hsu 
et al., 1996). Depending on the intracellular molecules and conditions, this complex of proteins 
can trigger activation of NF-κB and MAPKs, processing of caspase 8 and subsequently initiation 
of apoptosis, or phosphorylation of RIP3 and activation of necroptosis (Figure 1.2) (Devin et al., 
2000; Cho et al., 2009; Wilson, Dixit and Ashkenazi, 2009; Varfolomeev and Vucic, 2018). TNF 
signalling depends on linear ubiquitination of many of its associated molecules to regulate the 
activation of a specific signalling cascade. Linear polyubiquitination of RIP1 in the residues K11, 
K63 and K48 by E3 ligases cellular Inhibitor of Apoptosis 1 and 2 (c-IAP1 and 2) is one of the 
central regulatory mechanisms of TNFR1 activation (Devin et al., 2000; Lee et al., 2004; Bertrand 
et al., 2008; Mahoney et al., 2008; Varfolomeev et al., 2008; Varfolomeev and Vucic, 2018). cIAPs 
are proteins constitutively bound to TRAF2 and therefore recruited to the intracellular TNFR1 
complex after it has engaged the ligand TNFα (Devin et al., 2000; Park, Yoon and Lee, 2004; 
Mahoney et al., 2008). cIAPs1/2-mediated K63 ubiquitination of RIP1 in turn recruits 
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transforming growth factor b-activated kinase 1 (TAK1) through its ubiquitin-binding domain 
(Devin et al., 2000; Chen, 2005). Other proteins like TAK1 binding protein 2 and 3 (TAB2 and 3), 
and complexes IB kinase (IKK) and linear ubiquitin chain assembly complex (LUBAC) are also 
engaged (Sedger and McDermott, 2014). TAK1 phosphorylates the IKK complex, consisting of 
NF-B essential modulator (NEMO) and IB kinases 1 and 2 (IKK1/2), what allows NF-B 
translocation to the nucleus and induction of pro-inflammatory genes (Chen, 2005; Mercurio et 
al., 2018). E3 ligase HOIL-1 interacting protein (HOIP), haem-oxidized IRP2 ubiquitin ligase-1 
(HOIL-1) and SHANK-Associated RH Domain Interactor (Sharpin) proteins have been described 
to form the LUBAC complex which was also described to mediate NF-B activation in a RIP1-
independent way (Haas et al., 2009; Walczak, 2011). The LUBAC proteins SHARPIN and HOIL-1 
can ubiquitinate some of the TNFR1-associated molecules, such as TRADD, RIP1 and NEMO, and 
in that way activate the IKK complex and NF-B (Walczak, 2011; Varfolomeev and Vucic, 2018). 
Activation of TNFR1-mediated NF-B signalling is blocked when RIP1 is deubiquitinated by the 
deubiquitinases cylindromatosis (CYLD) and A20 or in conditions favouring depletion of cIAP1/2 
by Smac mimetics (Mahoney et al., 2008; Declercq, Vanden Berghe and Vandenabeele, 2009; 
Wilson, Dixit and Ashkenazi, 2009). Under those conditions, TNFR1 signalling can be driven 
towards two types of programmed cell death by means of RIP1 activity. The activation of the 
apoptotic and necroptotic types of cell death will be discussed in detail in sections 3.1.1.1 and 






Figure 1.2 Signalling pathways activated by TNFR1 signalling. 
Stimulation of cells with TNF can induce the activation of three signalling pathways. The first 
pathway is the inflammatory, where the binding of TNF ligand to its receptor induces the 
recruitment of TRADD, RIP1 and a number of E3 ligases (TRAF2, TRAF5, cIAP1 and cIAP2) to TNF-
R1 intracellular domain. Ubiquitination of RIP1 by the E3 ligases leads to activation of NF-B 
mediated by TAK1/IKK and consequently induction of pro-inflammatory signals and anti-
apoptotic proteins like cFLIP. Under condition mediating RIP1 de-ubiquitination or in the 
absence of cIAP1 and cIAP2, RIP1 can interact with FADD and procaspase 8 to form the Complex 
II or “ripoptosome”. Complex II facilitates caspase 8 auto-processing and triggers a downstream 
caspase cascade which ends in cell death by apoptosis. The E3 ligases Pellino 3 can block this 
signalling pathway by impeding Complex II formation. Finally, in absence of caspase 8, RIP1 and 
RIP3 can interact, autophosphorylate and assemble the necrosome. This structure allows the 
interaction of RIP3 with MLKL and subsequent phosphorylation that leads to the cellular 
membrane rupture and cell death by necroptosis. This last pathway can be inhibited by cleavage 




1.1.2 Innate immune signalling cascades  
The efficient and effective activation of an immune response depends on signalling cascades 
downstream of recognition of PAMPs, DAMPs or soluble molecules, engaging their 
corresponding receptors. The network of molecules involved in the signalling is extensive. 
However, the main effectors of TLR and TNF signalling are the pathways of the mitogen-
activated protein kinase (MAPKs), and the signalling cascade leading to the activation of nuclear 
factors NF-B and IRFs, which will be discussed next. 
1.1.2.1 Mitogen-activated protein kinase (MAPKs) 
Mitogen-activated protein kinases (MAPKs) are an extensive family of protein kinases that 
regulate essential cellular processes such as proliferation, differentiation, development and cell 
death in eukaryotic cells (Yang, Sharrocks and Whitmarsh, 2013). Three main subgroups have 
been identified and extensively studied: Extracellular Signal-Regulated Kinase (ERK), JNK/SAPK - 
P38 MAPK and ERK5 (Figure 1.3). Different stimuli activate a serial phosphorylation cascade of 
a set of three evolutionarily conserved kinases: a MAPK, a MAPK kinase (MAPKK) and a MAPKK 
kinase (MAPKKK) (Cargnello and Roux, 2011). Each set of kinases activates a specific signalling 
cascade that interacts with many different downstream kinases or transcription factors. The one 
activating ERK1 and ERK2 induces differentiation, cell division and proliferation in response to 
growth factors and mitogenic stimulus (Cargnello and Roux, 2011; Yang, Sharrocks and 
Whitmarsh, 2013). The second subgroup includes two signalling pathways, one characterised by 
activation of P38 and one for JNK kinases. They are usually described together because they 
share most of their activators at MAPKKK level and both are phosphorylated in response to 
stress stimuli such as inflammatory cytokines, ultraviolet irradiation, oxidative stress, heat 
shock, or osmotic shock (Cargnello and Roux, 2011; Kyriakis and Avruch, 2012). These two are 
mainly involved in regulation of cellular processes such as differentiation, inflammation, cycle 
cell arrest and apoptosis (Yang, Sharrocks and Whitmarsh, 2013). Finally, ERK5 has been 
described to be initiated by developmental cues to guide endothelial formation, cardiac 
morphogenesis and brain development (Regan et al., 2002; Glatz et al., 2013).  
1.1.2.2 NF-B 
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) is one of the main 
nuclear factors to be activated in response to stimuli such as bacterial or viral antigens, stress, 
cytokines, free radicals, ultraviolet irradiation among others (Gilmore, 2006). Two pathways of 





Figure 1.3 MAPKs signalling.  
Extracellular Signal-Regulated Kinase (ERK), JNK/SAPK - P38 MAPK and ERK5 are the three main 
subgroups of MAPKs that have been described. They are activated by specific stimulus which 
trigger a serial phosphorylation cascade of conserved kinases that in turn regulate essential 
cellular processes such as proliferation, differentiation, development and cell death. Growth 
factors and mitogenic stimulus are known to induce ERK1 and ERK2 activation which main 
response is to induce differentiation, cell division and proliferation. Meanwhile, stress stimuli 
such as inflammatory cytokines, ultraviolet irradiation, oxidative stress, heat shock, or osmotic 
shock have been described to mediate the activation of P38 and JNK kinases that regulate 
cellular processes such as differentiation, inflammation, cycle cell arrest and apoptosis. Finally, 
developmental cues activate ERK5 which in turn guides endothelial formation, cardiac 




nonclassical pathways. The first one is initiated by most TRAF dependent signalling pathways 
and regulates cell survival and inflammation, while the second one depends on TNFRs signalling 
and it is associated to B-cell survival, adaptive immune response and development of lymphoid 
organ development (Gilmore, 2006). The family of NF-B transcription factors includes five 
members which share an N-terminal Rel homology domain (RHD). This domain facilitates  
homo/heterodimerization and binding to target genes (Brasier, 2006; Gilmore, 2006). The five 
members of the family are p50/p105 (NF-B1), p52/p100 (NF-B2), p65, c-Rel and Rel-B. The 
last three contain a C-terminal transcription activation domain (TAD) in addition to RHD 
(Gilmore, 2006). NF-B subunits are present in the cytoplasm as homo or heterodimers in an 
inactive form due to inhibition by IB proteins (Karin and Ben-neriah, 2000; Brasier, 2006). The 
IB proteins (IBα, IBβ and IBε) contain multiple ankyrin repeats that mediate binding to NF-
B dimers, and their function is regulated by post-translational modifications such as 
phosphorylation and acetylation (Karin and Ben-neriah, 2000). All the IBs are targeted for 
proteasomal degradation in response to pro-inflammatory signalling induced by TLRs or TNFα 
(Brasier, 2006). IBs degradation unmask the nuclear localization signal (NLS) of NF-B dimers 
and allows for their translocation to the nucleus where it binds to the promoter regions of genes 
encoding  proinflammatory cytokines, cell adhesion molecules, growth factors, antiapoptotic 
proteins and other target genes (Brasier, 2006; Gilmore, 2006).  
1.1.2.3 Interferon Regulatory Factors (IRFs)  
The Interferon regulatory factors (IRFs) are another important family of transcription factors 
activated by PRRs signalling. They are known to mediate cellular process such as cell cycle, 
apoptosis and tumour suppression, but their main role is to the initiate anti-viral response by 
inducing the expression of type 1 interferons (IFN, IFN-α and IFN-β) (Honda, Takaoka and 
Taniguchi, 2006). Nine members of this family have been described, with IRF3 and IRF7 being 
the most broadly studied (Mamane et al., 1999; Barnes, Field and Pitha-Rowe, 2003). The 
previously described proteins TBK1 and IKKε activate IRF3 and IRF7 by phosphorylation of their 
C-terminal serine residues (see section 1.1.1.1 TLRs) (Fitzgerald et al., 2003). IRF3 activation is 
activated first, and it binds to the IFN promoter inducing production of IFN-β which in turn 
activates the IFN pathway and induction of IRF7 expression (Moynagh, 2005).    
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1.1.3 Regulation of innate immune signalling pathways 
Immune responses are a complex network of interactions between proteins of different 
signalling pathways. Considering the potential negative impact on cell survival or tissue integrity 
as well as the energetic cost of activating the production of soluble proteins or initiating adaptive 
responses, it is understandably highly regulated. There are several layers to the regulation of the 
immune responses with post-translational modification being one of the most crucial ways of 
control (Liu, Qian and Cao, 2016). Modifications include  phosphorylation, ubiquitination and 
SUMOylation and they play various roles ranging from regulating formation of signalling 
complexes to compartmentalization or protein trafficking (Liu, Qian and Cao, 2016). Once the 
receptor recognizes a potential harmful ligand and the corresponding signalling cascades are 
activated by post-translational modification, a particular response is then initiated. Proliferation, 
differentiation, inflammation, cell death or metabolic modifications represent some of the 
functional consequences of these events. The early studies in this thesis focus on the role of 
ubiquitination in innate immune signalling pathways.       
1.1.3.1 Regulation of innate immune signalling pathways by ubiquitination 
Post-transcriptional modification of proteins by ubiquitination or deubiquitylation regulate a 
broad set of immunological responses, from cell differentiation, antigen processing to 
inflammation (Komander and Rape, 2012; Liu, Qian and Cao, 2016). Ubiquitination of proteins 
is frequently associated with covalent attachment of polyubiquitin chains with each ubiquitin 
protein being attached to the preceding one by an isopeptide bond between the C-terminal 
glycine residue and the  amino group of one of 7 lysine residues (K6, K11, K27, K29, K33, K48 or 
K63) of the preceding ubiquitin or the N-terminus of a second ubiquitin in a methionine residue 
(M1) (Komander and Rape, 2012; Swatek and Komander, 2016). The variety of polyubiquitin 
chains and the specific site of binding of subsequent ubiquitin governs the fate of the targeted 
proteins (Ravid and Hochstrasser, 2008; Komander and Rape, 2012; Swatek and Komander, 
2016). Furthermore, recent research has pointed other possible post-translational modifications 
on ubiquitin chains such as SUMOylation, phosphorylation and acetylation, which adds extra 
layers of complexity to the ubiquitin code (Swatek and Komander, 2016). Proteins ubiquitination 
was for long time defined as a signal for proteasomal degradation. However, more recent 
research has proven it also has roles in non-degradative processes labelling proteins for 
signalling purposes such as endocytosis or scaffolding and regulating a plethora of biological 
process including cell cycle, epigenetic, protein trafficking, mitophagy, response to DNA damage 
and NF-B signalling among others (Komander and Rape, 2012; Swatek and Komander, 2016).  
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The most well characterised ubiquitination linkages are via lysine 48 (K48) or (K63). K63-
linked polyubiquitination mediates TLR signalling and the production of type I IFNs by regulating 
the activity of TRAF6, TAB2/3, NEMO, TRAF3, RIG-I, MAVS and STING (Liu, Qian and Cao, 2016). 
K63-linked polyubiquitination of RIP2 by Pellino 2 has also been proved to be essential in NOD2 
signalling (Yang, Wang, Humphries, et al., 2013). In addition, ubiquitination of ASC by LUBAC and 
deubiquitination of NLRP3 are required for the activation of the NLRP3 inflammasome (Broz and 
Dixit, 2016). K48-linked polyubiquitination is associated with tagging of proteins for proteasomal 
degradation with  IB  degradation being an exemplar of this process (Chen, 2005; Brasier, 2006; 
Gilmore, 2006; Mercurio et al., 2018). The proteasome mediates degradation of K48-linked 
ubiquitinated proteins. The proteasome can be blocked by pharmacological agents such as 
MG132 with some inhibitors such as Bortezomib being used clinically to treat cancers such as 
multiple myeloma. These inhibitors are used in the present study to further characterise the role 
of the proteasome in control of the anti-inflammatory pathways.  
Over the last years, research has indicated other types of polyubiquitination linkages 
through K6, K11, K27, K29 or K33 to play important roles in immune signalling and inflammation 
(Heaton, Borg and Dixit, 2016; Liu, Qian and Cao, 2016). Protein ubiquitination relies on the 
sequential activation of 3 types of enzymes (Deshaies and Joazeiro, 2009; Komander and Rape, 
2012; Inobe and Matouschek, 2014). They include a ubiquitin activating enzyme (E1), ubiquitin 
conjugating enzyme (E2) and ubiquitin ligase (E3)(Komander and Rape, 2012; Metzger et al., 
2014). Part of this thesis will focus on a particular family of E3 ubiquitin ligases known as Pellino 
proteins and their role in innate immune signalling with particular focus on regulation of cell 
death. There are three members of this family containing common RING and forkhead-
associated (FHA) domains (Lin et al., 2008; Moynagh, 2014). The E3 Pellino family have been 
linked to mediate the ubiquitination of several proteins in a variety of signalling pathways 
including TLR, NOD and TNF signalling (Moynagh, 2014). They are closely associated with RIP 
kinases at the molecular and functional level and for this reason are explored in this thesis in the 
context of cell death. 
1.1.3.2 Cell death and inflammation 
Cell death plays important roles in  regulation of inflammation and innate immunity (Kolb et al., 
2017). Cell death was first seen as an accidental process occurring when cellular functions were 
beyond repair. However, an extensive amount of research has described different types of 
regulated cell death including apoptosis, necroptosis (a regulated subtype of necrosis), 
autophagy and pyroptosis (Galluzzi et al., 2014; Kolb et al., 2017). Apoptosis and autophagy are 
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regarded as anti-inflammatory types of cell death while necroptosis and pyroptosis have been 
suggested to be pro-inflammatory (Taylor, Cullen and Martin, 2008; Kaczmarek, Vandenabeele 
and Krysko, 2013; Pasparakis and Vandenabeele, 2015; Kolb et al., 2017). However, some 
researchers have proposed necroptosis to also be anti-inflammatory (Kaczmarek, Vandenabeele 
and Krysko, 2013; Kearney et al., 2015). Apoptosis and necroptosis molecular pathways are 
closely related in terms of triggers, mediators and key molecular regulators (Humphries et al., 
2014; Huang et al., 2015; Vasudevan and Ryoo, 2015). The family of receptor interacting protein 
(RIP) kinases are key determinants in the  types of cell death (Moriwaki and Chan, 2013; 
Humphries et al., 2014). As previously described in Section 1.1.3.1, post-translational 
modifications are essential for the regulation of RIP kinases activity, particularly ubiquitination 
mediated by E3 ligases like the Pellino family (Humphries et al., 2014; Moynagh, 2014). This will 
be further characterised in this thesis.  
1.1.3.3 Hypoxia and innate immune pathways 
Ubiquitination plays important roles in regulation of transcription factors like NF-B and cell 
death pathways in innate immune signalling. It is also critically important in responding to 
conditions of low oxygen (hypoxia) an environment that is typically found at sites of 
inflammation. Hypoxia regulates the activation of multiple genes associated with essential 
cellular process such as cell migration, metabolism, signalling and cell fate (Iyer, Leung and 
Semenza, 1998; Lisy and Peet, 2008). The cellular responses to hypoxia are coordinated by a 
group of proteins known as hypoxia-inducible transcription factors (HIFs) that under normal 
oxygen tension are degraded by the ubiquitin proteasome system (Lisy and Peet, 2008). 
Inflammation and tissue hypoxia have been correlated in several diseases from inflammatory 
bowel disease (IBD) to obesity (Colgan and Taylor, 2010; Cummins et al., 2016). Its upregulation 
has also been extensively discussed as a mechanism of survival for malignant cells (Campbell et 
al., 2014; Campbell and Colgan, 2015; Cummins et al., 2016). HIF signalling has been associated 
with multiple immune pathways including TLR3 and TLR4 signalling, and its molecular functions 
are also linked with transcription factors such as NF-B, STAT3 and AP-1 (Noman et al., 2009; 
Oblak and Jerala, 2011; Bruning et al., 2012; Tewari et al., 2012; Pawlus, Wang and Hu, 2014; 
Veyrat et al., 2016; Matijevic Glavan et al., 2017). In addition, research from our group has 
described interaction between TRAF6, HIF-1α and IL1β as a mechanism mediating insulin 
resistance in a murine model of obesity (Yang et al., 2014). In this thesis, we explore the interface 





1.2 Project aims 
 
 
1.2.1 Overarching Objective 
Innate immune signalling is crucially important in triggering activation of transcription factors 
such as NF-B and HIF that regulate expression of genes encoding pro-inflammatory and anti-
inflammatory cytokines. However, there is also an emerging appreciation of the important 
contribution of necrotic forms of cell death to inflammation. The ubiquitin/proteasome system 
(UPS) is a key regulator of all of these processes. The overarching theme of this study is revise 
the roles of the ubiquitination and proteasome systems in innate immune signalling with 




1.2.2 Specific aims 
 
• Explore the role of Pellino 2 and Pellino 3 E3 ubiquitin ligases in the regulation of the 
programmed type of cell death known as necroptosis. 
• Characterise of the ability of TLRs to trigger HIF-1α signalling. 
• Delineate the mechanism underlying the interplay between the proteasome and 
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2.2.1 Cell culture and sample preparation 
2.2.1.1 Cell culture 
2.2.1.2 Bone-Marrow Derived Macrophages (BMDMs) 
2.2.1.3 Murine embryonic fibroblasts (MEFs) 
2.2.1.4 PCR-based genotyping 
2.2.1.5 Concentration of the inhibitors 
2.2.1.6 Isolation of proteins for Western Blot 
2.2.1.7 Isolation of total RNA 
2.2.1.8 Synthesis of first strand cDNA from messenger RNA (mRNA) 
2.2.1.9 Real –time quantitative PCR 
2.2.2 Molecular, Cellular and biochemical methods 
2.2.2.1 Western Blot  
2.2.2.2 ELISA 
2.2.2.3 Lactate dehydrogenase (LDH) release 
















Bioscrip Reaction Buffer (5X) Bioline 
Bioscrip Reverse transcriptase Bioscience 
Birinapant APExBIO 
Bortezomib (PS-341) Selleckchem 
Bradford Reagent Sigma 





Complete mini protease Inhibitor cocktail Roche 
CpG ODN 1668 Invivogen 
Cycloheximide (CHX) Sigma 




dNTPs (deoxyribonucleotide triphosphates) BioLabs 
DTT Sigma 
EDTA (Ethylenediaminetetraacetic acid) Sigma 
Ethanol Sigma 
FBS Thermo fisher 
GelRed Nucleic acid stain Biotium 
Glacial acetic acid Sigma 
Glycerol Sigma 
Glycine Fisher 
GoTaq®Green Master Mix Promega 
Hydrochloric acid (HCL) Merk 
Igepal Sigma 












NewBlotTM Nitro Stripping buffer Licor Biosciences 
NF-B SN50 Enzo 
PBS Sigma 
Pellino 3 SiRNA Life tech 
Penicillin Streptomycin Gibco 
PMSF Sigma 
Poly(I:C) Invivogen 
Protease Inhibitor Cocktail Roche 
Protein A/G beads Santa Cruz 
Protein K Qiagen 
Protein ladder Fisher 
Protogel National diagnostics 
Random primers Invitrogen 
Rapamycin Invivogen 
RIPK inhibitors (GSK'872) GSK 
RPMI Fisher 
SDS Sigma 
Skim milk powder Tesco 
Sodium chloride (NaCl) Sigma 
Sodium hydroxide (NaOH) Sigma 
Sodium orthovanadate (Na3VO4) Sigma 
Sodium Phosphate (Na3PO4) Sigma 
Sucrose Sigma 
Sulfuric acid (H2SO4) Sigma 
Taq polymerase Invitrogen 
TEMED Sigma 
TMB ultra sensitive substrate Moss substrates 
TNFα R&D Systems 
Trizma - Tris Sigma 
Trizol Ambion 
Trypsin EDTA free Gibco 
Trypsin-EDTA solution Sigma 
Tween 20 Sigma 
WesternBright ECL Substrate Advansta 
X-Ray Developer RG 
X-Ray Fixer RG 
zVAD-fmk Enzo 







FITC Annexin V Apoptosis Detection kit BD Pharmingen™ 
CytoTox 96® Non-Radioactive Cytotoxicity Assay Promega 
Mouse CXCL2/MIP-2 DuoSet ELISA R&D Systems 
Mouse IL-10 ELISA R&D Systems 
Mouse IL-6 ELISA R&D Systems 
Mouse KC /CXCL1 R&D Systems 





Caspase-3 Santa Cruz 
Cleaved caspase-8 Cell Signalling 
Cleaved PARP Cell Signalling 
CREB (86B10) Cell Signalling 
FLIP Cell Signalling 
GAPDH Cell Signalling 
HIF-1α Novusbio 
p38 MAPK (Thr180/Tyr182)  Cell Signalling 
P44/42 MAPK (Erk1/2) Cell Signalling 
P-CREB Cell Signalling 
Phospho-MLKL Abcam 
Phospho-p38 MAPK (Thr180/Tyr182) (D3F9)  Cell Signalling 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Cell Signalling 
Phospho-SAPK/JNK (Thr183/Tyr185) Cell Signalling 
Phospho-Stat3 (Tyr705) Cell Signalling 
P-Ikkαβ Cell Signalling 
P-Ikβα Cell Signalling 
P-NF-B p65 Cell Signalling 
P-TBK1 Cell Signalling 
RIP1 BD 
RIP3 Cell Signalling 




IRDye 800CW Goat Anti-Rabbit Licor Biosciences 
IRDye 680 Goat Anti-Mouse Licor Biosciences 
IRDye 800CW Donkey Anti-goat Rockland 








FM1: 5'AGGGATTTGAATCACGTTTG  
RM1: 5'TTTACTGGCAACATCAACAG  
CXCL10 
FM1: 5'AAAAAGGTCTAAAAGGGCTC  
RM1: 5'AATTAGGACTAGCCATCCAC  
GLUT-1 (Slc2a1) 
FM1: 5'AAGTCCAGGAGGATATTCAG  
RM1: 5'CTACAGTGTGGAGATAGGAG 
VEGF 
FM1: 5'TAGAGTACATCTTCAAGCCG  
RM1: 5'TCTTTCTTTGGTCTGCATTC 
IL10 
FM1: 5'CAGGACTTTAAGGGTTACTTG  
RM1: 5'ATTTTCACAGGGGAGAAATC  
Genotyping for  
Pellino 3 KO 
2092_25: CCCAACATAGGTGTTTCCTCTCC    
2092_29: GTGCATACACATTCATGCAAGC   
2091_27: GACACGTGTGGAGATAATGAGG   
2091_28: ACCCAGGCACAAGTCAAGC  
Genotyping for  
Pellino 2 KO 
4892_127: GCCTCTACAGGATGCTCATTT  










5% Non-fat dry milk in Tris buffered saline plus Tween 20 
(TBST) 
Cell lysis Buffer 
20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.2% (v/v) Igepal, 
10% (w/v) glycerol, 50 mM   NaF,1 mM Na3VO4, 1 mM DTT, 
1 mM PMSF, complete protease inhibitor cocktail (Roche, 
mini) 
Laemmli sample buffer   
Loading buffer (1X) 
62.5 mM Tris-HCl, pH 6.8, 10% (w/v) glycerol, 2% (w/v) SDS, 
0.7 M β-mercaptoethanol, 0.001% (w/v) bromophenol blue 




2.7mM KCl, 1.5mM KH2PO4, 137mM NaCl, 8mM Na2HPO4, 
pH 7.4  
Reagent diluent for ELISA  0.1% (w/v) BSA, 0.05% (v/v) Tween in TBS  
SDS Running buffer (10X) 0.25M Tris, 1.92M glycine, 1% SDS, dH2O 
TAE (Tris-acetate-EDTA) buffer 40 mM Tris base, 0.1% (v/v) glacial acetic acid, 1 mM EDTA  
Transfer buffer 250 mM Tris, 192 mM glycine, 15%/20% methanol, dH2O 
Tris buffered saline (TBS) 25mM Tris, pH7.4, containing 0.14M NaCl. 
Tris buffered saline (TBST) Tris-buffered saline, 0.1% Tween 20 




iBMDMs WT  WT Immortalized Bone Marrow Derived Macrophages 
iBMDMs TRIF-/- TRIF-/- Immortalized Bone Marrow Derived Macrophages 
iBMDMs IRF3-/- IRF3-/- Immortalized Bone Marrow Derived Macrophages 
L929 Mouse fibroblasts 
THP-1 Human monocytes 
 
Immortalized BMDMs cell lines were generated by infection with J2 recombinant retrovirus 
(Roberson and Walker, 1988). Macrophage cell lines from wild-type (C57BL6), TRIF-/- and IRF3-/- 
mice were generated and are referred to as iBMDMs WT, iBMDMs TRIF-/- and iBMDMs IRF3-/-. 
Primary BMDMs were incubated in L929 conditioned medium for 3–4 days to induce 
macrophage differentiation (See Section 2.2.1.2). Cells were then infected with J2 recombinant 
retrovirus and maintained in culture for 3–6 months slowly weaning off the percentage of L929 
conditional medium until cells were growing in its absence. Macrophage phenotype was 
confirmed by surface marker expression for CD11b and F480 and functional parameters such as 
responsiveness to TLR ligands and bacterial uptake.  







Pellino 2 and Pellino 3 deficient mice were generated by Taconic Artemis using RNAi-modified 
transgenic mice proprietary technology which allows for the development of custom-
engineered knockout mouse models. This technology is based on the development of a target 
vector where the gene of interest is silenced. The vector is then sequenced and electroplated 
into C57BL/6NTac ES cells. Clones are validated via Southern Blot and subsequently injected into 
mouse blastocysts for transfer to pseudopregnant females. First generation clones are bred to 
delete mice and remove selection markers until second generation knockout mice are 
determined to be a competent germline. After their development by Taconic Artemis, Pellino 2 
and Pellino 3 deficient mice and their wild-type counterparts were bred at the animal facility at 
Biosciences, Maynooth University. Genotyping was performed by PCR analysis of genomic DNA 
from ear punches as described in 2.2.1.4 and genotypes were reconfirmed after the completion 
of experiments. The mice were housed in standard rodent cages, enriched with cardboard 
housing and nesting material. The animals were kept at room temperature (22 – 24°C) in a 12hr 
light/dark cycle (lights on at 8:00 a.m.) with ad libitum access to food and water. All mice were 
used under the guidelines of The Health Products Regulatory Authority (HPRA), and all 
procedures were approved by the research ethics committee of the Maynooth University. 
Double knockout Peli2-/-Peli3-/- mice were generated by crossing Peli2-/- and Peli3-/-. Genotyping 
was performed as described in section 2.2.1.4 by performing three independent reactions for 
the corresponding alleles in the same sample (See Section 2.1.4).  
 
2.1.8 Gifts 
Immortalized BMDMs WT, TRIF-/- and IRF3-/- were kindly provided by Prof. Kate Fitzgerald at 







2.2.1 Cell culture and sample preparation 
2.2.1.1 Cell culture 
L929 and THP-1 cells were cultured in RPMI medium supplemented with 10% (v/v) fetal bovine 
serum (FBS, Thermo fisher), 100 µg/mL of Penicillin Streptomycin (Penstrep, Gibco). Cells were 
incubated at 37°C in a humidified atmosphere of 5% CO2 and passaged every 2 to 3 days by 
scraping and subsequent centrifugation. Cells were then resuspended in new medium and 
seeded for experiments or for expansion of the cell cultures. Conditional M-CSF media: L929 
were seeded at a confluency of 5x105 cells/mL in 40 mL RPMI in a T175 flask and incubated for 
7 days at 37°C in a humidified atmosphere of 5% CO2. After 7 days, supernatant was transferred 
to a 50mL tube and centrifuged at 600 g for 5 min to remove dead or floating cells. Cells were 
cultured for a maximum of 25 passages to avoid excessive genetic drift. Supernatants were 
collected and stored at -80°C until use.  
Immortalized cell lines for WT, TRIF-/- and IRF3-/- BMDMs were also used and cultured as follows: 
cells were cultured in DMEM medium supplemented with 10% (v/v) fetal bovine serum (FBS, 
Thermo fisher), 100 µg/mL of Penicillin Streptomycin (Penstrep, Gibco). Cells were incubated at 
37°C in a humidified atmosphere of 5% CO2 and passaged every 2 to 3 days by scraping. Cells 
were then resuspended in new medium and seeded for experiments or for expansion of the cell 
cultures. 
2.2.1.2 Bone-Marrow Derived Macrophages (BMDMs) 
Bone marrow was flushed from tibia and femur of Peli3+/+, Peli2+/+, Peli2-/- and Peli3-/- mice. 
BMDMs were differentiated by culture of bone marrow cells in RPMI medium supplemented 
with FBS, Penstrep and 10% conditioned medium of L929 mouse fibroblasts (macrophage-
colony stimulating factor (M-CSF); 20 ng/ml) for 5 to 7 days.  
2.2.1.3 Murine Embryonic Fibroblast (MEFs) 
Thirteen or fourteen days embryos from breeding of Pellino 3 heterozygous (Peli3+/-) mice were 
obtained from pregnant female mice. Females were euthanized by cervical dislocation according 
to standard protocols. The uterus was removed under sterile conditions and embryos 
transferred separately into Petri dishes with sterile PBS. The head of each embryo was separated 
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and processed for genotyping, and the red tissue (heart and liver) cut off to obtain the carcasses. 
Embryo carcasses were transferred to 50 mL tubes with 4 ml trypsin-EDTA solution, macerated 
and incubated at 37 °C for 15 min. Maceration was repeated twice, each time with a 10 min 
incubation at 37°C. DMEM (10% FBS and Penstrep) (12 mL) was added to inactivate trypsin and 
samples were pipetted up and down several times. Clumps of tissue were removed and media 
containing cells transferred into T75 tissue culture flasks, cells were incubated at 37°C in a 
humidified atmosphere of 5% CO2. Peli3+/+, Peli2+/+, Peli2-/- and Peli3-/- MEFs were selected after 
genotyping and passaged every 3 to 4 days using Trypsin-EDTA solution. MEFs reach crisis phase 
around passage 10 and proliferation decreases at that stage precluding their further use. For 
genotyping embryo’s heads were digested in 100µl Direct PCR Lysis Reagent (Tail) (Viagen 
Biotech) with 0.5 µl Proteinase K (QIAGEN). Samples were incubated at 55°C for at least 3 hrs or 
overnight. Subsequently, digested tissue was incubated at 85°C for 45mins to inactivate 
Proteinase K and diluted 1:10 in distilled water for PCR processing. 
2.2.1.4 PCR-based genotyping 
PCR amplification was performed on genomic DNA using GotoTaq DNA polymerase and specific 
primers to detect heterozygous/homozygous conventional alleles (See Section 2.1.4).  
Reaction:  
Template 2 μl 
5X Buffer 5 μl 
MgCl2 (25mM) 2 μl 
Primers (4pmol/μl) 2.5 μl each 
dNTP mix (10mM each) 1 μl 
GotoTaq (5u/μl) 0.15 μl 
PCR-grade water to 25 μl 
 
For each target the samples were initially heated to 94°C for 5 min. This was followed by 35 
cycles at 95°C for 30s, at 60°C for 30s and at 72°C for 1 min. Samples were then incubated at 
72°C for 10 min and stored at 4°C. The PCR products were subjected to electrophoresis on a 2% 
(w/v) TAE agarose gel containing 5μg/ml GelRed Nucleic acid stain (Biotium) at 120 Volts for 20 
minutes. Nucleic acids were visualized under ultraviolet light (UV) (254nm) and images were 





2.2.1.5 Concentration of the inhibitors 
The concentration for the different inhibitors was selected based on the corresponding 
Datasheet, the literature or optimization experiments performed in the laboratory. 
Concentration for IAPs inhibitors (BV6, LCL161 and Birinapant), used in Chapter Three of this 
thesis, were determined by Dr. Fiachra Humphries using dose-dependency experiments. 
Concentrations for inhibitors used in Chapter Four (MG132, DMOG, Chloroquine, 2-DOG) were 
selected based on literature review and information from the providers. Concentration of 
Bortezomib was evaluated by dose-dependency experiments as described in section 5.2.3. 
2.2.1.6 Isolation of proteins for Western Blot 
Cells were plated in 12-well plates at a density of 1.0x106/ml and treated as indicated. 
Depending on the type of study, harvest was carried as follows: (A) for cell death analysis, cells 
were scraped and transferred to 1.5mL microcentrifuge tubes. They were then centrifuged at 
6000g for 1 min. Supernatants were retained and cells washed in ice-cold PBS, followed by 1 min 
centrifugation at 6000g. PBS was discarded and 80uL of sample buffer added. Samples were 
incubated 20min at 100°C and stored at -20°C. (B) for hypoxia analysis, media was discarded. 
Cells were washed once with cold PBS, and 100μL sample buffer added to each well. Cells were 
scraped into the sample buffer and transferred into new Eppendorf tubes to be heated at 95°C 
for 10 minutes. Samples were stored at -20°C until used. 
2.2.1.7 Isolation of total RNA 
Cells were seeded at a concentration of 1.0x106 in 12-well plates. RNA isolation was carried out 
under RNase-free conditions to avoid introducing RNase contamination. For adherent cells, 
growth media was removed, and cells washed with 0.5mL of ice-cold PBS. TRIzol® Reagent (0.5 
mL) was added directly to the cells in a 12-well plate and allowed to lyse by slowly shaking at 
room temperature for approximately 2 minutes. TRIzol containing the RNA was then transferred 
into new Eppendorf tubes and stored at -20°C or used immediately for RNA isolation which was 
done as per manufacturer’s protocol. Briefly: 100 μL of chloroform were added to tubes 
containing the samples in TRIzol, the mixture was then vortexed for 15 sec and incubated at RT 
for 3 minutes. After incubation, samples are centrifuged at 12,000 g for 15 minutes at 4°C. 
Approximately 120 μL of the colourless-RNA upper aqueous phase was transferred to a new 
sterile tube and 250 μL of isopropanol added to the aqueous phase and subsequently vortexed 
for at least 5 sec. Samples were incubated at RT for 10 minutes, followed by centrifugation at 
12,000 g for 10 minutes at 4°C. The isopropanol was carefully removed without disturbing the 
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precipitated RNA pellet and 1mL of 75% (v/v) ethanol were added. Samples were vortexed 
briefly and centrifuged at 7,500g for 5 min at 4°C. Ethanol was removed and the RNA pellets 
were air dried on a heating block at 60°C for up to 10 min. The RNA pellet was re-suspended in 
30μL of RNase free water and incubated at 65°C for 10 minutes. Concentrations and purities of 
isolated RNA were determined by means of a Nanodrop™ Spectrophotometer using absorbance 
at 260 and 280nm wavelengths. RNA was stored at -20°C. 
2.2.1.8 Synthesis of first strand cDNA from messenger RNA (mRNA) 
cDNA was produced from total RNA extracted as previously described. RNA (1 μg) was diluted 
in nuclease free water to a final volume of 11.5 μl. Random primers (0.5 μl) were added and the 
mix incubated at 70°C for 5 min. Next, the mixture was allowed to cool down on ice before 
adding the following components:  
 
Reagent Vol. 
Bioscript reverse transcriptase (200U/μl) 0.5μl 
dNTPs (10mM) 1μl 
5 x Bioscript Reaction Buffer 4μl 
H2O 2.5 μl 
 
The reaction mixture was incubated at 42°C for 1h, heated at 70oC for 10mins to deactivate 
Bioscript reverse transcriptase, and cooled at 4oC for 5mins. cDNA was then stored at -20oC. 
 
2.2.1.9 Real –time quantitative PCR  
cDNA samples were diluted 1:100 by addition of PCR-grade water. The real-time PCR reaction 
mixture was prepared in 96-well plates as follows to a final volume of 20μl: 
Reagent Vol. 
Master Mix (2x) SensiMix SYBR No-ROX 10 μl 
Primers (4pmol/μl) 2,5 μl each 
PCR-grade water Up to 20 μl (3μl) 
Samples 2 μl each well 
 
Samples were assayed in duplicate and normalised relative to levels of a housekeeping gene 
(HPRT). Primer sequences were as described in Materials. Once the mix was set up, the cyclical 
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RT-PCR reactions were performed in an Applied Biosystems Step One PLUS real-time instrument 
as follows: denaturation was carried at 95°C for 15 minutes, followed by 40 cycles at 95°C for 30 
seconds, 57°C for 30 seconds (according to primer) and 72°C for 30 seconds. Integration of the 
fluorescent SYBR Green into the PCR product was monitored after each annealing step. 
Amplification of one specific product was confirmed by melt curve analysis where a single 
melting peak eliminated the possibility of primer-dimer association. For melting curve analysis 
to be performed the products were heated from 60°C to 95°C after the 40 cycles. The PCR 
reactions were conducted in a Bio-Rad ICycler realtime PCR instrument. Targeted gene 
expression activity was determined as relative quantification using the Cycle Threshold (CT) 
method. CT represents the number of cycles required to detect a fluorescent signal, 
corresponding to the target amplicons, intersecting a preprogramed fluorescence threshold line. 
The concentration of target nuclei acid is inversely proportional to CT values, the higher the 
concentration of target the less cycles are necessary to detect the signal. The variations in the 
target nuclei acid (∆CT) value is calculated by subtracting the CT value of a control (for this thesis 
the control gene used was HPRT) from the target CT value. Fold changes in the relative gene 





2.2.2 Molecular, Cellular and biochemical methods 
2.2.2.1 Western Blot  
Electrophoresis: Samples were loaded and electrophoresed through a 5% SDS polyacrylamide 
stacking gel at 80 V, and then through a 7-15% SDS polyacrylamide resolving gel at 110 V for 
approximately an hour, or until the dye front ran off the bottom of the gel. The size of the protein 
determined the percentage of the resolving gel to be used. 
Electrotransfer, blocking and antibody incubation: after separation in the polyacrylamide gel, 
samples were transferred to nitrocellulose membranes using a sandwich system as follows: 
three pieces of filter paper, membrane, polyacrylamide gel and three more pieces of filter paper, 
all soaked in Transfer buffer. The ensemble was then placed in a Hoefer TE 70 Semiphor semi-
dry transfer unit and run at 200mA for 1.20 min. Subsequently, membranes were blocked with 
5% skimmed milk in TBST for 1 hour to avoid non-specific binding of the antibodies. Following 
three times washing in TBST for 10min, primary antibodies in 5% skimmed milk or BSA (w/v) 
were added and incubated overnight at 4°C. An additional three washes in TBST was done before 
adding secondary antibody in 5% skimmed milk and incubation for 1 hour. Membranes were 
washed in TBST three times for 10min each before detection of bands based on manufacturer’s 
instructions for the secondary antibodies used. Immunoreactive bands were detected through 
Odyssey infrared imaging system from Licor Biosciences, or by means of E.C.L 
chemiluminescence reaction in dark room. For proteins with low expression like HIF-1α, anti-
mouse or anti-rabbit secondary antibodies containing enzyme horseradish peroxidase (HRP) 
were used. The chemiluminescent HRP substrate WesternBrightTM E.C.L was added to 
membranes with this type of secondary antibody after the final three washing steps with TBST. 
The buffer was then drained, and membranes covered with 5mL of working solution mix with 
equal volumes of WesternBrightTM ECL (luminol/enhancer solution) and WesternBrightTM 
Peroxide (stabilized peroxide solution) for 2 min. Membranes were placed between two pieces 
of plastic sheets in a metal cassette and two to three pieces of ultraradiography film were placed 
on top for the time required until signals could be determined (range was from 5min to 1.5 
hours). Films were then reveal by imbruing the films in X-Ray Developer, followed by X-Ray fixer 
and finally washed with water at room temperature.  
2.2.2.2 ELISA 
Cell supernatants were collected following specific treatments and stored at -20°C until ELISA 
analysis. NUNC “Maxisorb” 96-well plates were coated with the corresponding capture 
antibodies and incubated overnight at room temperature (See table of concentrations and 
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diluents below). Plates were then washed three times with wash buffer (PBS with 0.05% Twee-
20) and dried. The washing procedure was done in the same way after every step of the ELISA 
analysis. Plates were blocked for 1h in PBS containing 1% (w/v) BSA. Standard concentrations of 
analyte were added in duplicates and experimental samples assayed in triplicates. Standards 
were diluted in reagent diluent with concentrations ranging between 0 and 2000pg/ml 
depending on the protein to be evaluated. Plates were incubated for at least two hours (at room 
temperature) or overnight (4°C). Biotinylated detection antibody was added to each well and 
incubated at room temperature for 2 hours. Streptavidin-HRP conjugate was added and 
incubated for 20min in the dark. Next, 100μL of liquid substrate TMB ultrasensitive substrate 
(2.08 mM) solution was added and incubated in the dark for no longer than 20mins. The reaction 
was stopped with 50 µl per well of 1 NH2SO4, and optical depth (OD) was determined by means 
of an ELx800TM microplate reader and GEN5 Data Analysis Software. The OD was defined for 
each well at 450nm with correction of 590nm. Standards were used to construct a standard 










1:120 in PBS Reagent diluent 




1:40 in Reagent 
diluent 
IL10 ELISA 
1:120 in PBS Reagent diluent 




1:40 in Reagent 
diluent 
IL6 ELISA 
1:120 in PBS Reagent diluent 




1:40 in Reagent 
diluent 
KC /CXCL1 ELISA 
1:120 in PBS Reagent diluent 




1:40 in Reagent 
diluent 
TNFα ELISA 
1:120 in PBS Reagent diluent 









2.2.2.3 Lactate dehydrogenase (LDH) release  
Lactate dehydrogenase (LDH) is a stable cytosolic enzyme that is released upon cell lysis. A non-
radioactive colorimetric assay was used to measure LDH release (CytoTox 96® Non-Radioactive 
Cytotoxicity Assay, Promega) in supernatants of cells treated with the indicated compounds and 
ligands for the time points specified in each experiment. The assay consists of a 30-minute 
coupled enzymatic reaction which produces a red formazan from a tetrazolium salt (INT) 
conversion. The number of cells lysed is proportional to the colour produced which is 
determined by means of optical density (OD). The supernatant of at least 3 wells of non-treated 
cells were used as control for spontaneous LDH release. To establish the maximum release of 
LDH, triplicate control wells with the same number of cells used per experiment were treated 
with 20μl of 10X lysis solution (total volume per well was 200μl, final concentration of lysis 
solution was 1X, diluted in the media) added forty-five minutes prior to the end point of the 
experimental times. The same volume of warm media (20μl) was added to the experimental 
wells and controls to compensate for volume differences. Following supernatant collection at 
the specific time points, 40μl of the supernatants were transferred to a flat-bottom 96-well 
enzymatic assay plate. Reconstituted Substrate Mix (50μl) was added to each well. Plates were 
covered and incubated at room temperature in the dark for no longer than 30 minutes. The 
same volume of Stop Solution was used to end the colorimetric reaction, and absorbance was 
read at 490nm with correction of 680n in a ELx800TM microplate reader and GEN5 Data Analysis 
Software. Results were present as percentage of cytotoxicity: (LDH activity (treated cells) – 
Spontaneous LDH release activity)/(Maximum LDH activity – Spontaneous LDH activity))*100. 
 
2.3 Statistical Analysis 
 
Statistical analysis was done using Prism 5 GraphPad software. Two-tailed Student’s t-test was 
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Regulated cell death is an essential mechanism in the development of organisms. It is also 
responsible for keeping balance in response to extracellular or intracellular damage threatening 
homeostasis of a given biological system. The first form of regulated cell death  was defined in 
the early 70s with the description of apoptosis, but more recently, many other types of cell death 
have been characterized (Galluzzi et al., 2014). Initially, it was believed apoptosis represented 
the “organized” and highly controlled type of cell death, and necrosis was a more random and 
uncontrolled process. Nevertheless, in more recent years a regulated form of necrosis has been 
identified and termed as necroptosis. Being such a definitive fate, all types of cell death have 
been proven to be tightly regulated. There are several signals of activation or conditions within 
the cell that are required to initiate cell death. Many proteins are involved in the signalling 
pathways as facilitators or effector molecules with a family of kinases known as receptor 
interacting proteins (RIPs) being especially critical in regulating cell death. Given the crucial role 
of RIP kinases in the finality of a process like cell death, it is hardly surprising that they are subject 
to tight regulation as well. The activity of RIP kinases is especially dependent on post-
translational modifications like ubiquitination. Multiple E3 ubiquitin ligases, proteins mediating 
the covalent attachment of ubiquitin to target proteins, have been associated with RIP1 post-
translational regulation in the context of apoptosis (Humphries et al., 2014). Such E3 ligases 
include members of the Pellino E3 ligase family. Considering the close interplay between 
apoptosis and necroptosis, as it will be described in more detail below, the question on how 
Pellino proteins can regulate other types of cell death was contemplated. Consequently, in this 
chapter, the role of members of the Pellino E3 ligase family are explored in the context of 
necroptosis.  
 
3.1.1 Programme cell death 
It is generally accepted cell death is a decisive process when loss of cellular function is 
irreversible. The criteria to define such a definitive mechanism have been widely discussed. For 
many years, sudden and "chaotic" loss of plasma membrane integrity or “organized” 
fragmentation and packing of cellular content were the binary forms of cell death. They were 
for a long time named necrosis and apoptosis or autophagy, respectively. However, many years 
of research has expanded the knowledge on molecular characteristics allowing for a better 
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understanding of the mechanisms and subtypes of cell death. Accordingly with the 
Nomenclature Committee on Cell Death (NCCD) (2015), the main subdivisions for cell death are 
“accidental” and “regulated” (Galluzzi et al., 2014). The first one, it is a consequence of physical, 
chemical or mechanical damage, and it cannot be prevented or stopped. Cells dying in this way 
release damage-associated molecular patterns (DAMPs) which can be recognized by cells of the 
immune system and trigger cytotoxic responses. The regulated (including programmed) types 
of cell death have well defined molecular machinery. They are triggered due to unsuccessful 
efforts to restore cellular homeostasis or as part of developmental evolution of an organism. 
Alterations in the signalling pathways that control regulated cell death have been associated 
with several diseases including autoimmunity, infectious diseases and cancer. Some of the 
regulated types of cell death that have being described include apoptosis, necroptosis (a 
regulated subtype of necrosis), autophagy, pyroptosis, ferroptosis, among others (Table 3.1) 
(Galluzzi et al., 2014; Kolb et al., 2017). The molecular pathways of some of them are closely 
related as is the case for apoptosis and necroptosis, the two types of cell death that will be 
discussed in this section.   
3.1.1.1 Apoptosis 
Apoptosis was the first type of cell death officially described in early 1970s. It means “falling off” 
in ancient Greek, and it was characterized by cytoplasmic decline, chromatin condensation, 
nuclear fragmentation, but most notoriously by the formation of discrete bodies enclosing 
cytoplasmic content (Elmore, 2007; Galluzzi et al., 2014). It was this last characteristic that 
defined apoptosis as a “controlled” type of cellular suicide that restricts the spilling of DAMPs 
and triggering of unwanted inflammatory responses. Apoptosis is not only activated because of 
damaged cells, but it is also essential to maintain homeostasis in cellular populations and as a 
developmental mechanism of tissue rearrangement. Two main ways of activation are described 
for apoptosis, an intrinsic pathway and an extrinsic pathway which are promoted by intracellular 
and extracellular signals respectively. Intrinsic apoptosis is initiated by cytochrome c and other 
molecular mediators released from the outer mitochondrial membrane (Tait and Green, 2010). 
It depends on a loss in balance between proapoptotic and antiapoptotic signals from the BCL2 
family of proteins, important in regulation of cell fate (Siddiqui, Ahad and Ahsan, 2015). 
Intracellular stress signals like DNA damage, accumulation of damaged proteins, hypoxia among 
others, trigger the permeabilization of mitochondrial membrane and tilts the balance towards 
proapoptotic signals. Once released, cytochrome c activates downstream signalling through the 
adaptor APAF-1 and caspase-9 which ultimately turns on effectors caspases like caspase-3 and 




Type of cell 
death 
Triggers Mediator and effector 
molecules 
Final cellular events 
Apoptosis Intrinsic: developmental 
signals or stress-induced 
stimuli. 
Extrinsic: ligands to 
extracellular death 
receptors (DRs) such as 




members of the BCL2 
family, 
initiator caspases 
(caspase-2, -8, and -9) 
and executioner 
caspases (caspase-3, -















deprivation or chemical 
fluctuations. 
Inhibited by the mTOR 
complex, class III 
phosphoinositide 3-
kinase (PI3K) complex 
(Beclin1, VPS34 (the 
class III PI3K), and 
VPS15). Effectors: 




disruption of the 
endoplasmic reticulum 
and focal swelling up 
of perinuclear space.  
Ferroptosis Accumulation of toxic 
radicals.  
Erastin and RSL3. 
Iron-dependant 
oxidative stress in the 
cell with increase of 
reactive oxygen 
species (ROS) and lipid 
peroxide species. 
Condensation, rupture 
and shrinkage of the 
mitochondria. 
Potentially membrane 
rupture (yet to be 
confirmed, described 
as released of DAMPs). 
Necroptosis RHIM-containing proteins 
like TLR adapter TRIF and 
the DNA sensor DAI. 
Ligands to extracellular 
death receptors (DRs) 
such as TNF, TRAIL, CD95L 
or FasL. 













pore formation and 





Table 3.1 Types of programmed cell death and their corresponding triggers, molecular 
mediators and effectors, and final cellular events. DAMPs, damage-associated molecular 
patters; NLRs, nucleotide-binding oligomerization domain-like receptors; TLR, Toll-like receptors 






Figure 3.1 Intrinsic and extrinsic pathways of apoptosis.  
Two main types of apoptosis pathways have been described: (A) intrinsic apoptosis where 
intracellular signals like DNA damage or endoplasmic reticulum (ER) stress trigger a signalling 
cascade dependent on permeabilization of the mitochondrial outer membrane and release of 
cytochrome c and other factors like SMAC and OMI (inhibitors to X-linked inhibitor of apoptosis 
protein - XIAP). A strict balance between pro-apoptotic and anti-apoptotic members of the B cell 
lymphoma 2 (BCL-2) family determines mitochondrial permeabilization. In the cytosol, 
cytochrome c interacts with apoptotic protease-activating factor 1 (APAF1) initiating the 
formation of an apoptosome, and a subsequent cascade of activated caspases that ultimately 
leads to cell demise. (B) extrinsic apoptosis activated by extracellular signals mainly mediated 
by stimulation of death receptors. Activation of the later recruits FAS-associated death domain 
protein (FADD), RIP1 and procaspase 8. This complex, also known as ripoptosome, mediates 
caspase 8 activation and the cascade of caspase signalling (Adapted from Tait & Green, 2010).  
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External signals can also stimulate apoptosis by means of death receptors in the extrinsic 
pathway (Figure 3.1B). Tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand 
(TRAIL), and CD95 (Fas/Apo1) are some of the best described activators of death receptors 
(Wilson, Dixit and Ashkenazi, 2009; Walczak, 2011; Fulda, 2015; Kolb et al., 2017). Engagement 
of death receptors trigger aggregation of protein complexes at their intracellular domain 
inducing the formation of a multiprotein complex known as death-inducing signalling complex 
(DISC) or ripoptosome. Binding of TNF to TNFR1 recruits a series of proteins to its intracellular 
domain, including TNFR1-associated death domain protein (TRADD) and RIP1. Subsequently, E3 
ubiquitin ligases such as TRAF2 and cIAPs1/2 interact with RIP1 mediating its ubiquitination and 
downstream activation of NF-B as described previously (See Section 1.1.1.2) (Wilson, Dixit and 
Ashkenazi, 2009). However, deubiquitination of RIP1  mediated by enzymes CYLD or A20, or 
absence of cIAPs, blocks RIP1-dependant activation of NF-B (Declercq, Vanden Berghe and 
Vandenabeele, 2009; Wilson, Dixit and Ashkenazi, 2009; Humphries et al., 2014). 
Deubiquitinated RIP1 can then bind to Fas-associated death domain (FADD) and procaspase 8 
to form the ripoptosome (Micheau and Tschopp, 2003; Wang, Du and Wang, 2008). In the 
ripoptosome procaspase 8 is processed to caspase 8 initiating a caspase cascade that leads to 
cell demise by apoptosis (Figure 3.1B) (Wilson, Dixit and Ashkenazi, 2009). There are multiple 
levels of regulation for the apoptotic pathway. One of them is the absence of cellular inhibitor 
of apoptosis protein 1 and 2 (cIAP1/2), which normally mediate TNFα dependant inflammation 
by ubiquitinating RIP1 (For detailed explanation on cIAP1/2 mediated TNF-signalling see section 
1.1.1.2 of this thesis) (Wang, Du and Wang, 2008; Haas et al., 2009; Feoktistova et al., 2011; 
Tenev et al., 2011; Huang et al., 2015; Vasudevan and Ryoo, 2015). Another one is the targeting 
of RIP1 by the Pellino 3 E3 ubiquitin ligase that blocks ripoptosome formation induced by TNF 
signalling and consequently activation of apoptosis (Yang, Wang, Tang, et al., 2013). Even though 
the extrinsic and intrinsic pathways initiate apoptosis in different ways, the final executor 
molecules are the same caspases (Figure 3.1). Caspases are the core intermediary proteins of 
cell death by apoptosis. They are not only mediators in the signalling cascades in apoptosis, they 
are also their executioners. Caspases are a family of cysteine proteases usually subdivided into 
initiator (caspase-2, -8, and -9), executioner (caspase-3, -6, and -7) and inflammatory (human 
caspase-1, -4, and -5) caspases (Elmore, 2007; Shalini et al., 2015; Kolb et al., 2017). Initiator 
caspases are activated by dimerization and autocatalytic cleavage while executioner caspases 
gain their proteolytic activity by cleavage and conformational changes (Boatright et al., 2003; 
Kolb et al., 2017). Once active, executioner caspases cleave over 600 cellular substrates which 
coordinate dismantling of crucial cellular organelles and structures (Taylor, Cullen and Martin, 
2008; Creagh, 2014). Apoptosis has been described as a “silent” type of cellular death, because 
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one of its main characteristics is the packing of potentially immunogenic cellular content in 
plasma membrane bodies to avoid activation of inflammatory signals (Taylor, Cullen and Martin, 
2008; Kolb et al., 2017). Interestingly, other types of regulated cell death have the opposite 
function triggering inflammatory responses, with necroptosis being of major current interest. 
3.1.1.2 Necroptosis 
Contrary to apoptosis, necroptosis has been mainly described as a pro-inflammatory type of cell 
death. It was described 10 years ago by Hitomi and co-workers as a new form of cell death 
resembling necrosis, the classical type of accidental cell death, and therefore it was named 
accordingly (Galluzzi and Kroemer, 2008; Hitomi et al., 2008). Necroptosis is a lytic form of cell 
death where cells swell, the plasma membrane is disrupted, and intracellular content is spilled 
releasing DAMPs, just as in necrosis (Galluzzi and Kroemer, 2008). However, a genome-wide 
siRNA screen for genes regulating the response to death receptors for FasL and TNFα proved it 
to be a tightly regulated process. Up to 432 genes were recognized in the screen as regulators 
of necroptosis (Hitomi et al., 2008). The researchers identified an extensive signalling network 
including genes related to RIP1 kinase activity, death receptor activation, and innate immunity 
regulation. Further studies have expanded the knowledge on other types of regulated necrosis 
and described their triggers and specific molecular mechanisms (Vanden Berghe et al., 2014). 
Proteins containing RHIM domains (like RIP1, RIP3, TLR adapter TRIF and DNA sensor DAI) have 
been identified as important triggers of necroptosis (Upton, Kaiser and Mocarski, 2012; Kaiser 
et al., 2013). Activation of the RHIM-domain proteins is initiated by several pathways including 
agonists for TNFR family of death receptors (TNFR, FASL/ APO‑1L, TRAIL, TWEAK), TLRs (TLR3 or 
TLT4), interferons (IFNs), virus‑mediated activation of DNA‑dependent activator of 
IFN‑regulatory factors (DAI), retinoic acid inducible gene I (RIG‑I)‑like receptors (RLRs) as well as 
genotoxic stress and polyclonal stimulation of T cell receptor (TCR) (Figure 3.2) (Upton, Kaiser 
and Mocarski, 2012; Kaiser et al., 2013; Thapa et al., 2013; Dillon et al., 2014; Vanden Berghe et 
al., 2014). However, the best-known signalling mechanism is the one mediated by death 
receptor TNFR1.  
Signalling triggered by TNFR1 mediates several different responses in the cell depending 
on the molecular context or the type of cell. Inflammation mediated by TNFα has been broadly 
described as depending on RIP1 ubiquitination facilitated by E3 ligases like cIAP1/2, TNF 
receptor-associated factor 2 (TRAF2) or TRAF5 (For detailed explanation on TNFα and TNFR1 
signalling see section 1.1.1.2 of this thesis) (Wang, Du and Wang, 2008; Haas et al., 2009; Gyrd-





Figure 3.2 Triggers of necroptosis.  
Several triggers of necroptosis have been described, including many members of the TNFR family 
(like TNFR, FASL/APO‑1L, TRAIL and TWEAK), TLR3/4, (RIG‑I)‑like receptors (RLRs), IFN-like 
receptors, or even genotoxic stress, polyclonal stimulation of TCR (T cell receptor), 
virus‑mediated activation of DNA‑dependent activator of IFN‑regulatory factors (DAI) or 
anticancer drugs. Triggering of any of these signalling pathways when caspases are inhibited, 
allows for RIP3 activation and formation of a necrosome where MLKL is recruited, 
phosphorylated and mediates the lysis of the plasma membrane (Adapted from Vanden Berghe 





RIP1, in its unubiquitinated form, binds the ripoptosome and triggers the caspase-mediated 
apoptotic pathway as described previously. Furthermore, when RIP1 cannot be ubiquitinated 
and the caspases are absent or inactive, RIP1 can interact with RIP3 through their RHIM domains 
creating an amyloid structure also known as the necrosome (Cho et al., 2009; Li et al., 2012; 
Vanden Berghe et al., 2014; Wu et al., 2014; Almagro and Vucic, 2015). It was later described 
that RIP1-RIP3 interaction was required to facilitate RIP3 homo-interaction and auto-
phosphorylation (Wu et al., 2014). An extensive amount of evidence came to light supporting 
the essential role of RIP3 and its kinase activity in necroptosis (Cho et al., 2009; He et al., 2009; 
Zhang et al., 2009; Newton et al., 2014). Necrosome formation and RIP1-RIP3 interaction within 
it, allows the recruitment and phosphorylation of mixed lineage kinase domain-like protein 
(MLKL) (Sun et al., 2012; Rodriguez et al., 2016). Further research showed MLKL is the central 
effector molecule of necroptotic cell death since MLKL-deficient mice are resistant to this type 
of regulated cell death (Murphy et al., 2013; Wu et al., 2013). Sun and co-workers (2012), using 
a small molecule known as necrosulfonamide, that inhibits necroptosis downstream of RIP3, 
described some of the main characteristics of MLKL and its interaction with RIP3. They showed 
it is a pseudokinase which binds to RIP3 through its C-terminal kinase-like domain, and the 
binding depends on phosphorylation of RIP3 in S227 (Sun et al., 2012). Once phosphorylated, 
MLKL undergoes homo-oligomerization and translocates to the plasma membrane (Sun et al., 
2012; Dondelinger et al., 2014). In the membrane, MLKL alters cellular ion homeostasis by 
binding to phosphatidylinositol phosphates (PIPs) and triggers osmotic cell membrane rupture 
(Dondelinger et al., 2014; Wang et al., 2014). All necroptotic stimuli induce formation of the 
necrosome and promote phosphorylation of RIP3 and MLKL with the subsequent rupture of the 
membrane. However, some of them are independent of TNFR signalling as is the case with 
TLR3/4 and DAI induced-necroptosis (Upton, Kaiser and Mocarski, 2010, 2012; He et al., 2011; 
Kaiser et al., 2013). In the case of TLR3/4-induced necroptosis, RIP3 interacts with the RHIM 
domain in the adapter protein TRIF as a platform for necrosome formation (He et al., 2011; 
Kaiser et al., 2013). In a similar way, the DNA-sensing receptor DAI also binds to RIP1 and RIP3 
through the RHIM domain to activate NF-B signalling but its necroptotic activity relies only in 
its binding to RIP3 (Kaiser, Upton and Mocarski, 2008; Upton, Kaiser and Mocarski, 2010, 2012). 
Considering necroptosis spills DAMPs as a consequence of membrane rupture, it has 
been typically described as a pro-inflammatory type of cell death. In that sense it has been 
suggested that necroptosis may play roles in the pathogenesis of inflammatory diseases like 
colitis, skin inflammation, retinal degeneration, acute pancreatitis and in transplant rejections 
(Kaczmarek, Vandenabeele and Krysko, 2013; Pasparakis and Vandenabeele, 2015). However,  it 
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has also been suggested that necroptosis can regulate inflammation by clearing cells and 
removing pathogens and so limiting their replicative environments (Kaczmarek, Vandenabeele 
and Krysko, 2013; Kearney et al., 2015). Certainly, necroptosis is an important regulatory 
mechanism of innate immunity and inflammation. In that sense, a complete understanding of 
its molecular signalling and how it is regulated becomes necessary. Given RIP Kinases play such 





3.1.2 Protein kinases of the receptor interacting protein (RIP) family 
The receptor-interacting protein (RIP) kinase family of proteins have an essential role in 
activation of immune responses and regulation of cell death (Declercq, Vanden Berghe and 
Vandenabeele, 2009; Zhang, Lin and Han, 2010; Humphries et al., 2014). They mediate 
important signals of intracellular and extracellular stress. A homologous N-terminal kinase 
domain is the common feature of the seven members of this family which contain other specific 
functional domains (Figure 3.3) (Zhang, Lin and Han, 2010; Humphries, 2012). Those specific 
domains, located at the C-terminal portion of the proteins in most of the family members, seem 
to underpin the functional diversity of the RIP family. From the seven members, RIP1 to 3 are 
the best known in terms of functional relevance and molecular signalling, while research on RIP4 
to 7 is just in its infancy. RIP1 was the first member of the kinase family to be described in 1995 
with a death domain (DD) as its main characteristic (Meylan and Tschopp, 2005). This domain 
facilitates RIP1 interaction to death receptors containing a similar domain, like FASL/ APO‑1L 
and TNFR, hence its vital role in regulated cell death signalling (Stanger BZ et al., 1995; Hsu et 
al., 1996). RIP1 also contains an intermediate domain that facilitates its interaction with TNF-
receptor-associated factor (TRAF)-1, -2 and -3 (Hsu et al., 1996; Meylan and Tschopp, 2005). 
Additionally, RIP1 shares a C-terminal RIP homotypic interaction motif (RHIM) domain with RIP3, 
which allows them to bind and initiate necroptosis (see section 3.1.1.2 Necroptosis). Another 
member of the family, RIP2, bears a CARD domain associated to caspase activation and 
recruitment (Meylan and Tschopp, 2005). Like RIP1, RIP2 has an intermediate domain which 
facilitates its interaction with many TRAF members (Zhang, Lin and Han, 2010). RIP4 and RIP5 
also contain intermediate domains as well as ankyrin motifs. The last two members, RIP6 and 
RIP7, have been described to carry ankyrin, leucine-rich repeat and Roc/COR domains. (Meylan 
and Tschopp, 2005; Zhang, Lin and Han, 2010; Humphries et al., 2014). Even though the 
structure of all the RIP family members is well known, the functional and physiological relevance 
of RIP4-7 is still under research. Some of them have been linked to activation of NF-B (RIP4), 
induction of apoptosis (RIP5) and recognition of DAMPs or PAMPs (RIP6/7) (Humphries et al., 
2014). Considering the interest of this thesis is regulated cell death, our focus will be on RIP1 
and RIP3 signalling. 
Given RIP1 was the first member of the RIP kinase family described more than 20 years ago, 
its interaction with cell death receptors and downstream signalling pathways have been 
extensively studied. Post-translational modifications of RIP1 are essential to determine its role 
as a pro-inflammatory signal activating mitogen-activated protein kinases (MAPKs) and NF-κB, 





Figure 3.3 Structure of the RIP kinase family.  
The domain structures of members of the RIP kinase family are indicated. Roc, Ras of complex 






activation of TNF-R1 by TNF recruits TNF-R1-associated death domain protein (TRADD) and RIP1 
through its death domain (Hsu et al., 1996). Subsequently, a number of E3 ubiquitin ligases like 
TRAF2/5 and cIAP1/2 bind to RIP1 and mediate the attachment of a polyubiquitin chain to lysine 
63 (K63) (Devin et al., 2000; Lee et al., 2004; Bertrand et al., 2008; Mahoney et al., 2008; 
Varfolomeev et al., 2008). Furthermore, RIP1 has been suggested to further induce its auto- 
phosphorylation and ubiquitination in response to TNF signalling (Lee et al., 2004). Once 
polyubiquitinated, RIP1 binds the ubiquitin-binding domains of proteins that associate with IB 
kinase (IKK) and TAK1 (Devin et al., 2000; Chen, 2005). TAK-1 then facilitates activation of IKKs 
by phosphorylation triggering a signalling cascade that will allow translocation of NF-B to the 
nucleus and induction of pro-inflammatory genes (Chen, 2005; Mercurio et al., 2018). 
Deubiquitination of RIP1 by the deubiquitinases cylindromatosis (CYLD) and A20 or depletion of 
cIAP1/2 by mediators of depletion like Smac mimetics, switches RIP1 towards cell death 
mechanisms (Mahoney et al., 2008; Varfolomeev et al., 2008; Declercq, Vanden Berghe and 
Vandenabeele, 2009; Wilson, Dixit and Ashkenazi, 2009). The deubiquitinated form of RIP1 can 
then interact with Procaspase 8 and FADD in the ripoptosome or interact with RIP3 in the 
necrosome (under conditions of caspases depletion) as it was described previously. It is clear 
that the ubiquitination status of RIP1 plays a critical role in determining the downstream 
consequences of RIP1 engagement and so much interest has focused on identifying the E3 
ubiquitin ligases that catalyse RIP1 ubiquitination. In addition to TRAFs and cIAP E3 ligases,  Yang 
and co-workers described how Pellino 3, another E3 ubiquitin ligase, interacts with RIP1 
affecting its capacity to bind the ripoptosome and thereby reducing TNFα-induced apoptosis 
(Yang, Wang, Tang, et al., 2013).  
In addition to TNFR-dependant activation of pro-inflammatory and cell death pathways, 
RIP1 and RIP3 are also crucial players in TLR signalling pathways, especially those triggered by 
TLR3 and TLR4. Both of these receptors use an adaptor protein named TRIF to activate NF-B 
signalling when stimulated (Yamamoto et al., 2002; Sato et al., 2003; Cusson-Hermance et al., 
2005). TRIF recruits RIP1 through their common RHIM domain as part of the signalling activating 
NF-B (Meylan et al., 2004; Cusson-Hermance et al., 2005). RIP1 ubiquitination is also necessary 
in TRIF-mediated activation of NF-B, and it has been described that Pellino 1, another member 
of the Pellino E3 ligase family, is responsible for its post-translational modification in the context 
of TLR3 and TLR4 signalling (Chang, Jin and Sun, 2009). In a similar way to TNFR-dependant 
signalling, in the absence of caspases, the adaptor TRIF can bind directly to RIP3 through the 
RHIM domain and, thereby, initiate necroptosis by stimulation of TLR3 and TLR4 (He et al., 2011; 
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Kaiser et al., 2013). Clearly, the E3 ubiquitin ligase Pellino family has an important role in 
regulation of RIP kinases, therefore, their interaction will be discussed next.  
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3.1.3 E3 ubiquitin ligase Pellino family 
3.1.3.1 Ubiquitin enzyme system 
The regulation of protein degradation is critically important in controlling cell signalling 
pathways. Multiple proteins are implicated in the complex system that mediates recognition, 
labelling and subsequent degradation of the proteins to be discarded. This set of proteins and 
molecular mechanism is known as the ubiquitin proteasome system (UPS) (Komander and Rape, 
2012; Inobe and Matouschek, 2014). Proteins to be degraded are labelled with ubiquitin tags or 
degrons. Ubiquitination is not only a signal to degrade or not degrade a protein, the nature and 
complexity of the labelling also indicates the order and time of degradation (Deshaies and 
Joazeiro, 2009). The covalent binding of polypeptide chains of ubiquitin, a 76 amino acids 
protein, to the -amino group of  lysine residues in target proteins allows for their proteasome 
recognition and degradation (Ravid and Hochstrasser, 2008; Komander and Rape, 2012). 
Diversity of branched or linear polyubiquitin chains and the specific lysine or other residue 
where it is attached determines whether target proteins are marked for degradation or as 
signalling-related modification (Ravid and Hochstrasser, 2008; Ernst et al., 2013; Swatek and 
Komander, 2016). For example, Lys48-linked polyubiquitin chains are usually associated with 
proteasomal degradation while Lys63-linked chains are described as anchor site for signalling 
complexes (Swatek and Komander, 2016). A group of enzymes catalyze the sequential process 
of ubiquitylation: ubiquitin activating enzymes (E1), ubiquitin conjugating enzymes (E2) and 
ubiquitin ligases (E3) (Figure 3.4A) (Komander and Rape, 2012). Activating enzymes (E1) forms 
a thioester bond with ubiquitin in an ATP-dependent way, then conjugating (E2) enzymes accept 
the ubiquitin from E1. Finally, E3 ubiquitin ligases recognizes the target protein and binds the 
ubiquitin-loaded E2 enzyme, to then catalyze the attachment of polyubiquitin chains (Deshaies 
and Joazeiro, 2009). Proteins can be ubiquitinated in different residues as it is the example of 
RIP1 that can be ubiquitinated in seven different residues depending on its interaction with 
specific E2-E3 ligases (Figure 3.4B). E2-E3 complexes are responsible for the diversity in the 
modification on target proteins (Metzger et al., 2014). While only 2 subtypes of E1 enzymes have 
been described approximately 40 E2s and between 500 and 1000 human E3s are recognized 
(Pelzer et al., 2007; Komander and Rape, 2012; Stewart et al., 2016; Swatek and Komander, 
2016). E3 ligases are a highly conserved, wide and diverse group of enzymes. In eukaryotes, 
mainly two types are recognized: HECT or RING domain. Up to 616 different types of RING 
domain ligases have been described to be expressed in human cells (Deshaies and Joazeiro, 
2009; Komander and Rape, 2012). Considering the Pellino E3 ligase family has been linked to RIP 






Figure 3.4 The ubiquitylation pathway.  
(A) The ubiquitylation pathway mediates the binding of a isopeptide chain made of ubiquitin to 
a target protein as a mark for proteasome-dependent degradation or as a post-translational 
modification to regulate its function, structure or location. The polyubiquitin chains are mostly 
attached to lysine residues in the C-terminal portion of the target protein. The complexity and 
nature of the polyubiquitin chain and the residue where it is attached determines the biological 
function of the mark. For example, Lys48-linked ubiquitin chains is a signal for proteasomal 
degradation while Lys63-linked chains facilitates the formation of signalling complexes. This 
process is catalyzed by a series of enzymes known as ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2), and a ubiquitin ligase (E3). E1 and E2 facilitate the binding and loading 
of ubiquitin molecules while E3 ligases catalyze the ligation of the same to target proteins 
(Adapted from Moynagh, PN. 2014). (B) Example of the different point of ubiquitination of RIP1. 
RIP1 can be ubiquitinated in seven residues in its kinase, intermediate and C-terminal death 
domain. RIP1 can also be post-translationally modified by phosphorylation and acetylation. It 
has been described that ubiquitin-binding the death domain are essential for signalling associate 
to the death receptor and the apoptotic pathway, while ubiquitin-binding the intermediate 





3.1.3.2 Pellino family 
Pellino proteins form a family of  E3 ubiquitin ligases with a C-terminal RING domain and a N-
terminal forkhead-associated (FHA) domain containing wing structures specific to this family 
(Figure 3.5) (Lin et al., 2008; Moynagh, 2014). The RING-domain has been indicated as the 
portion of the protein responsible for the E3 ubiquitin catalytic activity mediating the Lys11, 
Lys48 or Lys63 polyubiquitination of target proteins while the FHA-domain recognizes and binds 
phosphorylated targeted proteins (Moynagh, 2014). Three members have been identified in 
mammalians: Pellino 1, Pellino 2 and Pellino 3 (L. E. Jensen and Whitehead, 2003; Liselotte E. 
Jensen and Whitehead, 2003; Strelow, Kollewe and Wesche, 2003; Moynagh, 2014). 
Interestingly, Pellino proteins were first identified as scaffold proteins in TLR/IL-1R signalling, 
interacting with interleukin-receptor-associated kinase (IRAK) and MAPKs (L. E. Jensen and 
Whitehead, 2003; Liselotte E. Jensen and Whitehead, 2003; Strelow, Kollewe and Wesche, 2003; 
Butler, Hanly and Moynagh, 2005). Later, it was described that they have E3 ubiquitin ligase 
functions with Pellino-mediated ubiquitination of IRAK1 being demonstrated in vitro 
(Schauvliege, Janssens and Beyaert, 2006; Butler, Hanly and Moynagh, 2007). All members of 
this family can interact with several E2 enzymes to mediate Lys11-, Lys48- and Lys63-linked 
polyubiquitin chains (Ordureau et al., 2008). Activation of Pellino’s E3 ligase activity seems to be 
specific to the signalling pathway being initiated. IRAK proteins have been described to 
meditated Pellino phosphorylation and activation  in the context of IL1 stimulation while 
TBK1/IKKε-mediated phosphorylation of Pellinos has been associated to TNFR1 and TLRs 
signalling pathways  (Devin et al., 2000; Chen and Goeddel, 2002; Goh et al., 2012). 
The Pellino family of E3 ligases has been shown to interact with RIP kinases family in a 
context-dependent way. Pellino 1 has proven to mediate Lys63 polyubiquitination of RIP1 in a 
TRIF-dependant way in macrophages activated through TLR3 or TLR4 (Chang, Jin and Sun, 2009). 
Ubiquitination of RIP1 in Lys63 allows for the recruitment of transforming growth factor b-
activated kinase 1 (TAK1) which associates and phosphorylates the IB kinase (IKK) complex 
releasing NF-B (See sections 1.1.1.2 and 1.1.2.2 from general introduction) (Devin et al., 2000; 
Chen, 2005; Chang, Jin and Sun, 2009; Mercurio et al., 2018). Interestingly, Pellino 3 also 
interacts with RIP1 but in a completely different context. Pellino 3 deficiency sensitizes cells to 
TNF-induced apoptosis (Yang, Wang, Tang, et al., 2013). Yang and co-workers (2013) described 
a Pellino 3 FHA domain-dependant interaction with RIP1 triggered by TNF signalling which 
restricts RIP1 binding to FADD and pro-caspase 8 and therefore ripoptosome formation. It is to 
note that Pellino1 and Pellino 3 interact with RIP1 in a domain-specific way to trigger two 





Figure 3.5 Pellino domain structure.  
This E3 ligase family contains a core forkhead‑associated (FHA) domain with two inserts that 
form a ‘wing’ and a RING‑like domain. The sites for ubiquitylation (Ub), sumoylation (Su) and 
phosphorylation (P) are indicated based on their corresponding sites of occurrence in Pellino 1. 
Sites phosphorylated particularly by interleukin‑1 receptor‑associated kinase (IRAKs) and 
TANK‑binding kinase 1 (TBK1) are in the wing domain at the N-terminal portion of the protein. 
The green stars specify phosphorylation sites that fully activate the E3 ubiquitin ligase activity of 
Pellino 1. Addition of phosphate molecules into those particular phosphorylation sites facilitates 
a conformational change in the structure of Pellino proteins allowing its interaction with E2 
ligases and the target protein, and therefore mediating its functional activation (Adapted from 





Pellino 3 regulating a type of cell death. Furthermore, Pellino 3 has been linked to RIP2 kinase in 
a model of experimental colitis. In this model, Pellino 3 was showed to mediate the response of 
the intracellular receptor NOD2 by enabling Lys63 polyubiquitination of RIP2  (Yang, Wang, 
Humphries, et al., 2013). NOD1 and NOD2 are members of the pattern recognition receptors 
(PRRs) and recognize bacterial peptidoglycans (Kumar, Kawai and Akira, 2011). NOD2 signalling 
requires RIP2 ubiquitination by Pellino 3 and X-Linked Inhibitor of Apoptosis Proteins (XIAPs) 
leading to recruitment of TAK1 and IKK complexes and activation of NF-B and MAPKs 
(Humphries et al., 2014). Ubiquitination of RIP2 is essential for NOD2 signalling and its activation 
of NF-B (Yang et al., 2007; Hasegawa et al., 2008). Whilst Pellinos play roles in inflammation 
and in the case of Pellino 3 in apoptosis there are emerging reports for a role for Pellino 1 in 
necroptosis. Pellino 1 has been recently described to modulate necroptosis signalling by 
regulating both RIP1 and RIP3 (Wang et al., 2017; Choi et al., 2018). The latter report shows that 
ubiquitination of RIP1 by Pellino 1 is indispensable for its interaction with RIP3 and the 
subsequent formation of the necrosome and consequently initiation of necroptosis. 
Contrastingly, Choi and co-workers recently reported that Pellino 1 is a negative modulator of 
necroptosis by mediating the degradation of RIP3 (Choi et al., 2018). The basis to these 
contrasting reports are unknown. The initial studies in this thesis explore the role of Pellino 2 







3.2.1 Effect of Pellino 2 and/or Pellino 3 deficiency on TNFα-induced necroptosis in Mouse 
Embryonic Fibroblast (MEFs) 
Considering Pellino 3 has been proven to regulate RIP1 and RIP2, and knowing RIP kinases are 
essential mediators of cell death, the present Chapter aimed to explore the role of Pellino 3 and 
another family member Pellino 2 in the regulation of necroptosis (Yang, Wang, Humphries, et 
al., 2013; Yang, Wang, Tang, et al., 2013; Humphries et al., 2014). As previously described, 
necroptosis is a type of necrosis tightly regulated and dependent on interaction between RIP1 
and RIP3 (Hitomi et al., 2008; Vanden Berghe et al., 2014; Silke, Rickard and Gerlic, 2015). In 
order to study necroptosis, cells are treated with a combination of two different inhibitors (Z-
VAD and BV6) for 1 hour and then stimulated with TNFα for 6 or 24 hours. Z-VAD is a well-known 
pancaspase inhibitor and BV6 inhibits cellular IAPs by inducing their autoubiquitination and 
subsequent degradation by the proteasome (Müller-Sienerth et al., 2011; Vasudevan and Ryoo, 
2015). The blockade of cIAP–mediated ubiquitination of RIP1 prevents the latter from promoting 
downstream activation of NF-B and instead directs it to cell death pathways. However, Z-VAD 
prevents apoptosis and instead RIP1 interacts with RIP3 to trigger the signalling cascade for 
necroptosis. Phosphorylation of MLKL, the main effector molecule for necroptosis, as well as 
decrease in RIP1 expression and upward shift of RIP3 due to phosphorylation are expected as 
manifestation of this cell death mechanism.  
The first study explored the role of Pellino 2 in regulating TNF-induced necroptosis in 
murine embryonic fibroblasts (MEFs). WT or Pellino 2-deficient MEFs were treated alone or in 
combination with TNFα, Z-VAD and BV6 for an acute period of 6 hours. The combination of all 3 
treatments promoted high levels of P-MLKL consistent with this treatment regime causing 
necroptosis in MEFs (Figure 3.6A). Indeed, low levels of P-MLKL were also apparent when cells 
were treated only with BV6 and TNFα, indicating some necroptosis even in the absence of 
suppression of caspase activity. As for the RIP kinases, levels of RIP1 decreased with the different 
combinations of inhibitors, with the RIP1 immunoreactive band almost disappearing with Z-VAD, 
BV6 and TNFα. Meanwhile, RIP3 expression was evident for all the combinations of treatments. 
However, when the cells were driven toward necroptosis with all 3 agents, an upward shift was 
evident for RIP3, possibly due to changes in size derived from its phosphorylation and 
subsequent formation of the necrosome complex. Similar patterns of expression of P-MLKL, RIP1 





Figure 3.6 Pellino 2 deficiency has moderate effect on molecular markers of necroptosis 
induced with TNFα in murine embryonic fibroblasts (MEFs). 
Immunoblot analysis of phosphorylated (p-) MLKL (54 kDa) and total levels of RIP1 (74 kDa) and 
RIP3 (46-53 kDa) in cell lysates from WT and Peli2–/– MEFs pre-treated with 20 μM Z-VAD for an 
hour and stimulated with 10 μM BV6 and 40 ng/mL TNFα for (A) 6 hrs and (B) 24 hrs. GAPDH (37 
kDa) was used as constitutively expressed housekeeping protein. Data are representative of 






levels of P-MLKL in Peli2-/- MEFs in response to all 3 treatments were slightly less than 
corresponding samples from WT cells suggesting that Pellino 2 may play some modest part in 
TNF-induced necroptosis (Figure 3.6A). Variations in the levels of housekeeping molecules like 
β-actin and GAPDH were apparent in experiments, specifically at long time points with combined 
treatment. However, considering cells were being driven towards cell death, these observations 
were anticipated as proteins were degraded and cellular content lost.  
Similar experiments were also performed in which MEFs from WT and Peli2-/- MEFs were 
exposed to the different treatments for a longer period of 24 hours (Figure 3.6B). Similar profiles 
were observed as described above for 6h exposure to the various treatments. However, WT and 
Peli2-/- MEFs displayed the same responsiveness to the treatments suggesting that Pellino 2 is 
not involved in TNF-induced necroptosis over a more prolonged time frame. In addition to 
measuring molecular markers for necroptosis, the same model of treatment was used to 
measure cytotoxicity by assaying cell supernatants for levels of lactate dehydrogenase (LDH) 
that were released by dying cells. In this case, not only BV6 was used, but other two IAPs 
inhibitors (LCL161 and Birinapant) were tested to compare the effects of their inhibitory 
affinities for IAPs in the induction of cell death. Cellular IAPs 1 and 2 (cIAP1/2), and X-linked IAPs 
(XIAPs), have been described to regulate effector caspases and apoptosis and also TNFα and 
TLRs-mediated signalling (Vasudevan and Ryoo, 2015). The three IAPs inhibitors used in this 
research have been reported to have specific affinities for the two types of IAPs (cIAPs and 
XIAPs). BV6 blocks c-IAPs 1 and 2 but not XIAPs, whilst Birinapant targets  c-IAPs and XIAPs but 
with lower affinity for the latter (Condon et al., 2014; Lawlor et al., 2015). On the other hand, 
LCL161 displays high affinity for c-IAPs 1 and 2 and XIAP (Lawlor et al., 2015). To compare the 
cytotoxicity induced by the inhibitors, WT and Peli2-/- MEFs were treated with Z-VAD and either 
LCL161, BV6 or Bririnapant for 1 hour and then stimulated with TNFα for 24 hours (Figure 3.7). 
Treatment of WT cells with LCL161 alone was seen to induce cytotoxicity up to 50%, while the 
combined treatment of LCL161 with TNFα increased it to 60% and with Z-VAD and TNFα to 
approximately 65% (Figure 3.7A). Peli2-/- MEFs showed the same pattern of cytotoxicity as seen 
in WT when treated with LCL161 or any of the combined treatments with Z-VAD and TNFα. In 
contrast, cytotoxicity levels for WT MEFs treated with BV6 were low (approximately 20%) but 
when combined with TNFα or Z-VAD and TNFα considerably increased up to 70% and 80% 
respectively (Figure 3.7B). Pellino 2 deficient cells treated with BV6 or Z-VAD, BV6 and TNFα 
showed the same percentages of cytotoxicity as WT cells. However, there was a small reduction 
of up to 10% when the Peli2-/- MEFs were treated with BV6 and TNFα compared with WT cells. 





Figure 3.7 Pellino 2 deficiency does not affect TNF-induced necroptosis as measured by release 
of lactate dehydrogenase in MEFs. 
Cytotoxicity analysis by assay of LDH release in supernatant from WT and Peli2–/– MEFs pre-
treated with 20 μM Z-VAD for an hour and stimulated with 40 ng/mL TNFα and (A) 10 μM BV6, 
(B) 10 μM LCL161 or (C) 10 μM Birinapant (Birina) for 24 hrs. Data are presented as the mean ± 
SEM of two independent experiments. Maximum release of LDH was stablish for each biological 
























































































































































































TNFα or Z-VAD and TNFα the percentages were 60% and 50% respectively. However, Pellino 2 
deficient cells showed the same levels of cytotoxicity as WT cells with a minor decrease when 
cells were treated with Birinapant and TNFα. All together these results question the role, if any, 
of Pellino 2 in TNF-induced necroptosis. 
The next step was to evaluate the role of another Pellino family member, Pellino 3, in 
the regulation of TNF-induced necroptosis in MEFs. Thus, WT and Peli3-/- MEFs were pre-treated 
with Z-VAD and BV6 for an hour and then stimulated with TNFα for 6 hours (Figures 3.8A). The 
same molecular markers of necroptosis were tested as described above. Phosphorylation of 
MLKL was observed when cells were treated with Z-VAD or BV6 and TNFα, and with both 
inhibitors and TNFα. It was also present with BV6 treatment alone. WT and Peli3-/- MEFs showed 
the same patterns and profiles of P-MLKL immunoreactivity indicating that Pellino 3 is not 
involved in TNF-induced necroptosis. As before the slower migrating form of RIP3 was also 
evident for WT cells driven toward necroptosis by combined treatment of all 3 agents but this 
was also apparent in Pellino 3-deficient MEFs. RIP1, was also depleted in cells that were induced 
to progress to either apoptosis and necroptosis. However, there was no difference between WT 
and Pellino 3 knockout MEFs. Similar results were visible at 24 hours treatment (Figures 3.8B). 
Variations in the housekeeping protein, GAPDH, are explained by the strong induction of cell 
death in such a long period of treatment. These data indicate a lack of involvement of Pellino 3 
in regulation of necroptosis, at least in fibroblasts. 
Given the highly conserved nature of the primary and predicted secondary structures of 
the Pellino family members, studies next investigated if the lack of effect of Pellino 2 or Pellino 
3 deficiency in TNF-induced necroptosis may be explained by functional redundancy of the 2 
family members. To this end double knockout mice were generated by pairing homozygous 
Peli2-/- and Peli3-/- for breeding and subsequently genotyping these alleles in each mouse as 
described in the materials and methods (see sections 2.1.4 and 2.1.7). Additionally, double 
knockout Pellino 2 and 3 MEFs were assessed to rule out a potential compensation effect 
between both members of the family (Figure 3.9). As for previous experiments, phosphorylation 
of MLKL was apparent under conditions of apoptosis (TNFα and BV6) and more prominently 
under conditions of necroptosis (TNFα, BV6 and Z-VAD) (Figure 3.9). The upward shift in the RIP3 
immunoreactive band and reduced levels of RIP1 again coincided with these changes. However, 
WT and double knockout MEFs showed the same patterns and levels of P-MLKL, RIP1 and RIP3 






Figure 3.8 Pellino 3 deficiency has no effect on molecular markers of necroptosis induced with 
TNFα in MEFs. 
Immunoblot analysis of phosphorylated (p-) MLKL (54 kDa) and total levels of RIP1 (74 kDa) and 
RIP3 (46-53 kDa) in cell lysates from WT and Peli3–/– MEFs pre-treated with 20 μM Z-VAD for an 
hour and stimulated with 10 μM BV6 and 40 ng/mL TNFα for (A) 6 hrs and (B) 24 hrs. GAPDH (37 
kDa) was used as constitutively expressed housekeeping protein. Data are representative of 








Figure 3.9 Pellino 2 and Pellino 3 deficiency has no effect on molecular markers of necroptosis 
induced with TNFα in MEFs. 
Immunoblot analysis of phosphorylated (p-) MLKL (54 kDa) and total levels of RIP1 (74 kDa) and 
RIP3 (46-53 kDa) in cell lysates from WT and Peli2–/–Peli3–/– MEFs pre-treated with 20 μM Z-VAD 
for an hour and stimulated with 10 μM BV6 and 40 ng/mL TNFα for (A) 8 hrs and (B) 24 hrs. β-
actin (42 kDa) was used as constitutively expressed housekeeping protein. Data are 






3.2.2 Effect of Pellino 2 and Pellino 3 deficiency in TNFα-induced necroptosis in immune cells 
Although Pellino 2 and 3 appear to play negligible roles in regulation of TNF-induced necroptosis 
in embryonic fibroblasts, we were keen to examine their roles in this pathway in immune cells. 
Macrophages are essential in the initiation of immune responses, and more likely encounter 
signals triggering cell death due to their phagocytic function. Therefore, bone marrow-derived 
macrophages (BMDMs) were treated in the same way as MEFs in previous section. LCL161 was 
selected as the IAP inhibitor of choice since it is a pan cIAP/xIAP inhibitor and also preliminary 
experiments showed a lack of response of BMDMs to BV6 (Condon et al., 2014; Lawlor et al., 
2015). WT BMDMs treated with only Z-VAD or LCL161 for 6 hours induced low level 
phosphorylation of MLKL, but this was strongly augmented with triple treatment of Z-VAD, 
LCL161 and TNFα (Figure 3.10A). The RIP3 and RIP1 expression patterns in WT BMDMs was 
largely similar to MEFs, with the RIP3 band showing upward migration when necroptosis was 
induced with Z-VAD, LCL161 and TNFα. RIP1 significantly decreased with LCL161 treatment 
alone, or when treated with LCL161 plus TNFα, or Z-VAD, LCL161 and TNFα. Notably the levels 
and migration patterns of pMLKL, RIP1 and RIP3 in WT BMDMs were replicated in  Peli2-/- 
BMDMs (Figure 3.10A) and Peli3-/- BMDMs (Figure 3.10B). A kinetic study was also performed 
in which WT, Peli2-/- and Pel3-/- were subjected to the triple co-treatment of Z-VAD, LCL161 and 
TNFα and assessed for markers of necroptosis as described above. The same levels of MLKL 
phosphorylation, time dependant decrease of RIP1 and upward shift of RIP3 were apparent in 
WT BMDMs, Peli2-/- BMDMs and Pel3-/- BMDMs (Figure 3.10C). These results clearly indicate that 
neither Pellino 2 or Pellino 3 have a role in the regulation of TNF-induced necroptosis in BMDMs. 
LDH release was also used as a measure of cytotoxicity and necroptosis and evaluate 
the role of Pellino 2 and Pellino 3 in TNF-induced necroptosis in macrophages. These analyses 
lend themselves to higher throughput analysis than the approaches above that rely on 
immunoblotting. The cytotoxicity induced by IAPs inhibitors LCL161 and Birinapant when 
combined with TNFα or Z-VAD and TNFα was evaluated in WT and Peli2-/- BMDMs (Figure 3.11A), 
and WT and Peli3-/- BMDMs (Figure 3.11B). The cells were treated with Z-VAD and either LCL161 
(left panels) or Bririnapant (right panels) for 1 hour and then stimulated with TNFα for 24 hours 
(Figure 3.11). Treatment with LCL161 alone, LCL161 plus TNFα or Z-VAD, LCL161 and TNFα 
increased cytotoxicity to 80% in WT BMDMs with no differences in the percentages of 
cytotoxicity when compared with Peli2-/- BMDMs subjected to the same treatments (Figure 
3.11A, left). Cytotoxicity in WT and Peli2-/- BMDMs induced by Birinapant only or combined with 
TNFα or Z-VAD and TNFα increased up to 60% but with no difference between WT and Peli2-/- 





Figure 3.10 Effect of Pellino 2 or Pellino 3 deficiency on molecular markers of necroptosis 
induced with TNFα in BMDMs. 
Immunoblot analysis of phosphorylated (p-) MLKL (54 kDa) and total levels of RIP1 (74 kDa) and 
RIP3 (46-53 kDa) in cell lysates from WT, Peli2–/– and Peli3–/– BMDMs pre-treated with 20 μM Z-
VAD (Z) for an hour and stimulated with 10 μM LCL161 and 40 ng/mL TNFα (T) for the indicated 
times. Control of treatment at 6 hours in (A) WT and Peli2–/– BMDMs, and (B) WT and Peli3–/– 
BMDMs. (C) 2, 4 and 6 hours treatment time points in WT, Peli2–/– and Peli3–/– BMDMs. GAPDH 
(37 kDa) was used as constitutively expressed housekeeping protein. Data are representative of 








Figure 3.11 Pellino 2 or Pellino 3 deficiency does not affect TNF-induced necroptosis as 
measured by release of lactate dehydrogenase in BMDMs. 
Cytotoxicity analysis by LDH release in supernatant from (A) WT and Peli2–/– BMDMs or (B) WT 
and Peli3−/− BMDMs pre-treated with 20 μM Z-VAD for an hour and stimulated with either 40 
ng/mL TNFα and 10 μM LCL161 (left panels) or 40 ng/mL TNFα and 10 μM Birinapant (right 
panels) for 24 hrs. Data are presented as the mean ± SEM of two independent experiments. 
Maximum release of LDH was stablish for each biological replicate using lysis buffer provided 


















































































































































































































































cytotoxicity when compared with WT BMDMs for treatment with LCL161 or its combined 
treatment with TNFα or Z-VAD and TNFα (Figure 3.11B, left). Finally, Birinapant increased 
cytotoxicity to 60% when used alone or combined with TNFα, and to 80% when used with Z-VAD 
and TNFα (Figure 3.11B, right). Nonetheless, the difference between WT and Peli3-/- BMDMs 
was very modest. This further support the earlier conclusion that neither Pellino 2 or Pellino 3 
play any mediatory role in the process of necroptosis in macrophages.   
Necroptosis induced by TNFα was also studied in dendritic cells (DCs), another 
important antigen presenting type of cell from the immune system. As described for the studies 
with macrophages, Pellino 2 deficient and WT DCs were treated with different combinations of 
Z-VAD, LCL161 and TNFα for 0-6 hours (Figure 3.12). Again, elevated levels of P-MLKL, slower 
migrating forms of RIP3 and reduced levels of RIP1 were apparent in response to the death-
inducing signals but the same patterns were observed in Pellino 2 deficient cells and WT DCs 







Figure 3.12 Effect of Pellino 2 deficiency on molecular markers of necroptosis induced with 
TNFα in dendritic cells. 
Immunoblot analysis of phosphorylated (p-) MLKL (54 kDa) and total levels of RIP1 (74 kDa) and 
RIP3 (46-53 kDa) in cell lysates from WT and Peli2–/– DCs pre-treated with 20 μM Z-VAD (Z) for 
an hour and stimulated with 10 μM LCL161 (L) and 40 ng/mL TNFα (T) for the indicated times. 
(A) Control of individual treatments at 6 hours, and (B) 2, 4 and 6 hours treatment time points. 
GAPDH (37 kDa) was used as constitutively expressed housekeeping protein. Data are 






3.2.3 Effect of Pellino 2 and Pellino 3 deficiency in necroptosis induced by TLR4 and TLR3 in 
murine macrophages 
Whilst Pellino 2 and Pellino 3 does not appear to play a role in TNF-induced necroptosis, the next 
studies aimed to explore their potential role in TLR-induced cell death, especially given their 
previously reported roles in TLR biology. Indeed, cell death ligands like TNFα are not the only 
way to activate necroptosis. Necroptosis can also be triggered by Lipopolysaccharide (LPS), a 
main component of Gram-negative bacteria membranes, that acts as ligand for TLR4. TLR4-
induced necroptosis does not depend directly on RIP1/RIP3 interaction but instead is mediated 
by the interaction between TRIF and RIP3 (He et al., 2011; Kaiser et al., 2013). As in previous 
experiments, Pellino 2 deficient and WT BMDMs were pre-treated for 1 h with the pancaspase 
inhibitor Z-VAD and treated with LCL161 and the TLR4 ligand LPS for 6 or 24 hours. Strong 
phosphorylation of MLKL was apparent in WT BMDMs cells in response to 6 hours treatment 
with all 3 agents (Figure 3.13A). Phosphorylation of the necroptosis effector proteins was also 
faintly induced by Z-VAD alone. The levels of RIP1 decreased when cells were treated with LPS 
and Z-VAD in the absence and presence of LCL161 and with some retardation of the 
electrophoretic mobility of RIP3 when cells were treated with the pro-necroptotic treatment 
regime of all 3 agents. The same patterns of P-MLKL, RIP1 and RIP3 were also apparent in Pellino 
2 deficient BMDMs. Similar findings were observed at treatment periods of 24 h with an 
additional reduction of RIP1 and RIP3 when inhibitors Z-VAD and LCL161 were used (Figure 
3.13B). These studies indicate that Pellino 2 is not employed by the TLR4 pathway in triggering 
necroptosis in macrophages.  
Equivalent studies were also performed in WT and Peli3-/- BMDMs to explore the role of 
Pellino 3 in LPS-induced necroptosis and the patterns of MLKL phosphorylation and changes in 
levels of RIP1 an RIP3 were the same in cells from both mice (Figure 3.14). Together these data 
indicate that neither Pellino 2 or Pellino 3 mediate necroptosis that is induced by TLR4 signalling. 
Given the previously described role for Pellino proteins in TLR3 signalling coupled to the role of 
TLR3 in triggering necroptosis the next study explored the role of Pellino 2 and Pellino 3 in TLR3-
induced necroptosis (Chang, Jin and Sun, 2009; Siednienko et al., 2012). Poly(I:C), a ligand for 
TLR3, was used in absence or presence of the pancaspase inhibitor Z-VAD for 6 or 18 hours. 
Necroptosis molecular markers were measured in Pellino 2/Pellino 3 deficient BMDMs and 
compared with WT cells. Phosphorylation of MLKL was faintly seen at 6 hours for all the 
phenotypes but there was no consistent change between cells from WT and Pellino-deficient 
mice (Figure 3.15A). No obvious variations were observed for RIP3 and RIP1 at this time point. 
Treatment of cells with Poly(I:C) and Z-VAD for 18h promoted the appearance of high levels of 
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P-MLKL with comparable levels being apparent in WT, Pellino 2- and Pellino 3-deficient BMDMs 





Figure 3.13 Effect of Pellino 2 deficiency on molecular markers of necroptosis induced with LPS 
in BMDMs. 
Immunoblot analysis of phosphorylated (p-) MLKL (54 kDa) and total levels of RIP1 (75 kDa) and 
RIP3 (46-53 kDa) in cell lysates from WT and Peli2–/– BMDMs pre-treated with 20 μM Z-VAD for 
an hour and stimulated with 10 μM LCL161 and 40 ng/mL LPS for (A) 6 hrs and (B) 24 hrs. GAPDH 
(37 kDa) was used as constitutively expressed housekeeping protein. Data are representative of 








Figure 3.14 Effect of Pellino 3 deficiency on molecular markers of necroptosis induced with LPS 
in BMDMs. 
Immunoblot analysis of phosphorylated (p-) MLKL (54 kDa) and total levels of RIP1 (74 kDa) and 
RIP3 (46-53 kDa) in cell lysates from WT and Peli3–/– BMDMs pre-treated with 20 μM Z-VAD for 
an hour and stimulated with 10 μM LCL161 and 40 ng/mL LPS for (A) 6 hrs and (B) 24 hrs. GAPDH 
(37 kDa) was used as constitutively expressed housekeeping protein. Data are representative of 








Figure 3.15 Effect of Pellino 2 or Pellino 3 deficiency on molecular markers of necroptosis 
induced with Poly(I:C) in BMDMs. 
Immunoblot analysis of phosphorylated (p-) MLKL (54 kDa) and total levels of RIP1 (74 kDa) and 
RIP3 (46-53 kDa) in cell lysates from WT, Peli2–/– and Peli3–/– BMDMs pre-treated with 20 μM Z-
VAD for an hour and stimulated with 25 μg/mL Poly(I:C) for (A) 6 hrs and (B) 18 hrs. GAPDH (37 
kDa) was used as constitutively expressed housekeeping protein. Data are representative of 









Necroptosis is a lytic type of regulated cell death described nearly ten years ago (Galluzzi and 
Kroemer, 2008; Hitomi et al., 2008). Our understanding of its molecular mechanism and 
regulation has increased since then. So far, it is clear the family of RIP kinases, especially RIP1 
and RIP3, play essential roles as triggers and mediators in this type of cell death (Cho et al., 2009; 
Li et al., 2012; Vanden Berghe et al., 2014; Wu et al., 2014; Almagro and Vucic, 2015). RIP1 is a 
kinase that relies on ubiquitination to be activated and mediate pro-inflammatory or cell death 
signalling. Work from our laboratory and other researchers reported that the Pellino family of 
E3 ligases can regulate RIP kinase function in both inflammation and cell death (Chang, Jin and 
Sun, 2009; Yang, Wang, Humphries, et al., 2013; Yang, Wang, Tang, et al., 2013). Therefore, the 
role of Pellino E3 ligases in the regulation of necroptosis was explored. Inhibition of both the 
inflammatory and apoptotic signalling pathways by means of cIAP/XIAPs and caspases, 
respectively, allowed to drive the signalling cascades toward necroptosis when MEFs, BMDMs 
or DCs were stimulated with death receptor ligand TNFα. A number of molecular readouts were 
employed as indices of necroptosis. Immunoblotting of three critical proteins (MLKL, RIP3 and 
RIP1) involved in the necroptotic cascade were chosen as the best approach. Other techniques 
such as AnnexinV/PI staining and percentage of cytotoxicity by LDH release have also been 
reported as possible read outs of necroptosis but late apoptosis and other types of lytic cell 
death like pyroptosis can also increase these parameters (Galluzzi et al., 2014). A clear example 
of this was apparent in MEFs treated with Z-VAD, different inhibitors of IAPs (BV6, LCL161 and 
Birinapant) and TNFα stimulation when cytotoxicity was evaluated by means of LDH release 
(Figures 3.7 and 3.11). Treatment of cells with IAP inhibitors and TNFα, which were driving the 
cell to apoptosis, showed a similar percentage of cytotoxicity compared with cells stimulated 
with Z-VAD, IAP inhibitors and TNFα, that drive cells towards necroptosis. Hence, 
immunoblotting of MLKL, RIP1 and RIP3 were used as the preferred markers of activation of the 
necroptotic pathway.  
Phosphorylated MLKL was apparent across a number of cell types when stimulated with 
TNFα, Z-VAD and LCL161. These results are consistent with the working model of necroptosis 
signalling, where TNFR-dependant activation triggers phosphorylation of the effector molecule 
MLKL when the inflammatory and apoptotic signalling pathways are blocked (Sun et al., 2012; 
Vanden Berghe et al., 2014; Rodriguez et al., 2016).  P-MLKL was also present to a minor extent 
when IAPs inhibitors were used with TNFα stimulation. Expression in this situation was much 
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lower compared with necroptotic conditions that blocked caspase activity. Whilst, under 
conditions of co-stimulation with IAP inhibitors and TNFα, cells die primarily by apoptosis, a 
small proportion seems to take the necroptotic fate and it is interesting to speculate that this 
may represent secondary necroptosis in response to primary apoptosis. The use of pan-caspase 
inhibitors could be driving the cells which would spontaneously die by apoptosis towards 
necroptosis, or its prolonged use could be generating intracellular stress in a reduced number 
of cells in cell culture thus triggering necroptosis (Vanden Berghe et al., 2014; Shalini et al., 
2015). In a similar way, treatment with IAP inhibitors alone clearly induces cell death, as seen 
with the increase in cytotoxicity in both MEFs and BMDMs when BV6, LCL161 or Birinapant were 
used alone (Figures 3.2.2 and 3.2.6). However, LDH release does not allow to define the type of 
cell death. Immunoblot analysis indicates that a small proportion of cells died by necroptosis 
when antagonists of IAPs were used alone, and such an effect was more prominent with the use 
of LCL161 compared with BV6. The autoubiquitination of IAPs and subsequent degradation in 
response to IAP inhibitors sensitises mammalian cells to apoptosis (Vasudevan and Ryoo, 2015). 
However, our results also showed a moderate activation of the necroptotic pathway in particular 
for LCL161, which has been reported to have high affinity for both cIAP and XIAPs (Lawlor et al., 
2015). Interestingly, loss of XIAP or inactivation of its RING domain has been shown to decrease 
cell survival in a RIP3 dependant way in murine bone marrow derived dendritic cells (BMDCs) 
(Yabal et al., 2014). In the light of those findings and the results of this thesis, a potential 
regulation of RIP3 and downstream activation of necroptosis mediated by XIAP could be 
addressed in future studies.  
RIP3 and RIP1 expression was also evaluated in the present studies. Interestingly, when 
the cells were directed toward necroptosis, a slight increase in the size of RIP3 was observed, as 
evidenced by reduced electrophoretic mobility. The upward shift of RIP3 band seems to reflect 
its phosphorylation state characteristic of necroptosis signalling (Cho et al., 2009; He et al., 2009; 
Zhang et al., 2009; Newton et al., 2014; Alturki et al., 2018). In addition, when MEFs, BMDMs or 
DCs are driven towards apoptosis by IAP inhibitors and TNFα or TLR4 stimulation, RIP3 
expression is moderately reduced at 6 hours and more clearly lost at longer time points. It has 
been described that active caspase 8 cleaves RIP3 at Asp328 in the context of apoptosis (Feng 
et al., 2007). As expected, the levels of RIP1 were also reduced in apoptosis given it is degraded 
by caspase-8 under pro-apoptotic conditions (Lin et al., 1999; Chan et al., 2003). RIP1 was 
likewise considerably reduced or absent when cells were driven to necroptosis. However, it was 
not clear whether this was due to degradation of RIP1 induced after auto-phosphorylation of 
RIP3 and induction of its homo-interacting structure (Wu et al., 2014). Alturki and co-workers 
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(2018) reported recently the proteasomal degradation of RIP1 mediated by the E3-ubiquitin 
ligase Triad3a in macrophages stimulated with LPS in the presence of Z-VAD. They described a 
K48-ubiquitin-dependent proteasomal degradation of this kinase in early necrosome formation 
evident after 2 hours of stimulation. Interestingly, this research suggests that once necroptosis 
is initiated, the interaction between RIP3 and RIP1 mediates the degradation of the latter 
(Alturki et al., 2018). Such findings add to the complex interaction between these two kinases 
and their dual loop of regulation, since whilst RIP1 mediates formation of the necrosome with 
RIP3, it can also suppress basal activation of RIP3 (Kearney et al., 2014; Orozco et al., 2014). 
Evidently our model of necroptosis and the expression of the three main proteins associated 
with it fit consistently with the working model of this type of regulated cell death.  
The early studies in this thesis investigated whether E3 ligases Pellino 2 and 3 have a role 
in regulation of necroptosis. We found that loss of Pellino 2 and/or Pellino 3 had modest or no 
difference in the expression of the necroptosis markers evaluated across three types of cells 
(MEFs, BMDMs or DCs). A very modest decrease in the band for phosphorylated MLKL was seen 
in Pellino 2 deficient MEFs when compared with WT MEFs in the context of TNFα death receptor 
signalling. Interestingly, no difference was seen for the same protein in BMDMs or DCs when 
comparing Pellino 2-deficient cells with WT cells when stimulated with TNFα. However, there 
was a slight increase in P-MLKL in Pellino 2 deficient BMDMs compared with WT cells when 
necroptosis was induced via TLR signalling. The discreet increase in the band was seen at 6 hours 
treatment for both LPS and Poly(I:C) and corresponded to a similarly discreet increase in RIP3, 
but no evident change in RIP1. Interestingly, it seems the change is reversed or lost at longer 
time points for both ligands of TLR4 and TLR3 respectively. These results could suggest a minor 
role of Pellino 2 in regulating TRIF-dependant activation of the necrosome perhaps directly 
affecting RIP3 in early stages of the process. Another member of the Pellino family has been 
shown to regulate RIP1 in the context of TRIF-dependant signalling. TLR4 and TLR3 induced 
activation of NF-B, which was shown to depend on Pellino 1-induced ubiquitination of RIP1 
(Chang, Jin and Sun, 2009). Furthermore, the same member of the family was recently described 
to modulate necroptosis signalling by regulating both kinases, RIP1 and RIP3 (Wang et al., 2017; 
Choi et al., 2018). Using a similar approach to the one in this thesis, Wang and collaborators 
treated WT and Pellino 1-deficient MEFs with TNFα, Z-VAD and SM164, an inhibitor of cIAPs and 
XIAPs, and demonstrate that Pellino 1 induces K63 ubiquitination of RIP1 on K115. The authors 
concluded that ubiquitination of RIP1 by Pellino 1 is indispensable for the interaction of this 
kinase with RIP3 and the subsequent formation of the necrosome and initiation of necroptosis. 
It is to note that recognition of RIP1 by Pellino 1 seems to depend on RIP1 phosphorylation status 
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(Wang et al., 2017). In contrast, earlier this year, Choi and co-workers reported that Pellino 1 is 
an important inhibitor of necroptosis, by mediating the degradation of RIP3 (Choi et al., 2018). 
The authors showed that phosphorylated RIP3 is recognized by the FHA domain of Pellino 1 
which mediates K48 polyubiquitination of the kinase on its K363 residue. They too describe 
proteasomal degradation of this targeted RIP3 and downregulation of necroptosis. 
Furthermore, this study describes a correlation between increased expression of RIP3 and low 
levels of Pellino 1 in keratinocytes from toxic epidermal necrolysis (TEN) patients, and suggests 
that the increase in necroptosis due to the lack of Pellino 1 could be the mechanism explaining 
the pathogenesis of this disease (Choi et al., 2018). The basis for these conflicting reports on the 
role of Pellino 1 in necroptosis is unknown. Studies in this thesis extends to an investigation into 
the role of the other two Pellino family members, Pellino 2 and Pellino 3 and all of our data are 
consistent with a lack of involvement for Pellino 2 and Pellino 3 in necroptosis across a number 
of cell type. This highlights a lack of functional redundancy for members of the Pellino family 
with Pellino 1 likely playing some regulatory function in necroptosis whereas the other two-
family members lack of effect. This may be surprising since Pellino members are very similar in 
terms of primary structure and predicted secondary structure. Each member has a common FHA 
and RING-like domains. However, they appear to be functionally unique based on reports to 
date. In that sense, Pellino 1 has been described to promote TLR3 and TLR4-activation of NF-B 
by polyubiquitination of RIP1 in a RING-domain dependent mechanism, while Pellino 3 has been 
shown to interact with RIP1 through its FHA domain preventing the initiation of apoptosis 
(Chang, Jin and Sun, 2009; Yang, Wang, Tang, et al., 2013). Other variable roles have been 
described for Pellino 1 and Pellino 3 in the regulation of IL-1 signalling, where Pellino 1 is 
recognized as a positive regulator of IL-1 while Pellino 3 seems to negatively regulate the same 
pathway (Jiang et al., 2003; Xiao et al., 2008). Less is known about the function of Pellino 2, 
however, research from our laboratory has proven that it has an essential role in the regulation 
of activation of the NLRP3 inflammasome through both the FHA and RING-like domains 
(Humphries et al., 2018). Under circumstances of NLRP3 inflammasome activation, Pellino 2 also 
plays a mediatory role in a form of necrotic cell death known as pyroptosis. However, data 
described above clearly show that neither Pellino 2 or Pellino 3 regulate necroptosis, another 
form of cell necrosis. These findings clearly highlight the selectivity and specificity of Pellino 
action in different cell pathways and processes in innate immune signalling.  
Whilst Pellino 2 and Pellino 3 appear to lack a role of necroptosis in the context of 
inflammatory stimuli, our research group has previously demonstrated an important role for 
Pellino 3 in controlling the transcription factor HIF-1α (Yang et al., 2014). However, the latter 
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has been largely studied in the context of a response factor to low levels of oxygen. This thesis 
next moves to a broader evaluation of the ability of innate immune stimuli to affect HIF-1α.    
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Hypoxia is a state of low concentration of oxygen that damages tissue homeostasis. It is 
triggered when physiological, mechanical or external conditions decrease O2 levels, and it can 
happen at cellular, tissue or systemic levels. A considerable number of genes are induced under 
these conditions aiming to reduce the negative impact of cellular oxygen stress (Lisy and Peet, 
2008). The hypoxia-inducible transcription factors (HIFs) are the key proteins orchestrating this 
complex response which includes several cellular processes to regulate oxygen dependence and 
consumption, and the co-ordination of  effective oxygen delivery to cells (Lisy and Peet, 2008). 
Vascularization, vasodilation, cell migration, metabolism, signalling and cell fate decisions are  
some of the mechanisms altered by HIF signalling (Iyer, Leung and Semenza, 1998; Lisy and Peet, 
2008). Considering the influence of HIF proteins in such fundamental processes, they have also 
been shown to play a role in the pathophysiology of some human diseases such as cancer, 
coronary artery disease, rheumatoid arthritis, stroke, and inflammatory bowel disease among 
others (Iyer, Leung and Semenza, 1998; Scholz and Taylor, 2013; Balamurugan, 2016; Cummins 
et al., 2016). Research from our group has demonstrated a novel role for Pellino 3 in negatively 
regulating HIF signalling, and so protect against obesity-induced inflammation and insulin-
resistance (Yang et al., 2014). Whilst HIF has traditionally been studied in the context of oxygen 
sensing there is a growing interest in its role in regulating inflammation and the main goal of this 
chapter was to explore the potential regulatory effect of TLR signalling on HIF activation. 
4.1.1 HIF structure and signalling 
The functional activity of HIF proteins depends on the assembly of a heterodimer comprising an 
α and β HIF subunits (Wang and Semenza, 1995; Wang et al., 1995). Both subunits contain a 
transactivation domain and a DNA binding domain which belongs to the basic helix–loop–
helix/Per-Arnt-Sim homology (bHLH/PAS) family of transcription factors (Figure 4.1) (Jiang, Rue, 
et al., 1996; Bracken, Whitelaw and Peet, 2003; Chapman-Smith and Whitelaw, 2006). The 
stability and transcriptional activity of the HIF-α subunit are regulated by oxygen levels while 
HIF-β is constitutively expressed in the nuclei (Wang et al., 1995; Jiang, Semenza, et al., 1996). 
Both subunits have paralogues. HIF-α subunit can be found as HIF-1α, HIF-2α and HIF-3α, while 
HIF-β (also known as aryl hydrocarbon receptor nuclear translocator (Arnt), is found in the 





Figure 4.1 Hypoxia-inducible transcription factors (HIFs) structural domains.  
Functionally active HIF is a heterodimer formed by two subunits known as α and β. There are 
three paralogues of HIFα named HIF-1α, HIF-2α and HIF-3α. In addition, a spliced form of HIF3α 
recognized as IPAS has been described. HIF-1α forms a dimer with HIF-1β also known as ARNT. 
All of them have bHLH and PAS domains in common which allow for DNA recognition and 
binding. In addition, the three HIFα isoforms contain ODDDs, NADs and CADs domains, which 





and HIF-2α have been described to interact with HIF-1β to form the functional HIF transcription 
factor complexes responsible for the hypoxic response (Semenza, 1999; Lisy and Peet, 2008). In 
contrast, HIF-3α and its alternative spliced form known as inhibitory PAS domain protein (IPAS) 
have been described as negative regulators of HIF-mediated transcription (Gu et al., 1998; 
Makino et al., 2001). IPAS has been shown to dimerise with HIF-1β, sequestrating HIF-1β and 
interfering with its binding to HIF-1α (Makino et al., 2001). The carboxyl-terminal portion of HIF-
1α includes stabilizing and transactivation domains which determines its oxygen-dependant 
stabilization and transcriptional activity, while its amino-terminal portion contains bHLH/PAS 
domains that allow for heterodimerization with HIF-1β and DNA binding (Jiang, Rue, et al., 1996; 
Jiang, Semenza, et al., 1996; Jiang et al., 1997; Pugh et al., 1997).  
HIF-1α is constitutively transcribed, translated and constantly degraded within the cells 
under normoxia conditions (Huang et al., 1996; Yu et al., 1998). Its degradation in less than 5 
minutes is dependent on initial hydroxylation of two conserved prolyl residues within the central 
oxygen-dependent degradation domain (ODDD) in the C-terminal portion of the protein (Figures 
4.1 and 4.2) (Semenza, 1999; Lisy and Peet, 2008). HIFα hydroxylation is mediated by prolyl 
hydroxylases (PHDs) and it allows for HIFα recognition and polyubiquitination by the von Hippel-
Lindau protein (pVHL) (Maxwell et al., 1999; Semenza, 2004). Ubiquitinated HIFα becomes a 
target for proteasomal degradation (Figure 4.2). However, under hypoxic conditions, PHD 
hydroxylation activity is hampered (as it requires oxygen as a substrate) allowing for HIFα 
stabilization and translocation to the nucleus (Semenza, 2004). Increased stability of HIFα can 
also be achieved by its binding to heat-shock protein 90 (Hsp90) in an oxygen-independent way 
(Liu and Semenza, 2007). In addition to hydroxylation by PHDs, another member of the 
dioxygenase family of hydroxylases named factor-inhibiting HIF-1α (FIH-1) plays an important 
role HIF signalling. FIH-1 induces the hydroxylation of a single conserved asparagine residue in 
the C-terminal CAD domain under normoxia conditions (D. Lando et al., 2002; David Lando et 
al., 2002; Hewitson et al., 2002). Hydroxylation of this asparagine residue in position 803 inhibits 
HIFs transcriptional activity by blocking the interaction of its CAD domain with the essential 
transcriptional coactivator CREB-binding protein (CBP) or p300 (David Lando et al., 2002; 
Hewitson et al., 2003). Considering both types of hydroxylase enzymes require oxygen to 
exercise their enzymatic activity, they act as cellular oxygen sensors regulating HIF-1α 







Figure 4.2 HIF transcriptional regulation.  
HIFα is constantly been produced and degraded under normoxia conditions. At normal levels of 
oxygen, HIFα is hydroxylated by enzymes PHD and FIH that target the protein for degradation 
and blocks its transactivation function respectively. Once hydroxylated, VHL protein can 
recognize HIFα and mediate its polyubiquitination and subsequent degradation by the 
proteasome. In hypoxia, hydroxylase enzymes are inhibited, HIFα can then translocate to the 
nucleus and form a dimer with HIFβ. The heterodimer binds to the HRE sequence in its target 
genes and recruit cofactors like CBP and P300 that will facilitate the transcription of the 
corresponding genes. HIF-1α has also been described to accumulate in response to bacteria and 
bacterial products such as LPS in a signalling cascade dependent on NF-κB. CBP, CREB-binding 
protein; FIH, factor inhibiting HIF; HIF, hypoxia-inducible factor; HREs, HIF-responsive elements; 
LPS, lipopolysaccharide; P300, E1A binding protein; PHD, prolyl hydroxylase domain-containing 





When oxygen concentrations drop, HIF-1α hydroxylation is blocked, it is then translocated to 
the nucleus where it dimerises with HIF-1β through their common bHLH/PAS domains (Jiang, 
Rue, et al., 1996; Jiang, Semenza, et al., 1996; Jiang et al., 1997; Pugh et al., 1997). This domain 
recognizes the hypoxia response elements (HREs) in the promotor of over 70 genes (Liu et al., 
2012; Dengler, Galbraith and Espinosa, 2014). Two regions are recognized in the genes, a core 
HRE or HIF-binding site (HBS) containing the sequence (A/G)CGTG and the HIF ancillary sequence 
(HAS) (Semenza and Wang, 1992; Kimura et al., 2001). After its assembly on the HRE, HIF forms 
an initiation complex by recruiting transcriptional co-activators through its transactivation 
domains (Lisy and Peet, 2008). The oxygen-regulated C-terminal transactivation domain (CAD) 
and the N-terminal transactivation domain (NAD) are the portions of HIF-1α and HIF-2α 
responsible for recruiting coactivators CBP/p300, SRC-1, and transcription intermediary factor 2 
(TIF-2) (Arany et al., 1996; Jiang et al., 1997; Pugh et al., 1997; Ema et al., 1999; D. Lando et al., 
2002). These two transactivation domains of HIF-1α and HIF-2α have been shown to be the key 
modulators of HIF target genes and their activity has been reported to be regulated by oxygen 
levels, especially CAD (Jiang et al., 1997; Dayan et al., 2006). Nevertheless, a small number of 
HIF target genes seem to be dependent solely on NAD activity suggesting that these two 
domains are regulators of specific responses to low concentrations of oxygen (Dayan et al., 2006; 
Hu et al., 2007). The CAD domain  is also present in HIF-1β but contrary to its role in HIF-1α and 
HIF2α is believed not to be necessary for HIF transcriptional activation (Bracken, Whitelaw and 
Peet, 2003). CBP/p300 has been described as the main coactivator associated with the HIF 
heterodimer. It allows HIF binding to other coactivator complexes and its histone 
acetyltransferase activity facilitating the chromatin modifications required for gene 
transcription (Arany et al., 1996). HIF transcriptional activation regulates multiple cellular 
processes including angiogenesis, oxygen supply, proliferation, stemness/self-renewal, 
epithelial to mesenchymal transition (EMT), redox homeostasis, apoptosis and others (Table 
4.1) (Iyer, Leung and Semenza, 1998; Liu et al., 2012; Dengler, Galbraith and Espinosa, 2014). 
The switch between oxidative phosphorylation and glycolysis is one of the main cellular 
pathways influenced by HIF signalling (Dengler, Galbraith and Espinosa, 2014). HIF-mediated 
variations in glucose metabolism, cell migration, survival and angiogenesis have been shown to 
favour the development of solid tumours and the progression of several other diseases, 






Cellular processes and disease processes 
regulated by HIF transcription 
 
  
Angiogenesis and oxygen supply ADM EDN1 NOX2 
ANGPT1 EPO NOS2/3 
ANGPT2 PGF VEGF 
ANP FLK1 GPI 
PDGFβ CXCL12 HMOX1 
Apoptosis BNIP3/3L PP5 NDRG 
NOXA MCL1 NPM 
Cell migration CXCR4 c-MET   
Cell proliferation and survival CD73 IGFBP3 EDD1 
CTGF ITF STK15 
TGFβ3 
  
Epithelial to mesenchymal transition (EMT) ID2 SNAI1/2 TCF3 
TGF2 VIM ZEB1/2 
Glucose metabolism/energy metabolism ALDA LDHA DEC1 
GLUT1/3 PFKL PDK1 
GAPDH PGK1 BNIP3(L) 
COX412 PKM2  
Hormonal regulation EPO LEP   
Metastasis AMF LOX STC2 
ANGPTL4 LOXL2 TWIST1 
CXCL12 LOXL4 CTSC 
CXCR4 L1CAM MMP1/2/9/14 
pH regulation CA9 CA12   
Redox homeostasis GPX3 HMOX1 SOD2 
 
Table 4.1 Cellular processes regulated by HIFs transcriptional activation and its target genes.  
The list of HIF target genes is illustrative but not complete. ADM, Adrenomedullin; ALDA, 
Aldolase A; AMF, Autocrine motility factor; ANGPTL4, Angiopoietin-like protein 4; ANGPT1/2, 
Angiopoietin-1/2; ANP, Atrial natriuretic peptide; BNIP3(L), BCL2 Interacting Protein 3; CA9/12, 
Carbonic anhydrase 9/12; CD73, Ecto-5'-nucleotidase; COX412, cytochrome c oxidase subunit 
4I2; CTGF , Connective tissue growth factor; CTSC, Cathepsin C; CXCL12, C-X-C motif chemokine 
12; CXCR4, C-X-C chemokine receptor type 4; c-MET, Mesenchymal-epithelial transition factor; 
DEC1, Deleted In Esophageal Cancer 1; EDD1, E3 ubiquitin-protein ligase; EDN1, Endothelin 1; 
EPO, Erythropoietin; FLK-1, Fetal liver kinase-1; GAPDH, Glyceraldehyde 3-phosphate 
dehydrogenase; GLUT1/3, Glucose transporter 1/3; GPI, glycosylphosphatidylinositol; GPX3, 
Glutathione peroxidase 3; HMOX1, heme oxygenase (decycling) 1; ID2, DNA-binding protein 
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inhibitor; IGFBP3, Insulin-like growth factor-binding protein 3; ITF, Intestinal trefoil factor; 
L1CAM, L1 cell adhesion molecule; LEP, leptin; LDHA, Lactate dehydrogenase A; LOX, Lysyl 
oxidase; LOXL2/4, Lysyl oxidase homolog 2/4; MCL1, myeloid cell leukaemia sequence 1 protein; 
MMP-1/2/9/14, Matrix metalloproteinase 1/2/9/14; NDRG, N-myc downstream-regulated gene; 
NOXA, Phorbol-12-myristate-13-acetate-induced protein 1; NOS2/3, Nitric oxide synthase; 
NOX2, NADPH oxidase 2; NPM, Nucleophosmin/B23; PDGF-β, Platelet-derived growth factor-B; 
PDK1, Pyruvate dehydrogenase kinase 1; PFKL, 6-phosphofructokinase, liver type; PGF, Placental 
growth factor; PGK1, Phosphoglycerate kinase 1; PKM2, Pyruvate kinase M2; PP5, Serine 
threonine protein phosphatase type 5; SNAI1/2, Zinc finger protein; SOD2, Superoxide dismutase 
2; STC2, Stanniocalcin 2; STK15, Aurora/Ipl-1 related serine/threonine kinase; TCF3, Transcription 
Factor 3; TGF2, Transforming growth factor 2; TGFβ3, Transforming growth factor-β3; TWIST1, 
Twist Family BHLH Transcription Factor 1; VEGF, Vascular Endothelial Growth Factor; VIM, 
Vimentin; ZEB1/2, Zinc finger E-box-binding homeobox 1/2 (Adapted from Iyer, Leung and 




4.1.2 HIF-1α and inflammation 
Inflammation and tissue hypoxia have been correlated in a number of pathologies like 
inflammatory bowel disease (IBD), atherosclerosis, arthritis and obesity (Colgan and Taylor, 
2010; Cummins et al., 2016). Moreover, HIF-1α signalling has been described as a tumour-
associated inflammatory indicator (Mantovani et al., 2008; Mamlouk and Wielockx, 2013). 
Increased demand for oxygen in an inflammatory microenvironment (due to increase in 
metabolic activity), recruitment of inflammatory cells and disruption of oxygen delivery 
mechanisms are some of the circumstances favouring the activation of hypoxia signalling during 
prolonged and sustained inflammatory conditions (Cummins et al., 2016). In that sense, immune 
cells like neutrophils have been shown to promote hypoxic conditions by consuming high 
amounts of oxygen in the oxidative burst (Campbell et al., 2014; Campbell and Colgan, 2015). 
Like most cells, immune cells in a hypoxic microenvironment are subjected to activation of HIF-
1α signalling (Cramer et al., 2003; Walmsley et al., 2005; Dang et al., 2011; Scholz and Taylor, 
2013). Myeloid cell as well as Th1 and Th17 cell functions have been described to be impaired 
in the absence of HIF-1α (Cramer et al., 2003; Dang et al., 2011; Higashiyama et al., 2012). In 
contrast, HIF-1α seems to induce maturation of dendritic cells (DCs) in inflammatory conditions 
(Jantsch et al., 2008). In the myeloid lineage (granulocytes, monocytes, macrophages), activation 
of HIF signalling promotes cell aggregation and motility, and is a mechanism for bacterial killing 
(Cramer et al., 2003; Walmsley et al., 2005; Scholz and Taylor, 2013). Studies in a mouse model 
of sepsis with conditional deletion of HIF-1α in the myeloid linage showed reduced 
lipopolysaccharide (LPS)-induced mortality and sepsis-associated symptoms (Peyssonnaux et al., 
2007). Moreover, HIF-1α favoured infiltration of inflammatory cells in a DSS-induced colitis 
model aggravating the disease by regulating the expression of macrophage migration inhibitory 
factor (MIF) (Shah et al., 2009).  
The changes seen in immune cells under hypoxic conditions have been associated with 
activation of the transcription factor nuclear factor-kappa B (NF-B) (Bruning et al., 2012). 
Considering NF-B and HIF can both activate specific genes like interleukin-6 (IL-6), 
cyclooxygenase 2 (COX- 2), inducible nitric oxide synthase (NOS2), platelet endothelial cell 
adhesion molecule-1 (PECAM-1), matrix metalloproteinase 9 (MMP 9), BCL2, CXCR1 and CXCR2, 
it has been suggested they act together under hypoxic inflammation (Maxwell et al., 2007; 
Bruning et al., 2012; Hoesel and Schmid, 2013). The signal transducer and activator of 
transcription 3 (STAT3) has also been indicated to interact with HIF and NF-B in the regulation 
of other genes involved in survival (like mcl-1), proliferation (like c-myc or cyclin D1), invasion 
(MMP 2) and angiogenesis (VEGF) (Jung et al., 2005; Multhoff, Molls and Radons, 2012). Direct 
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interaction between STAT3 and HIF-1α has been shown to be crucial for activation of HIF target 
genes, and their association has been suggested to induce hypoxia-mediated immunoresistance 
in lung cancer cells (Noman et al., 2009; Pawlus, Wang and Hu, 2014). A positive association with 
chemoresistance and tumour progression due to a sustained inflammatory milieu induced by 
interaction between HIF-1α and TLR4 has also been described in glioblastoma and pancreatic 
adenocarcinoma (Zhang et al., 2010; Oblak and Jerala, 2011; Tewari et al., 2012). TLR3 
stimulation has also been shown to mediate metabolic reprogramming, and regulation of 
angiogenesis and apoptosis in a HIF-dependent mechanism in several types of cancer, including 
prostate cancer, head and neck carcinoma and pharyngeal cancer (Salaun et al., 2006; Paone et 
al., 2010; Veyrat et al., 2016; Matijevic Glavan et al., 2017). In addition, insulin resistance due to 
low-level inflammation triggered by the interaction between TRAF6, HIF-1α and IL1β has also 
been described in adipose tissue of a murine model of obesity (Yang et al., 2014). Furthermore, 
transcription factors c-Jun and AP-1, important mediators of MAPKs in TLRs signalling, have also 
been shown to participate in regulation of gene expression under hypoxic conditions (Alfranca 
et al., 2002; Salnikow et al., 2002). Altogether these reports support a close interplay between 









4.2.1 TLR pathways regulate levels of HIF-1α 
Increasing evidence shows the interplay between the HIF pathway and inflammation. Hypoxic 
conditions have been linked to a number of inflammatory disorders like rheumatoid arthritis, 
inflammatory bowel disease and chronic infection (Scholz and Taylor, 2013). Furthermore, HIF 
signalling has also been shown to have a role in cancer and to mediate obesity related insulin-
resistance and inflammation (Yang, Sharrocks and Whitmarsh, 2013; Lee et al., 2014; Yang et al., 
2014; Balamurugan, 2016). Based on this knowledge, this study was keen to investigate the 
regulation of HIF by various inflammatory signalling pathways with particular focus on the 
pathways triggered by members of the TLR family. BMDMs were stimulated for 6 hours under 
normoxic conditions by Zymosan (TLR2 ligand), Poly(I:C) (TLR3 ligand), LPS (TLR4 ligand), 
Flagellin (TLR5 ligand), CL097 (TLR7/8 ligand) and CpG (TLR9 ligand) and the levels of HIF-1α were 
determined by immunoblot analysis. The expected band of 110kDa of full length HIF-1α was 
observed following the 6 hours treatment by all of the ligands listed above (Figure 4.3A). Whilst 
CpG induced stabilization of HIF-1α, it was the least effective (Figure 4.3A). Interestingly a 
number of the TLR ligands also promoted increased immunoreactivity with proteins migrating 
slightly faster than the 110kDa band and at 40kDa. Given that HIF stabilization is typically 
triggered by hypoxia, to mimic the hypoxic conditions, cells were incubated in a hypoxic chamber 
containing 1% O2 for various time points and the levels of HIF-1α were measured by 
immunoblotting to assess if hypoxic conditions also promoted increased levels of proteins that 
migrate faster than 110kDa (Figure 4.3B). This resulted in increased levels of HIF-1α detected at 
110kDa, but hypoxia failed to increase the levels of immunoreactive proteins of lower molecular 
weight. In order to further characterise the pattern of HIF-1α stabilisation in response to TLR 
ligands, the effects of Poly(I:C), a representative TLR ligand, were characterised in more detail 
by performing dose-dependent and kinetic studies. Dimethyloxaloylglycine (DMOG), well known 
for stabilizing HIF-1α by inhibiting PHD, was used as a positive control for stabilisation of HIF-1α 
under conditions that functionally mimic hypoxia. BMDMs were treated with DMOG for 8 hours 
or Poly(I:C) (25µg/mL) for 0-8 hours (Figure 4.4A). In an attempt to separate the faster migrating 
bands at 40kDa from the non-specific bands detectable in all of the samples, the SDS-PAGE gels 
were electrophoresed for longer time periods. Once again, Poly(I:C) was seen to promote the 
HIF-1α stabilisation migrating at 110kDa. Interestingly the faster migrating band at 40kDa was 





Figure 4.3 Effect of TLR stimulation and hypoxia on levels of HIF-1α  
Immunoblot analysis of HIF-1α (120 kDa) in cell lysates from WT BMDMs stimulated with (A) 
1µg/mL Pam3 (TLR1/2), 1µg/mL Zymosan (TLR2), 25µg/mL Poly(I:C) (TLR3; High molecular 
weight – HMW), 100ng/mL LPS (TLR4), 1µg/mL Flagellin (TLR5), 1µg/mL CL097 (TLR7/8) and 
2µg/mL CpG 1668 (TLR9) for 6 hours. (B) Immunoblot analysis of HIF-1α (120 kDa) in cell lysates 
from WT BMDMs under normoxia (21% O2) and hypoxia (1% O2) conditions. β-actin (42 kDa) was 













Figure 4.4 Dose-dependent and kinetic analysis of the effect of Poly(I:C) on HIF-1α. 
Immunoblot analysis of HIF-1α (120 kDa) in cell lysates from WT BMDMs stimulated with (A) 25 
μg/mL for 2, 4, 6 and 8 hrs, or (B) increasing concentrations of Poly(I:C) (12,5 - 100 μg/mL) for 8 
hours. DMOG (0.5 mM) was used as control for stabilization of HIF-1α. GAPDH (37 kDa) was used 











HIF-1α stabilisation was also assessed following 8 hours stimulation with DMOG or increased 
concentrations of Poly (I:C) (12.5 – 100µg/mL). Both, the faster (40kDa) and the slower (110kDa) 
migrating bands were detected following the stimulations with Poly (I:C). However, stimulation 
of cells with DMOG resulted in expression of the higher molecular weight form only of HIF-1α 
(Figure 4.4B). Interestingly the latter migrates slower than the 110kDa band stabilised by 
Poly(I:C). These data suggest that whilst TLRs, like hypoxia, can promote increased levels of HIF-
1α, they differ from hypoxia in relation to the electrophoretic mobilities of the proteins that are 
detected by the anti-HIF-1α antibody. The faster migrating form that manifests in response to 
TLR stimulation may represent a processed form of HIF-1α that is not apparent in response to 
hypoxia. 
Studies next addressed if the lower molecular weight form of HIF-1α could represent a 
TLR-induced processing event, and if processing was facilitated by either of the 2 main protein 
degradation pathways in cells namely the ubiquitin-proteasome system or lysosomal-mediated 
processing. In order to examine if TLR signalling could trigger processing of full length HIF-1α 
(110kDa) to the smaller 40kDa form, full length HIF-1α was first stabilised with the PHD (prolyl 
hydroxylase domain-containing proteins) inhibitor Dimethyloxaloylglycine (DMOG), followed by 
LPS or Poly (I:C) treatment HIF-1α. DMOG interferes with PHD-dependant hydroxylation of HIF-
1α thus precluding ubiquitination and degradation resulting in HIF-1α up-regulation (Baader et 
al., 1994). As expected the upper band of HIF-1α was strongly induced with DMOG alone but 
notably the low molecular weight form was not detectable (Figure 4.5). Stimulation of the cells 
with the TLR3 and TLR4 ligands, Poly(I:C) and LPS respectively, resulted in increased levels of the 
higher and lower molecular weight forms of HIF-1α but interestingly neither ligand promoted 
augmentation of the levels of the lower form of HIF-1α when co-stimulated with DMOG. 
Phosphorylation of TBK1 and p65 was also examined to confirm signalling downstream of TLR3 
and TLR4. This suggests that TLR signalling cannot directly process full length HIF-1α already 
stabilised by DMOG. 
Next, we examined the ability of the lysosome to process HIF-1α into the faster 
migrating form of 40kDa following TLR activation. Chloroquine, a lysosomotropic agent was 
found to block the ability of Poly(I:C) to stabilise both the 110 and 40kDa forms of HIF-1α 
whereas, it was without effect on the ability of LPS to stabilise both forms (Figure 4.5). 
Furthermore, Chloroquine blocked TLR3-induced phosphorylation of TBK1 and p65 but did not 
affect their activation by TLR4. The lack of effect of Chloroquine on the levels of the 40kDa 
protein induced by LPS suggests that the lysosome does not mediate any processing of full 





Figure 4.5 Effect of Chloroquine, MG132 and DMOG on levels of faster migrating form of HIF-
1α in BMDMs.  
Immunoblot analysis of HIF-1α (120 kDa), phosphorylated (p-) TBK1 (84 kDa) and p-P65 (65 kDa) 
in cell lysates from WT BMDMs pre-treated for 1 hour with 20 μM Chloroquine, 20 μM MG132 
or 0,5mM DMOG, followed by 6 hours treatment with 25 μg/mL Poly(I:C) or 40 ng/mL LPS. 
GAPDH (37 kDa) was used as constitutively expressed housekeeping protein. Data are 







effective in blocking the responses of the TLR3 ligand Poly(I:C). It should be noted that the 
lysosomotropic agent Chloroquine interferes with endosomal acidification (Steinman et al., 
1983). TLR3 is predominantly located in endosomes and TLR4 is endocytosed into endosomes 
to initiate TRAM-TRIF signalling (Akira and Takeda, 2004; O’Neill, Golenbock and Bowie, 2013). 
Furthermore, endosomal acidification is essential for an adequate activation of TLR3 (Pohar et 
al., 2014). The selective inhibitory effects of Chloroquine on the response to Poly(I:C) and not 
LPS suggests that endosomal TLR3 can trigger downstream signalling to upregulate both forms 
of HIF-1α whereas plasma membrane located TLR4 is sufficient to achieve the same response.  
Given that the lysosome appears to play a selective role in early TLR3 activation and not 
any processing of HIF-1α, studies were next performed using the proteasome inhibitor MG132 
to examine if the proteasome contributes to possible processing of full length HIF-1α to the 
smaller 40kDA form. MG132 acts as an inhibitor of the 20S proteasome and calpain (Tsubuki et 
al., 1996). As HIF-1α is mainly degraded by the proteasome, after hydroxylation by PHDs and 
ubiquitination by pVHL, MG132 induces strong accumulation of the 110kDa form of HIF-1α 
(Figure 4.5). Cells were also treated with LPS or Poly(I:C) in order to assess whether these ligands 
could still induce the formation of the smaller 40kDa form in the presence of MG132. However, 
there was a dramatic reduction in the levels of 110 and 40kDa forms of HIF when cells were co-
treated with Poly(I:C) and MG132 with total loss of both forms when the latter was co-treated 
with LPS (Figure 4.5). Phosphorylation p65 was also undetectable when the cells were treated 
with MG132 followed by LPS or Poly(I:C) while phosphorylation of TBK was reduced but 
remained evident. These results were expected as phosphorylation of p65 depends on 
proteasomal degradation of NF-B inhibitory protein IB, but activation of TBK it is independent 
of the proteasome pathway. 
Since co-stimulation with MG132 and TLR ligands appear to block all downstream 
signalling, we were keen to assess if this was due to cytotoxicity. We were especially interested 
in exploring whether the cells were undergoing apoptosis since, as described in the previous 
chapter, NF-B is a pro-survival factor by upregulating anti-apoptotic proteins such as c-FLIP, 
IAPs and Bcl proteins, and MG132 will inhibit NF-B activation by blocking proteasomal 
degradation of the NF-B inhibitory protein IB. BMDMs were pre-treated with MG132 for 1 
hour followed by LPS stimulation for 30 minutes, 1 hour, 3 hours or 6 hours (Figure 4.6A). As 
expected the expression of HIF-1α stabilises following 3 hours and 6 hours treatment of MG132 
alone. Stimulation with LPS alone for 6 hours also induced HIF-1α stabilization, as did 1-hour 





Figure 4.6 Proteasome inhibition and TLR4 stimulation induce apoptosis in BMDMs.  
Immunoblot analysis of (A) HIF-1α (120 kDa), FLIP (55 kDa) and phosphorylated (p-) IBα (40 
kDa), or (B) p-MLKL (54 kDa), RIP3 (46-53 kDa), RIP1 (74 kDa), cleaved (c-) Caspase 8 (18 and 43 
kDa) and c-PARP (89 and 116 kDa) in cell lysates from WT BMDMs pre-treated for 1 hour with 
20 μM MG132, followed by 30 minutes, 1, 3 or 6 hours stimulation with 40 ng/mL LPS. β-actin 
(42 kDa) was used as constitutively expressed housekeeping protein. Data are representative of 












as previously seen, the 110kDa HIF-1α band was undetectable when co-stimulated with MG132 
(1-hour pre-treatment) and LPS (6 hours treatment). Cytotoxicity was then evaluated by 
determining the expression of apoptotic molecular markers such as cleaved Caspase 8 and PARP 
(Figure 4.6B). As described in section 3.1.1.1, cleavage of caspase proteins is essential for their 
activation resulting in formation of two subunits p43/p41 and p18 following Caspase 8 
activation, and p17 and p19 following caspase 3 activation. In addition, the processing of DNA-
repair protein Poly (ADP-ribose) polymerase (PARP) from its full length p116 into its cleaved 
form p89 was also examined as one of the apoptotic markers. Cleavage of both caspase 8 and 
PARP was induced following 1-hour pre-treatment with MG132 and 3 hours or 6 hours LPS 
stimulation. The inhibitor alone appeared to induce the cleavage of caspase 8 and PARP at the 
same time points but to a lesser extent than when combined with LPS. Next, the expression of 
RIP kinases, RIP3 and RIP1 was evaluated, considering their essential role in mediating different 
types of cell death regulation (Figure 4.6B). Both RIP3 and RIP1 were consistently expressed 
following 30 minutes and up to 6 hours stimulation, with no upward shift of RIP3 observed at 
any time point, as would be expected if necroptosis signalling was activated. Interestingly, a 
double band was seen for RIP1 when treated with MG132 or LPS, or the combination of both at 
different time points. Such observation is most likely reflecting post-translational modification 
of RIP1, such as phosphorylation or ubiquitination, induced by the treatments. Furthermore, 
following co-treatment with MG132 (1-hour pre-treatment) and 3 hours LPS treatment, the 
expression of RIP3 and RIP1 was decreased and completely diminished when LPS was left for 6 
hours. Evidently, inhibition of the proteasome with MG132 blocks NF-B activation and the 
additional stimulation with TLR4 ligand LPS drives the signalling pathway towards apoptosis, 
explaining the disappearance of the higher molecular weight form of HIF-1α.   
Studies next examined if the processing of HIF-1α following activation of TLR3 and TLR4 
was cell specific. In order to address this, murine embryonic fibroblast (MEFs) were pre-treated 
for 1 hour with either Chloroquine, DMOG or MG132 followed by stimulation with LPS or 
Poly(I:C) for 6 hours as previously done in BMDMs (Figure 4.7). Some stabilization of the higher 
molecular weight band of HIF-1α was seen following treatment with ligands alone but more 
interestingly, the lower migrating band of HIF-1α is undetectable following stimulation with 
Poly(I:C) and LPS in this cell type suggesting cell specificity. It is to note that the HIF-1α upper 
band stabilization was considerably stronger with DMOG and MG132 as expected, due to their 
role in interfering with HIF-1α proteasomal degradation. However, there was no decrease or 
loss of this upper band with the combination of MG132 and either LPS or Poly(I:C) as seen in 






Figure 4.7 Effect of Chloroquine, MG132 and DMOG on levels of faster migrating form of HIF-
1α in MEFs.  
Immunoblot analysis of HIF-1α (120 kDa) in cell lysates from WT MEFs pre-treated for 1 hour 
with 20 μM Chloroquine, 20 μM MG132 or 0,5mM DMOG, followed by 6 hours treatment with 
25 μg/mL Poly(I:C) or 40 ng/mL LPS. GAPDH (37 kDa) was used as constitutively expressed 






upper band, as the pattern was similar to stimulation with LPS or Poly(I:C) only. All together 
these results suggest the TLR3/4-induced lower band of HIF-1α is specific to macrophages, as 
well as the activation of apoptosis induced by proteasome inhibition and TLR4 stimulation with 
LPS. 
The possibility that the appearance of the lower migrating HIF-1α band induced by 
TLR3/4 activation could affect the expression of cytokines (TNFα, IL6 or IL10) (Figures 4.8 and 
4.10) and HIF responsive genes (Figures 4.9 and 4.11) was next examined. To evaluate cytokine 
production, BMDMs were treated with the corresponding inhibitors for 1 hour followed by 
stimulation with LPS or Poly(I:C) for 24 hours to allow for accumulation of the cytokines in the 
supernatant (Figures 4.8 and 4.10). As expected, activation of TLR4 by LPS alone resulted in 
induction of TNFα, IL6 and IL10 (Figure 4.8). However, when the cells were co-stimulated with 
DMOG (1-hour pre-treatment) and LPS a reduction in IL6 and IL10 production was seen. In turn, 
Chloroquine stimulation did not alter cytokine expression when compared with LPS treatment 
alone. These results correlate with previous observations where neither of the inhibitors were 
found to exert any change to the lower migrating band of HIF-1α. In contrast, inhibition of the 
proteasome with MG132 alone moderately increased the expression of TNFα, and strongly 
induced the expression of IL10. The latter effect prompted further questions regarding the 
capacity of the proteasomal inhibitors to induce this anti-inflammatory cytokine and this formed 
the focus of Chapter 5 of this thesis. Furthermore, the combined treatment of MG132 and LPS 
significantly reduced expression of TNFα, IL6 and IL10. Considering our previous findings 
showing triggering of apoptotic mechanism under proteasome inhibition and TLR4 stimulation, 
the reduction of cytokines under these conditions could be explained as a secondary effect of 
such program cell death pathway.   
The effect on HIF responsive genes was also assessed using BMDMs pre-treated with 
the above listed inhibitors followed by 6 hours stimulation with LPS. Messenger RNA (mRNA) 
was extracted and the levels of CXCL10, glucose transporter GLUT-1 and vascular endothelial 
growth factor (VEGF) were analysed by RT-PCR (Figure 4.9). CXCL10 was evaluated as a positive 
control of antimicrobial response induced by LPS, while GLUT-1 and VEGF are known to be 
induced under hypoxic conditions in a HIF-1α-dependant signalling (Sánchez-Elsner et al., 2001; 
Hayashi et al., 2005; Liu et al., 2012). Stimulation of the cells with TLR4 ligand LPS increased 
CXCL10 mRNA levels but did not change GLUT-1 and VEGF mRNA levels. This observation was 
expected considering TLR4 activation induces strong pro-inflammatory activation with 
chemokines like CXCL10 while GLUT-1 and VEGF are HIF specific responsive genes. In addition, 
the time point evaluated was not long enough to induce the expression of GLUT-1 and VEGF in 
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a TLR4 signalling-dependant activation. In contrast, the mRNA levels of both HIF responsive 
genes were seen to increase considerably with DMOG. Such effect was predictable given this 
inhibitor mediates HIF stabilization by blocking its hydroxylation. The combined treatment of 
DMOG and LPS had a moderate effect on GLUT-1 and VEGF mRNA levels with tendency to 
reduction. Meanwhile, Chloroquine had a negligible effect on CXCL10, GLUT-1 or VEGF mRNA 
levels by itself or when combined with LPS. Finally, proteasome inhibitor MG132 treatment 
alone increased GLUT-1 and VEGF levels modestly, with further decrease of GLUT-1 when 
combined with LPS stimulation. The levels of mRNA for the genes evaluated do not seem to 






Figure 4.8 Effect of Chloroquine, MG132 and DMOG on cytokine expression in BMDMs treated 
with LPS. 
ELISA analysis of cytokines TNFα (upper panel), IL6 (left-lower panel) and IL10 (right-lower panel) 
from supernatants of WT BMDMs pre-treated for 1 hour with 20 μM Chloroquine, 20 μM MG132 
or 0,5mM DMOG, followed by 24 hours stimulation with 40 ng/mL LPS. Data are presented as 
the mean ± SEM of three independent experiments and were subjected to two-tailed Student’s 






























































Figure 4.9 Effect of Chloroquine, MG132 and DMOG on genes activated by HIF-1α signalling in 
BMDMs treated with LPS. 
Quantitative PCR of mRNA expression for CXCL10 (upper panel), GLUT1 (left-lower panel) and 
VEGF (right-lower panel) in cell lysates of WT BMDMs pre-treated for 1 hour with 20 μM 
Chloroquine, 20 μM MG132 or 0,5mM DMOG, followed by 6 hours stimulation with 40 ng/mL 
LPS. Data are presented as the mean ± SEM of three independent experiments and were 









































































Similar analysis on cytokine expression and mRNA levels were performed using Poly(I:C) 
to determine possible variations related to the TLR3-induced lower migrating band (Figures 4.10 
and 4.11). Poly(I:C) stimulation also increased the expression of all the cytokines (TNFα, IL6 or 
IL10), however, the expression was not as strong as that observed with LPS treatment (Figure 
4.10). Cytokine expression was unaffected following the treatment with inhibitors, DMOG and 
Chloroquine alone, while MG132 increased IL10 (this will be further addressed in Chapter 5). 
However, the co-treatment of either DMOG or MG132 with Poly(I:C) significantly decreased the 
expression of TNFα, IL6 and IL10. In the case of Chloroquine with Poly(I:C), a reduction in the 
cytokines was expected as this TLR3 ligand requires acidification to bind the receptor, and 
acidification is blocked by Chloroquine. Meanwhile, the reduction in cytokine production 
following stimulation with DMOG or MG132, which promote HIF stabilisation, and Poly(I:C) 
could indicate cross-regulation between TLR3 and HIF signalling. In addition to cytokine 
expression, the effects on CXCL10, GLUT-1 and VEGF mRNA levels were also explored. BMDMs 
were pre-treated with DMOG, MG132 or Chloroquine followed by Poly(I:C) treatment (Figure 
4.11). TLR3-ligand by itself induced poor expression of GLUT-1 and VEGF, but increased CXCL10 
levels. DMOG, as seen with LPS, induced GLUT-1 and VEGF by itself and both were reduced when 
co-treated with Poly(I:C), where VEGF mRNA levels were found to be significantly lower when 
co-treated with DMOG and Poly(I:C) compared to DMOG treatment alone. Chloroquine had no 
major effect on CXCL10, GLUT-1 and VEGF mRNA levels, except for a tendency to reduce CXCL10 
levels when co-treated with Poly(I:C). Finally, with the proteasome inhibitor MG132, there was 
a reduction in GLUT-1 but not VEGF levels when co-stimulated with Poly(I:C), similar to results 
seen with MG132 and LPS co-stimulation. 
Considering TLRs can trigger metabolic re-programming from oxidative phosphorylation 
to glycolysis in innate immune signalling to trigger inflammation, studies next addressed the 
effect of blocking glycolysis on TLR-regulation of HIF-1α (Figures 4.12 to 4.14). A modified 
glucose molecule known as 2-Deoxy-D-glucose (2-DOG) was used as inhibitor of glycolysis. 2-
DOG acts a competitive inhibitor by blocking production of glucose-6-phosphate from glucose 
(Wick et al., 1957). BMDMs were treated with the inhibitor for 1 hour followed by either Poly(I:C) 
or LPS stimulation for 6 hours. Treatment with 2-DOG reduced TLR3/4-induced upper and lower 
band of HIF-1α when compared with treatment with ligands only (Figure 4.12). These findings 
suggest that glycolysis, one of the central processes regulated by HIF signalling, can positively 
regulate HIF expression. The effects of glycolysis inhibition and TLR3/4 activation on cytokine 






Figure 4.10 Effect of Chloroquine, MG132 and DMOG on cytokine expression in BMDMs 
treated with Poly(I:C). 
ELISA analysis of cytokines TNFα (upper panel), IL6 (left-lower panel) and IL10 (right-lower panel) 
from supernatants of WT BMDMs pre-treated for 1 hour with 20 μM Chloroquine, 20 μM MG132 
or 0,5mM DMOG, followed by 24 hours stimulation with 25 μg/mL Poly(I:C). Data are presented 
as the mean ± SEM of three independent experiments and were subjected to two-tailed 



































































Figure 4.11 Effect of Chloroquine, MG132 or DMOG on HIF-1α-responsive genes in BMDMs 
treated with Poly(I:C). 
Quantitative PCR of mRNA expression for CXCL10 (upper panel), GLUT1 (left-lower panel) and 
VEGF (right-lower panel) in cell lysates of WT BMDMs pre-treated for 1 hour with 20 μM 
Chloroquine, 20 μM MG132 or 0,5mM DMOG, followed by 6 hours stimulation with 25 μg/mL 
Poly(I:C). Data are presented as the mean ± SEM of three independent experiments and were 











































































Figure 4.12 Effect of 2-DOG on HIF-1α in BMDMs.  
Immunoblot analysis of HIF-1α (120 kDa) and phosphorylated (p-) TBK1 (84 kDa) in cell lysates 
from WT BMDMs pre-treated for 1 hour with 5 mM 2-DOG, followed by 6 hours stimulation with 
25 μg/mL Poly(I:C) or 40 ng/mL LPS. GAPDH (37 kDa) was used as constitutively expressed 
housekeeping protein. Long exposure corresponds to up to one hour or longer time of exposure 
of the film to the membranes cover with ECL, and short exposure to less than half an hour 










Figure 4.13 Effect of 2-DOG on expression of cytokines and HIF-1α-responsive genes in BMDMs 
treated with LPS. 
(A) ELISA analysis of cytokines TNFα (left panel), IL6 (centre panel) and IL10 (right panel) in 
supernatant and (B) quantitative PCR of mRNA expression for CXCL10 (left panel), GLUT1 (centre 
panel) and VEGF (right panel) in cell lysates of WT BMDMs pre-treated for 1 hour with 5 mM 2-
DOG, followed by 24 hours stimulation with 40 ng/mL LPS. Data are presented as the mean ± 
SEM of three independent experiments and were subjected to two-tailed Student’s t-test. *p < 






















































































































Figure 4.14 Effect of 2-DOG on cytokine expression and HIF-1α-responsive genes in BMDMs 
treated with Poly(I:C).  
(A) ELISA analysis of cytokines TNFα (left panel), IL6 (centre panel) and IL10 (right panel) in 
supernatant and (B) quantitative PCR of mRNA expression for CXCL10 (left panel), GLUT1 (centre 
panel) and VEGF (right panel) in cell lysates of WT BMDMs pre-treated for 1 hour with 5 mM 2-
DOG, followed by 24 hour stimulation with 25 μg/mL Poly(I:C). Data are presented as the mean 
± SEM of three independent experiments and were subjected to two-tailed Student’s t-test. *p 



















































































































next examined. Blocking glycolysis did not increase the expression of TNFα, IL6 and IL10 alone 
but was seen to reduce IL10 expression induced by TLR4 ligand LPS (Figure 4.13A). Furthermore, 
2-DOG treatment alone augmented GLUT-1 and VEGF mRNA levels (Figure 4.13B). In contrast 
to TLR4 signalling, blocking glycolysis followed by TLR3 stimulation with Poly(I:C) significantly 
reduced the expression of TNFα, IL6 and IL10 (Figure 4.14A). However, the combined treatment 
of 2-DOG and Poly(I:C) did not change GLUT-1 and VEGF mRNA levels compared to 2-DOG alone 
(Figure 4.14B). These results show glycolysis can regulate HIF upper and lower bands and 
expression of cytokines but does not affect GLUT-1 and VEGF mRNA levels.  
Altogether these findings point at a close interplay between HIF and TLR3 signalling. The 
immunoblotting analysis suggest the lower migrating form of HIF-1α might be induced in a TRIF-
dependant signalling. It also clearly indicates that such effect is restricted to macrophages and 
can affect the expression of pro and anti-inflammatory cytokines activated by TLR3/4 signalling. 
In addition, metabolic re-programming, that is triggered by TLRs, appears to play an important 




4.2.2 Investigating TLR3/4 downstream signalling on induction of faster migrating form of 
HIF-1α 
Whilst the pathways mediating hypoxia-induced stabilisation of HIF-1α are well understood the 
early signalling mechanisms that mediate the regulation of HIF-1α by TLRs are not well 
characterised. To this end, studies were then performed to map the receptor proximal signalling 
pathways that are likely to be employed by TLRs to drive increased levels of HIF-1α. We initially 
explored the role of signalling downstream of TRIF in mediating the response to Poly (I:C) and 
LPS (Figure 4.15). WT and TRIF- or IRF3- deficient immortalized BMDMs (iBMDMs) were 
stimulated with LPS or Poly(I:C) for 4 or 6 hours. The higher migrating band of HIF-1α was 
strongly induced in WT iBMDMs following stimulation with both TLR-ligands for 4 and 6 hours 
(Figure 4.15). Meanwhile, the lower migrating band of HIF-1α was apparent at 6 hours treatment 
with both LPS and Poly(I:C) but, contrary to the observation in primary cells, it was less 
prominently induced by Poly(I:C). The expression of the higher migrating band of HIF-1α in trif-/- 
iBMDMs was similar to WT control cells. However, the lower migrating band disappeared in the 
cells deficient for TRIF compared with WT cells, potentially indicating a crucial role of TRIF 
signalling in inducing the lower form of HIF-1α (Figure 4.15A). The next step was to probe 
signalling downstream of TRIF and the role of IRF3 was evaluated using iBMDMs deficient for 
this transcription factor (Figure 4.15B). IRF3-deficient cells showed reduced expression of the 
higher migrating form of HIF-1α for both treatments with LPS and Poly(I:C). Moreover, the 
expression of HIF-1α lower migrating band was also clearly reduced in irf3-/- iBMDMs treated 
with LPS and completely lost when the cells were treated with Poly(I:C) (Figure 4.15B). These 
results indicate the TLR3-induced lower migrating form of HIF-1α depends on IRF3 activation, 
while TLR4-induced lower migrating band may require additional signalling pathways such as 
the MyD88 pathway that is mediated by interleukin-1 receptor-associated kinase (IRAKs).  
The role of early molecular signalling downstream of TLR4 specifically mediated by IRAKs 
was next explored. Primary WT BMDMs were treated with LPS or Poly(I:C) in the presence or 
absence of a benzimidazole compound which selectively inhibitors IRAK1 and IRAK4. Cells were 
pre-treated with the inhibitor for 1 hour and then stimulated with the ligands for TLR4 and TLR3 
for 6 hours (Figure 4.16). Expression of HIF-1α upper and lower bands was apparent in cells 
subjected to either LPS or Poly(I:C) treatment. Inhibition of IRAK1/4 did not affect the expression 
of the higher migrating form of HIF-1α however, the expression of lower migrating form of HIF-
1α in response to LPS, was diminished when the cells were treated with the inhibitor and it 





Figure 4.15 TLR4/3-induced stabilisation of HIF-1α is dependent on TRIF and IRF3 signalling. 
Immunoblot analysis of HIF-1α (120 kDa) in cell lysates from (A) WT and TRIF–/–, or (B) WT and 
IRF3–/– immortalized BMDMs stimulated for 4 or 6 hours with 40 ng/mL LPS or 25 μg/mL 
Poly(I:C). β-actin (42 kDa) was used as constitutively expressed housekeeping protein. Data are 












Figure 4.16 Inhibition of IRAK1/4 reduces TLR4/3-induced lower migrating form of HIF-1α in 
BMDMs. 
Immunoblot analysis of HIF-1α (120 kDa) in cell lysates from WT BMDMs pre-treated for 1 hour 
with 20 μM IRAK1/4 inhibitor, followed by stimulation with 40 ng/mL LPS or 25 μg/mL Poly(I:C) 
for 6 hours. β-actin (42 kDa) was used as constitutively expressed housekeeping protein. Data 







results suggest TLR3/4-induced lower form of HIF-1α depends on downstream activation of their 
signalling pathways.  
Having shown that the IRAK inhibitor affects the levels of the 40kDa migrating form of 
HIF-1α, studies next explored the role of the Pellino E3 ubiquitin ligases in regulation of HIF since 
Pellino proteins are substrates for IRAK kinase activity. Furthermore, our group has previously 
suggested that TNF receptor associated 6 (TRAF6) can mediate stabilisation of HIF-1α under 
conditions that simulate obesity and that the ubiquitin ligase Pellino 3 negatively regulates such 
TRAF6-induced HIF-1α stabilization in  obesity-induced inflammation (Yang et al., 2014). We 
were thus interested in exploring the wider role of Pellino 2 and Pellino 3 in TLR-induced 
regulation of HIF-1α. Since TRAF6 is employed by TLR4 but not TLR3 we were especially 
interested to evaluate the effects of Pellino deficiency on HIF-1α stabilization in response to LPS 
and Poly(I:C). WT, Peli2-/- and Peli3-/- BMDMs were treated with Poly(I:C), LPS or both for 8 hours 
(Figure 4.17). Phosphorylated TBK1 was used as an indicator of TRIF-dependent signalling 
(typical of TLR3 and TLR4 signalling). Again, in WT BMDMs both LPS and Poly(I:C) led to 
stabilisation of both the higher migrating form (110kDa) and the lower migrating form (40kDa) 
of HIF-1α. However, the expression levels of the 40 kDa form of HIF-1α in cells co-treated with 
both LPS and Poly(I:C) was slightly reduced compared to the levels of the same band in cells 
treated with either ligand alone. As previously described in our lab, Peli3-/- BMDMs treated with 
LPS showed increased expression of HIF-1α compared with WT BMDMs as evidenced by 
increased levels of the 110kDa band (Yang et al., 2014). Interestingly, Pellino 3 deficiency did not 
affect the expression levels of the lower 40kDa band that was manifested by LPS. In addition, 
the levels of the 110kDa band were comparable in samples from WT and Peli3-/- BMDMs treated 
with Poly(I:C) suggesting that the negative effects of Pellino 3 on HIF-1α is restricted to the TLR4 
pathway. This is hardly surprising since TLR3 does not employ TRAF6. The patterns of HIF-1α 
stabilised by LPS and Poly(I:C) in Peli2-/- BMDMs were largely the same as in WT cells. These data 
indicate that Pellino 3 negatively regulates TLR4- but not TLR3-induced stabilisation of HIF-1α 





Figure 4.17 Differential roles for Pellino 2 and 3 in regulating TLR4/3-induced stabilisation of 
HIF-1α. 
Immunoblot analysis of HIF-1α (120 kDa) and phosphorylated (p-) TBK1 (84 kDa) in cell lysates 
from WT, Peli2–/– and Peli3–/– BMDMs stimulated with 25 μg/mL Poly(I:C) and/or 40 ng/mL LPS 
for 8 hours. GAPDH (37 kDa) was used as constitutively expressed housekeeping protein. Data 









HIF signalling has been shown to interact with inflammatory pathways at many levels.  Several 
transcription factors, including NF-B, STAT3 and AP-1 , essential in inflammation and innate 
immune response have been closely linked with  HIF activation, (Alfranca et al., 2002; Salnikow 
et al., 2002; Jung et al., 2005; Maxwell et al., 2007; Bruning et al., 2012; Pawlus, Wang and Hu, 
2014). The present study evaluated the changes in HIF-1α expression induced by stimulation of 
different TLR signalling pathways. When a panel of six ligands for TLRs was evaluated, increased 
levels of HIF-1α was seen at the typical molecular size of 110kDa. This data is to be expected 
since TLR-induced NF-B signalling has been shown to upregulate expression of HIF-1α (Rius et 
al., 2008; van Uden, Kenneth and Rocha, 2008). However, in addition to the upper band, a lower 
form of HIF-1α of approximately 40kDa was observed when murine BMDMs were treated with 
Poly(I:C) or LPS (Figure 4.3A). This lower form of HIF-1α has not been previously described. 
Indeed, publications in the HIF field tend to show regions of immunoblots corresponding to 
mobilities of proteins of 75kDa and above. As TLR3 has been previously described to modulate 
a number of cellular processes through HIF signalling in inflammation and cancer, a potential 
isoform induced by this specific viral associated pathway was considered worthy of further 
characterisation. Interestingly, this lower form of HIF-1α was evident in response to treatment 
of cells with Poly(I:C) but not in response to hypoxic conditions (Figures 4.3B and 4.4). The 
nature of this lower form of HIF-1α is not yet understood. Two mRNA isoforms of HIF-1α have 
been described in mice, encoded from different promotors and exons: I.1 and I.2 (Wenger et al., 
1998; Lukashev et al., 2001). The expression of I.1 has been described to be tissue specific being 
expressed highest in kidney, tongue, stomach, and testis in mice, while the I.2 isoform is 
ubiquitously expressed in all tissues (Wenger et al., 1998; Paone et al., 2010). It could be 
considered that one of these isoforms corresponds to the lower band observed in the 
macrophages treated with LPS or Poly(I:C). However, Lukashev and co-workers reported in 2001 
that the main difference between the proteins encoded by the isoforms I.1 and I.2 is a loss of a 
12 N-terminal amino acid residues in the protein encoded by I.1 (Lukashev et al., 2001). Such a 
modest truncation would not explain the appearance of a protein of ~40kDa in size. Based on 
the results of this thesis, it cannot be ruled out that the 40kDa form of HIF-1α corresponds to a 
potential spliced form of one of these isoforms. However, further studies are required to address 
this possibility. It is to note that the lower band was only seen with the antibody from the 
company Novus, a polyclonal antibody that recognizes the region between residues 775 and the 
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C-terminus (residue 826) of HIF-1α (Novus NB 100-449; Species cross-reactivity: human, mouse, 
rat, chicken, monkey and non-human primate). The other three well-known and widely used 
antibodies from BD (CAT# 610958; Species cross-reactivity: human), Cell signalling (CAT# 14179; 
Species cross-reactivity: human, mouse, rat and monkey) and Abcam (CAT# ab16066; Species 
cross-reactivity: human, mouse, cow, pig, non-human primate) are monoclonal and correspond 
to residues 610-727 and residues surrounding Lys460 and 530-826 (C-terminal) respectively. The 
immunoreactvity of the faster migrating HIF form with an antibody raised against region 775-
826 suggest the 40kDa protein is likely a C-terminal fragment of HIF-1(Figure 4.18).  
We explored the hypothesis that TLR signalling may promote the processing of full 
length HIF-1 into a smaller 40kDa form by assessing if TLR3 or TLR4 ligands could generate this 
smaller form from full length HIF-1 previously stabilised by the PHD inhibitor DMOG. However, 
both TLR agonists were unable to trigger such processing. We also examined if the putative 
processing of HIF-1 could be mediated by the proteasome or lysosomal-mediated degradation. 
However, the interpretation of these studies was complicated by ancillary effects of the 
inhibitors of these pathways. The use of the proteasome inhibitor MG132 in conjunction with 
the TLR ligands resulted in cell apoptosis and this is likely due to MG132 precluding IB 
degradation and NF-B activation thus preventing the induction of pro-survival proteins such as 
c-FLIP, IAP proteins and bcl proteins (Brasier, 2006; Gilmore, 2006). The lysosome inhibitor 
chloroquine inhibited the stabilisation of HIF-1α in response to Poly(I:C) but this does not 
necessarily relate to effects on the lysosome since all downstream TLR3 signalling was blocked 
by chloroquine. Instead the effects of chloroquine are likely due to inhibition of initial activation 
of TLR3 in the endosome.  
Interestingly and unlike BMDMs, MEFS did not display the lower form of HIF-1α and did 
not undergo apoptosis in response to co-stimulation with LPS and MG132. Such findings may 
relate to different isoforms of HIF-1α being upregulated in a tissue-specific manner and a novel 
TLR-mediated mechanism of regulating macrophages’ retraining or pattern of tolerance 
(Wenger et al., 1998; Paone et al., 2010; Butcher et al., 2018). Indeed, HIF-1α may have specific 
roles in macrophages and this may underlie the close relationship of hypoxic and inflammatory 
signalling in the myeloid lineage (Cramer et al., 2003; Palazon et al., 2014). Upregulation of 
proinflammatory cytokines and chemokines or their corresponding receptors has been 
described to be a HIF/NF-B-mediated mechanism activated by TLR signalling in different types 
of immune cells and diseases such as rheumatoid arthritis, sepsis and cancer (Maxwell et al., 





Figure 4.18 Schematic representation of the binding of different antibodies to HIF-1α. 
The antibody used for this research work recognizes the region between residues 775 and 826 
in the C-terminus of HIF-1α (Polyclonal, Novus NB 100-449). The other three well-known 
antibodies are monoclonal and correspond to residues 610-727 (BD, CAT# 610958) and residues 





interest in the importance of metabolic re-programming to glycolysis for inflammatory function 
in macrophages. HIF-1α plays a key role in this process by upregulation of glycolytic enzymes 
(Dengler, Galbraith and Espinosa, 2014). However, we now show that a glycolysis inhibitor can 
reduce levels of HIF-1α suggesting a regulatory loop between the HIF-1α pathway and glycolysis.  
Efforts were also made to identify the receptor proximal signalling molecules that are 
used by TLRs to stabilise HIF-1α including its smaller 40kDa form. Immortalized BMDMs deficient 
for TRIF and IRF3 provided evidence of a TRIF/IRF3-dependant signalling axis upstream of HIF-
1α stabilisation. This was especially true for the TLR3 pathway. We also further probed the role 
of TLR4 proximal molecules and demonstrated important roles for IRAK kinases but not for their 
E3 ubiquitin ligases Pellino 2 and Pellino 3. Such findings suggest that whilst both TLR3 and TLR4 
can similarly regulate HIF-1α, the upstream signalling components that effect this common 
outcome differ between the 2 TLR pathways. 
The functional relevance of HIF-1α to TLR signalling is likely to extend beyond effects on 
inflammation. Indeed, this relationship may have functional relevance to  the metabolic and 
immunological reprogramming that favours the chemoresistance and tumour progression 
induced by TLR3 and TLR4 in different types of cancer (Salaun et al., 2006; Paone et al., 2010; 
Zhang et al., 2010; Oblak and Jerala, 2011; Tewari et al., 2012; Veyrat et al., 2016; Matijevic 
Glavan et al., 2017). In addition, HIF-2α has been shown to be overexpressed in tumour-
associated macrophages (TAMs) and to upregulate proinflammatory cytokine/chemokines in 
LPS-activated macrophages in vitro (Imtiyaz et al., 2010). This research also described that mice 
lacking HIF-2α in myeloid cells were resistant to LPS-induced endotoxemia and present less TAM 
infiltration in murine models of hepatocellular and colitis-associated colon carcinoma (Imtiyaz 
et al., 2010). Evidently, understanding the innate immune signalling-mediated regulation of HIF-
1α isoforms in macrophages could facilitate the targeting of these cells in pathological scenarios. 
Whilst the present studies add some insight into the mechanisms by which TLRs can trigger likely 
stabilisation of HIF-1α, they also highlight novel and additional complexity in that TLRs promotes 
the formation of smaller forms of HIF-1α than the classical 110kDa form. The dominant smaller 
form with mass of ~40kDa has not been previously described. It is likely to represent some C-
terminal processed form or fragment of HIF-1α since it is recognised by a highly specific anti- 
HIF-1α antibody and is only evident when full length HIF-1α is also visible. Table 4.2 summarises 
the findings of this research regarding the expression of HIF-1α lower form in the different types 










WT LPS ++ 








WT LPS +++ 
 Poly(I:C) + 
TRIF-deficient LPS NB 
 Poly(I:C) NB 
IRF3-deficient LPS + 
 Poly(I:C) NB 
 
Table 4.2 Summary of the observed expression of HIF-1α lower band (~40kDa) in primary 
BMDMs and immortalized BMDMs (WT, TRIF-/- and IRF3-/-) treated with LPS or Poly(I:C). 





Interestingly as part of these studies a very novel and unanticipated finding was 
observed when macrophages were treated with MG132 to explore the potential role of the 
proteasome in any putative processing of HIF-1α. Efforts were also made to correlate any effects 
on HIF-1α processing with expression of TLR-responsive cytokines. Intriguingly, as part of these 
approaches, it was noted that treatment of macrophages with MG132 alone induced high levels 
of IL-10. This highlighted a potential new relationship between the proteasome and anti-
inflammatory IL-10 and warranted more detailed characterisation as described in the next 
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As previously described, the immune system has multiple ways of self-regulating its 
inflammatory responses to protect tissues and biological systems from excessive and prolonged 
activation of soluble or cellular pro-inflammatory signals. The cytokine IL10 is an important 
immunotolerant signal. This cytokine has an essential role in regulating the response of the 
immune system to pathogens and it is commonly induced  by cells in the  innate and adaptive 
immune system (Saraiva & O’Garra, 2010). However, increased levels of the IL10 in patients with 
cancer has also been described as an indicator of poor prognosis and disease progression, 
especially in the case of multiple myeloma (MM) (Mannino et al., 2015). The proteasome 
inhibitor Bortezomib is one of the first line treatments for MM, but a number of patients have 
been shown to become refractory to the treatment. The reason for loss of responsiveness is not 
well understood. In the previous chapter, murine primary macrophages treated with the 
proteasome inhibitor MG132, produced high levels of IL-10. This raised the intriguing possibility 
that Bortezomib could also induce IL-10 in macrophages that would be counter-productive in its 
treatment of MM. This may have serious consequences in terms of its therapeutic efficacy and 
so the regulation of IL-10 by proteasome inhibitors was considered worth of further 
investigation in this study. 
5.1.1 IL10 biology, cellular expression and signalling pathways 
Interleukin (IL)-10 is one of the most studied anti-inflammatory soluble proteins. Its main 
function is to regulate excessive immune response to infectious pathologies and to restrict 
autoimmune responses. Structurally, human IL10 is a homodimer of subunits of approximately 
35kDa (Zdanov et al., 1995). Multiple single nucleotide polymorphisms (SNPs) have been 
described for the IL10 promoter and its receptor, some of them with strong correlations to 
cancer or autoimmune diseases (Jung et al., 2016; Kasamatsu et al., 2017). Most immune cells 
types have the capacity to produce IL10. Its upregulation by a particular kind of cell is specific to 
the nature of tissue affected, the stimulus being activated and the time of the immune response 
(Sabat et al., 2010). As reviewed by Saraiva and O’Garra in 2010, IL-10 is largely derived from 
monocytes-macrophages, dendritic cells (DCs), mast cells, natural killer (NK) cells, neutrophils 
and eosinophils in the innate immune system. Additionally, many T lymphocytes subpopulations 
have been identified as producers of IL10, among them T helper 1 (TH1), TH2 and TH17, as well as 
TReg, CD8+ lymphocytes and B cells in the adaptive immune system (Figure 5.1). In cells from the 





Figure 5.1 IL10 expression by immune cells.  
(A) Macrophages and myeloid dendritic cells (DCs), produce IL10 in response to microbial 
products mostly through ERK-dependent signalling. Meanwhile, production of IL10 by (B) T 
helper (Th) cells requires of a specific profile of cytokines expression depending on the cell 
subtype. Differentiation and downstream signalling activation of STAT and ERK pathways is 
necessary for production of IL10 in naive CD4+ T cells. The Th1 subtype depends on high doses 
of antigen presented by DCs and/or IL-12 to differentiate from naïve cells and produce 
interferon-γ (IFNγ) or IL10. IL-4 and STAT6 signalling pathways are necessary for Th2 cells to 
produce IL10. In the case of Th17 the signalling mechanism is not clear but is believed to depend 
on TGFβ, IL6, IL-21 and/or IL-27 and STAT3 signalling. Other cells like TReg, CD8+ T cells, B cells, 
mast cells and eosinophils, also produce IL10 (Adapted from Saraiva & O’Garra, 2010).  
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pathogens or endogenous signals from apoptotic cells by limiting TH1 and TH2 responses and 
upregulating differentiation of TReg cells. In addition, IL10 produced by T helper 1 (TH1), TH2 and 
TH17 cells negatively regulates the activation of DCs and macrophages (Saraiva and O’Garra, 
2010).  
Macrophages are a rich source of IL10 especially in response to ligands which are 
recognized by TLR2, TLR3, TLR4 and TLR9 (Boonstra et al., 2006; Saraiva and O’Garra, 2010; 
Teixeira-Coelho et al., 2014). IL10 can also regulate different functions of macrophages. IL10 can 
enhance macrophage-induced immunotolerance by inhibiting production of pro-inflammatory 
soluble mediators like TNF-α, IL-1β, IL6, IL-8, G-CSF, and GM-CSF, and by limiting antigen 
presentation (Malefyt et al., 1991; Sabat et al., 2010). At the same time, IL10 boosts the release 
of anti-inflammatory molecules such as IL-1 receptor antagonist and soluble TNFα receptors 
(Sabat et al., 2010). 
TLR-dependant IL10 production in macrophages depends on downstream activation of 
both MyD88 and TRIF signalling pathways (Boonstra et al., 2006). Activation of P38 and N-
terminal kinase (JNK) MAPK signalling cascades mediated by MyD88 and its associated 
mediators IL-1R-associated kinase and TNF receptor- associated factor 6 (TRAF6) has been 
broadly described (O’Neill, Golenbock and Bowie, 2013). In addition, extracellular signal-
regulated kinases (ERK), another essential MAPK protein, has also been shown to be strongly 
activated in response to TLRs stimulation through TPL-2 signalling (Kaiser et al., 2009).  
Continuous phosphorylation of P38 and ERK, or their chemical inhibition or deficiency in cells 
has been proven to regulate the respective upregulation or downregulation of IL10 production 
in activated T helper cells and macrophages (Chi et al., 2006; Saraiva et al., 2009). P38 and ERK 
act by stimulating the downstream  kinases MSK1 and MSK2 which will induce phosphorylation 
of transcription factors CREB and AP1, and their consequent binding to IL10 and DUSP1 gene 
promoters (Ananieva et al., 2008; Wen, Sakamoto and Miller, 2010). Once produced and 
released, IL10 binds to its receptor IL10R and exerts its function through Janus kinase (JAK)1 and 
STAT3 by triggering the anti-inflammatory cascade (Lang et al., 2002; Murray, 2006) (Figure 5.2). 
IL10 can also engage in self-regulatory pathways. On one side, CREB or STAT3-
dependant production of DUSP1 can negatively regulate P38 activation and consequently IL10 
(Hammer et al., 2005; Ananieva et al., 2008). Furthermore, IL10R dependant activation of STAT3 
induces TPL-2 expression and a positive feedback loop of activation by means of ERK (Lang et 






Figure 5.2 TLRs signalling and IL10 production in macrophages.  
Activation of MAPKs, p38 and ERK, downstream TLRs signalling cascades has been shown to 
induce IL10 expression in a signalling dependent on MSK1/MSK2, and the transcription factors 
CREB and AP1 in macrophages. The production of IL10 in this context is regulated by interferon-γ 
(IFNγ) and IL10 itself. Expression of dual-specificity protein phosphatase 1 (DUSP1) induced by 
IL10 negatively regulates p38 phosphorylation and consequently IL10 production mediated by 
this MAPK. IL10 can also upregulate its own expression by inducing tumour progression locus 2 




inhibit activation of ERK and P38 MAPKs decreasing CREB activity or induce GSK3 which blocks 
the transcription factors CREB and AP-1  (Hu et al., 2006; Wen, Sakamoto and Miller, 2010).  
Considering its crucial role in immunotolerance, IL10 overexpression or downregulation 
has been associated with the pathogenesis of multiple diseases. An increase of the cytokine can 
promote the progression of some stablished infections or some types of cancer like B/T/NK-cell 
lymphomas, melanoma and lung cancer (Mannino et al., 2015). Meanwhile, IL10 deficiency is 
generally associated with pathologies where the immune system is over activated like Crohn’s 
disease or rejection of organ transplantation. It has also been associated with multiple 
autoimmune disease like psoriasis and rheumatoid arthritis (Sabat et al., 2010; Mannino et al., 
2015). In the interest of this thesis, we will focus on the role of IL10 in a type of B cell lymphoma 





5.1.2 Multiple myeloma (MM) 
5.1.2.1 Multiple myeloma 
Multiple myeloma is a type of mature B cell neoplasm lymphoma derived from plasma cells 
(NCCN Foundation, 2018). It represents approximately 10% of all lymphomas and 1% of all 
neoplasm diseases. MM has been described to be more common at aged 65 and over, and two 
times more frequent in African-Americans than Caucasians (Rajkumar, 2016). One of the main 
characteristics of the disease is bone damage, but fatigue, weight loss, anemia, renal failure, and 
infections have also been described as clinical symptoms (Rajkumar, 2016; NCCN Foundation, 
2018). MM can be subdivided into five subtypes depending on cytogenetic characteristics of the 
disease, with trisomic multiple myeloma and IgH translocated multiple myeloma being the most 
frequent (Rajkumar, 2016). Additionally, deletions in chromosomes 1p, 17p and 13, gains in 1q, 
mutations in MYC, RAS and proteins in the NF-B pathways, as well as Ig translocations, have 
been associated with poor prognosis of MM (Chesi et al., 2014). These cytogenetic abnormalities 
are essential in driving disease progression, but also influence the response to treatment and 
prognosis.  
A combination of drugs is used as standard treatment for MM, with thalidomide, 
Bortezomib and lenalidomide being the most commonly used (Palumbo and Rajkumar, 2009). 
Many others have been recently approved for treatment of relapsed patients, including 
carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab (Rajkumar, 
2016). Overall, thalidomide, lenalidomide, and pomalidomide act mainly by inducing cytotoxicity 
(Wells, Parman and Wiley, 1999), while Bortezomib, carfilzomib, and ixazomib are proteasome 
inhibitors which initiate cell arrest and apoptosis in cells with high rates of defective proteins, as 
is the case with malignant plasma cells in MM (Kubiczkova et al., 2014; Rajkumar, 2016). Other 
drugs like Elotuzumab, daratumumab and panobinostat act by targeting specific characteristic 
signals or mechanisms particular to malignant proliferation in MM and are mainly used in 
patients who have relapsed (Anderson, 2016; Rajkumar, 2016). Regardless the combination of 
drugs used, many patients become resistant or have relapses after the treatment. Therefore, 
studies have focussed in understanding the immunomodulatory mechanism that can be 





5.1.2.2 MM and IL10 
Among the potential immune molecules and signalling mechanisms studied in correlation to 
MM progression, IL10 production and its polymorphisms have been extensively investigated. 
Pappa and co-workers described in 2007 a significant positive correlation between cell 
proliferation and high levels of IL10 in serum of non-treated MM patients when compared with 
healthy controls (Pappa et al., 2007). A positive correlation between IL10 and different markers 
of angiogenesis like vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG-2), as 
well as proliferation markers have also been reported in serum from MM patients in a more 
recent publication (Alexandrakis et al., 2015). In the same sense, increased serum levels of IL10 
were also correlated to the stage of disease, with MM stage III patients expressing more IL10 
compared with stage I patients (Shekarriz, Janbabaei and Kenari, 2018). Similar results were 
showed in a human cell line of MM named RPMI 8226, where IL-4 and IL10 were increased 
together with the chemokines CXCL12, CCL5, MIP-1β, and CXCL10 (Freire-de-Lima et al., 2017). 
Moreover, single-nucleotide polymorphism (SNP) of both IL10 and its receptor have been shown 
to be associated with drug resistance, specifically to treatment with thalidomide and/or 
Bortezomib, and in general to poor prognosis in MM (Kasamatsu et al., 2017; Nielsen et al., 
2017). All this evidence suggests IL10 to play a role in the pathogenesis and progression of MM, 
and it may also be relevant for diagnosis and defining clinical treatment. However, further 





5.1.3 Proteasome inhibition in cancer treatment 
As previously mentioned, Bortezomib is one of the classic treatments for MM and two more 
proteasome inhibitors have been recently approved as new generation drugs, carfilzomib, and 
ixazomib. Degradation of proteins mediated by the proteasome is an essential mechanism of 
regulation at cellular level. Therefore, its inhibition can significantly impact cell viability and 
potentially trigger immunoregulatory mechanisms in biological systems. Hereby, the role of 
proteasome inhibitors in the context of immunity and cancer will be explored. 
5.1.3.1 Proteasome biology 
Protein production is a central process in all types of cells and due to its essential role, it’s a 
highly regulated one. The ubiquitin proteasome system is one of the main mechanisms used by 
eukaryotic cells to control quality and concentration of proteins in cell. It also mediates the 
inactivation of biological signalling pathways by degrading active proteins once they are no 
longer required. The proteasome is the core effector of this system. It is a proteolytic complex 
of high molecular weight (2.5MDa) which recognizes mainly ubiquitin targeted proteins and cuts 
them into small peptide chains of 8-12 amino acids (by Inobe & Matouschek, 2014).  
Structurally, the proteasome has been described as a cylindrical complex made primarily 
of two subunits known as 20S core particle (CP) and 19S regulatory particle (RP) which together 
form what is known as the 26S proteasome (Figure 5.3) (Murata, Yashiroda and Tanaka, 2009; 
Kish-Trier and Hill, 2013). The core particle includes 28 subunits arranged in four rings of 7 units 
each, two external rings made of α-units and two internal rings made of β-units. The proteolytic 
active sites of the proteasome are in the inner space of both β-rings, and α-rings act as gateways 
to the proteolytic chamber. Subunits β1, β2 and β5 of 20S in eukaryotes have been described to 
have hydrolytic caspase, trypsin, and chymotrypsin-like activity, respectively (Murata, Yashiroda 
and Tanaka, 2009). Inhibition of the proteasome proteolytic rings is a key target for therapeutic 
studies in cancer treatment, as it will be described later in this section. In addition to the well-
known proteasome, a specialised immunoproteasome that is induced by IFN-γ or type I 
interferons has been identified in hematopoietic cells. The immunoproteasome is made of 
specific catalytical subunits similar to the constitutive β1, β2 and β5 known as low molecular 
mass polypeptide 2 (LMP2 or β1i), multicatalytic endopeptidase complex-like 1 (MECL-1, or β2i), 
and LMP7 (β5i), which are integrated in de novo proteasomes (Griffin et al., 1998; Khan et al., 
2001; Shin et al., 2006). It is generally accepted immunoproteasomes produce hydrophobic C-
terminus peptides that are to be presented by MHC class I molecules (Gaczynska et al., 1994; 





Figure 5.3 Schematic representation of 26S proteasome structure.  
The 26S proteasome consists of a 20S core particle and 19S regulatory particles. The different 
colors indicate the subunit composition for the 26S proteasome: 20S is made of four rings: two 
outer α-rings and two inner β-rings (catalytic subunits), and 19S which is subdivided in base 
(triple-A or RPT subunits) and lid (non-ATPase or RPN subunits) subcomplexes (Adapted from 





The second major structural component of proteasomes is the regulatory particle 19S. 
It is known to be the portion responsible for recognizing, binding and delivering the proteins 
labelled to be degraded. 19S is ATP-dependent and it contains 19 subunits arranged in two 
subcomplexes usually described as the base and lid that can be attached to one or both ends of 
the core particle. The base contains six ATPases (Rpt1–6), two large subunits (Rpn1 and Rpn2), 
and two ubiquitin receptors Rpn10 and Rpn13. Those subunits allow the identification and 
binding of proteins carrying polyubiquitylated chains, and their unfolding to enter through the 
α-rings. Nine non-ATPase subunits (Rpn3, 5–9, 11, 12, and 15) integrate the lid of 19S complexes, 
from which Rpn11 it is known to have deubiquitylase activity and mediates de-ubiquitylation of 
proteins before their degradation (Kish-Trier & Hill, 2013; Murata et al., 2009). Understanding 
the structure and function of the proteasome will allow a better understanding of its relevance 
in the context of cancer therapy and the mechanistic understanding of clinical treatments based 
on proteasome inhibition, which will be expanded next. As mentioned, for the proteins to be 
recognized and degraded by this system, a polyubiquitin chain most be attached to them. The 
mechanism by which the proteins are labelled was discussed in detail in Section 3.1.3. 
5.1.3.2 Proteasome inhibitors in cancer therapy: Bortezomib  
Cancer cells are often characterized as having multiple alterations from single nucleotide 
mutations to major changes at chromosomal level. It is to be expected that such changes would 
affect protein quality and concentrations in malignant cells, and furthermore transformed cells 
would be more dependent on proteasomal efficiency (Figure 5.4) (Deshaies, 2014). In this sense, 
Torres and co-workers showed in 2007 that proliferation of aneuploidy yeast was hampered 
using the proteasome inhibitor MG132 (Torres et al., 2007). This and previous evidence on 
cancer research using proteasome inhibitors in cancer cell lines supported induction of the so 
called proteotoxic crisis as a clinical approach to cancer treatment (Deshaies, 2014; Teicher & 
Tomaszewski, 2015). This strategy suggests that, by using inhibitors of the protein quality control 
system within the cells, effector mechanism of homeostasis (as cell death) could be activated in 
response to accumulation of toxic signals (Manasanch et al., 2014). The proteotoxic crisis 
approach seems to be more effective in cancers derived from mature B lymphocytes such as 
multiple myeloma and mantle cell lymphoma, perhaps due to their high rate of protein 
production in the form of immunoglobulins. 
Given the essential role of the proteasome system in cellular biology, using molecules 
that could inhibit its activity as a therapeutic approach was not considered possible at first. 





Figure 5.4 Proteotoxic crisis in cancer cells.  
(A) It is expected the rate of protein production (to the left) and protein degradation by the 
proteasome (represented to the right) would be in balance in normal cells. However, in cancer 
cells (B), it is believed this balance is altered due to overexpression of proteins or their mutant 
versions what would affect degradation efficiency by the ubiquitin proteasome system (UPS) 





models began in the early 90s with a compound called PS-341, also known as Bortezomib 
(Teicher & Tomaszewski, 2015). This boronic acid inhibitor binds in a reversible way mainly to 
β5-subunits in the 20S portion of the proteasome blocking its chymotrypsin activity. 
Subsequently, multiple in vitro studies showed MM cell lines and patients samples were more 
sensitive to apoptosis, and their proliferation was inhibited in the presence of this proteasome 
inhibitor (Hideshima et al., 2001; Ma et al., 2003). Based on these and other findings, Bortezomib 
became the first inhibitor to be approved as a frontline treatment for MM, relapsed/refractory 
MM and mantle cell lymphoma in the past fifteen years (Buac et al., 2013; Teicher & 
Tomaszewski, 2015).  
Treatment with Bortezomib alone or in combination with other immunomodulatory 
drugs (like thalidomide and lenalidomide) increased the overall survival rate for MM patients up 
to three times. Nevertheless, the treatment has not proved to be effective in solid tumours and 
at least one third of the patients have been reported not to respond or to develop resistance to 
treatment (Ping Dou and Zonder, 2014; Moreau et al., 2015). In addition, it has been suggested 
that Bortezomib treatment induces permanent peripheral neuropathy (PN) in some patients 
(Argyriou et al., 2008). In light of these evidence, a second generation of proteasome inhibitors 
(Carfizomib, Ixazomib, Delanzomib, Oprozomib and Marizomib) has been approved or are under 
study for clinical use (Ping Dou and Zonder, 2014). In addition, recent findings have shed light 
on why Bortezomib might not be effective in some cases. On one side, it has been shown in 
preclinical models for immunological disorders like lupus erythematosus (SLE), myasthenia 
gravis (MG) and autoimmune haemolytic anaemia that treatment with proteasome inhibitors 
downregulates short- and long-lived plasma cells (Škrott and Cvek, 2014). It is suggested the 
efficiency of treatment with proteasome inhibitors is enhanced in types of cancer where the 
protein production rate is also high, as it would be the case of MM, a plasma cell-derived 
malignancy. Furthermore, Pitcher and co-workers have proved that nano molar concentrations 
of Bortezomib induced up to 95% inhibition in chymotrypsin-like active sites and structural 
changes of the proteasome specifically in MM cells compared to other cancer cells, which would 
trigger a proteotoxic crisis (Pitcher et al., 2015).  
Multiple approaches have been explored to tackle Bortezomib-resistance and increase 
its efficiency in treatment. Identification of cytogenetic abnormalities like 1q21 gain as a 
biomarker correlated to Bortezomib resistance and poor survival were described in high-risk 
MM patients (Wu et al., 2018). These findings show the importance of personalized treatment 
based on specific risk factors for each MM patient. Multiple studies have focused their efforts in 
testing combined treatment of Bortezomib with other cancer drugs like lenalidomide, 
139 
 
dexamethasone and Ibrutinib, or with small molecules to overcome patients relapsed or 
refractory response to treatment with the proteasome inhibitor (Richardson et al., 2014; Murray 
et al., 2015; Siegel et al., 2015). However, Bortezomib treatment and direct induction of IL10 
production in MM has not been associated. As part of a screening of multiple inhibitors in 
Chapter Four of this thesis, a proteasome inhibitor MG132 was shown to induce IL10 in murine 
macrophages. This would appear to be highly counterproductive for its treatment of MM which 
is driven by IL10 so further studies were performed to better understand the regulation of IL10 







5.2.1 Proteasome inhibition by MG132 induces IL10 expression in BMDMs 
Proteasome inhibition by Bortezomib is a widely used clinical approach for the treatment of 
Multiple Myeloma (MM), mantle cell lymphoma, and some child autoimmune diseases (Buac et 
al., 2013; Khandelwal et al., 2014; Kouroukis et al., 2014; Škrott and Cvek, 2014). As described 
in the previous chapter, anti-inflammatory cytokine IL10 expression was increased in 
macrophages treated with MG132, another known proteasome inhibitor more commonly used 
as a research tool to study proteasome biology. Considering the correlation of IL10 with 
progression and poor prognosis of MM, and that proteasome inhibitors are important in the 
treatment of this disease, the potential role of the inhibitors in inducing the anti-inflammatory 
cytokine was contemplated. To address this question, expression of cytokines IL10 and IL6 was 
assessed in supernatants of BMDMs treated with MG132 for 1h and then stimulated for 24hrs 
in the absence/presence of the TLR4-ligand LPS (Figure 5.5) or TLR3-ligand Poly(I:C) (Figure 5.6). 
When cells were treated with LPS, both cytokines, IL6 and IL10, were significantly induced and 
their expression was reduced when cells were pre-treated with MG132 before stimulation with 
LPS. However, IL10 was induced by MG132 treatment alone when compared with non-treated 
cells (Figures 5.5A and 5.6A). MG132 alone failed to induce significant levels of IL6 suggesting 
some specificity for induction of IL10. To further explore the degree of specificity of this 
response, the effects of MG132 on the expression of pro-inflammatory chemokines CXCL1 and 
CXCL2 were also measured (Figures 5.5B and 5.6B). LPS induced high levels of both CXCL1 and 
CXCL2 which were reduced in the presence of MG132. Interestingly MG132 alone induced some 
modest basal expression of CXCL2 whereas CXCL1 expression remained undetectable. These 
results suggest that the proteasome inhibitor MG132 strongly induces the anti-inflammatory 
cytokine IL10 with more modest effects on CXCL2 expression without affecting the expression 
of other pro-inflammatory cytokines like IL6 or CXCL1.  
The kinetic profile of MG132-induced expression of IL10 was next characterised in more 
detail. IL10 was first detected at 8h post MG132 challenge and increased strongly up to 24hrs 
(Figure 5.7A). The mRNA levels of Il10 at the same time points were next measured to assess if 
MG132 could promote the transcriptional up-regulation of Il10. When assessed for IL10 mRNA 
levels at the same time points, a modest 7-fold rise was observed at 4 hours with further 60-fold 
and 100-fold increments at 8h and 24h (Figure 5.7B). These data indicate a direct effect of 





Figure 5.5 Effect of MG132 and LPS treatment on cytokine and chemokines expression in 
BMDMs. 
ELISA analysis of (A) cytokines IL6 and IL10, and (B) chemokines CXCL1 and CXCL2 in supernatant 
of BMDMs pre-treated for 1h with 20 μM MG132, and subsequently stimulated for 24 hrs with 
40 ng/mL LPS. Data are presented as the mean ± SEM of three independent experiments and 























































































































































Figure 5.6 Effect of MG132 and Poly(I:C) treatment on cytokine and chemokines expression in 
BMDMs. 
ELISA analysis of (A) cytokines IL6 and IL10, and (B) chemokines CXCL1 and CXCL2 in supernatant 
of WT BMDMs pre-treated for an hour with 20 μM MG132, and subsequently stimulated for 24 
hrs with 25 μg/mL Poly(I:C). Data are presented as the mean ± SEM of three independent 
experiments and were subjected to two-tailed Student’s t-test. ns: not significant, *p < 0.05, **p 






















































































































































Figure 5.7 Inhibition of the proteasome with MG132 induces IL10 expression at protein and 
mRNA levels after 4 hours treatment. 
(A) ELISA analysis of IL10 and (B) quantitative PCR of mRNA expression for IL10 in supernatants 
and cell lysates of WT BMDMs treated at different times with 20 μM MG132. Data are presented 
as the mean ± SEM of four (A) and two (B) independent experiments. 
 
  


































The next study aimed to address if the stimulatory effects of MG132 on IL10 expression 
is restricted to macrophages a cell type well known to be abundant in tumour 
microenvironment, and usually described as a facilitators of malignant cell migration and 
metastasis (Balkwill, Capasso and Hagemann, 2012). To determine the cell specificity of IL10 
induction by MG132, murine derived dendritic cells (BMDCs) and a human monocytic cell line 
THP-1 were evaluated following the conditions previously employed with BMDMs (Figure 5.8). 
Protein levels of IL10 and CXCL2 were measured in both cell types after 1-24hrs of MG132 
treatment. Neither BMDCs or THP-1 cells showed a significant increase in the expression of IL10 
in the presence of the proteasome inhibitor MG132 at any of these time points. These data 
suggest that the stimulatory effects of MG132 on IL10 expression may be restricted to 






Figure 5.8 MG132 does not induces IL10 expression in dendritic cell or monocytes. 
ELISA analysis of IL10 in supernatants of (A) WT BMDCs and (B) THP-1 cells treated at different 
times with 20 μM MG132. Data are presented as the mean ± SEM of three independent 
experiments. 
  
































5.2.2 p38 and JNK MAPKs mediate MG132 induced expression of IL10  
Given IL10 expression was induced specifically in BMDMs and the response seems to be initiated 
within the first 4 hours of proteasome inhibition with MG132, studies next explored the 
mechanism underlying this induction. Macrophages are part of the first line of response in innate 
immunity, and one of the most important signalling pathways activated through TLRs is the 
activation of mitogen activated protein kinases (MAPKs) (Saraiva & O’Garra, 2010). Research 
from our group has previously showed that P38 signalling pathway is essential for the induction 
of IL10 (Mellett et al., 2011).Therefore, activation of the three main kinases of this signalling 
pathway, P38, JNK and ERK, were measured in response to MG132 (Chi et al., 2006; Ananieva et 
al., 2008; Saraiva et al., 2009; Wen, Sakamoto and Miller, 2010). In addition, the transcription 
factor CREB which also has an important role in activation of IL10 was examined (Wen, 
Sakamoto, & Miller, 2010). Activation of these proteins was assessed by evaluating their 
phosphorylation status, using phospho-specific antibodies, in cell lysates from BMDMs treated 
for different times with MG132. Phosphorylated forms of P38 and JNK were not detected in 
untreated cells but were strongly induced in response to MG132 at 30 min and remained 
sustained for up to 6 hours. (Figure 5.9). On the contrary, ERK (also known as P44/42) was 
present in its phosphorylated forms in untreated cells but diminished with increasing time 
exposure to MG132. These data clearly indicate that MG132 induces activation of P38 and JNK 
MAPKs but suppresses the ERK pathway in the BMDMs. Since MG132 promotes the 
transcriptional upregulation of IL10, we next measured its ability to promote activation of CREB, 
a key transcription factor that induces transcription for the Il10 gene. Using phosphorylation of 
CREB as an index of its activation, MG132 was shown to promote time-dependent 
phosphorylation of CREB with a kinetic profile that closely mirrored the activation of P38 and 
JNK.  
Studies next addressed if these MAPKs are part of the underlying mechanism mediating 
the expression of IL10 in response to MG132. To this end, selective inhibitors of the P38 and JNK 
pathways were used to block their activation. BMDMs were pre-treated with AMG548 and 
AEG3482 (inhibitors for P38 and JNK respectively) for 1 h and later stimulated with MG132 for 
24 hours. IL10 and CXCL2 expression were then measured in the supernatant of the cells. Both 
inhibitors, when used individually or combined, suppressed the MG132-induction of IL10 (Figure 
5.10A). However, the P38 inhibitor AMG548 was more effective than the JNK inhibitor AEG3482 
in inhibiting IL10 expression. Indeed AMG548, alone or in combination with AEG3482, abrogated 
the ability of MG132 to induce IL10. The MAPK inhibitors showed similar suppressive effects on 





Figure 5.9 Proteasome inhibitor MG132 induces phosphorylation of P38 and JNK. 
Immunoblot analysis of phosphorylated (p-) and total P38 (43 kDa), JNK (46-54 kDa), P44/42 (42-
44 kDa) and CREB (43 kDa) in cell lysates from WT BMDMs treated at different times with 20 μM 
MG132. β-actin (42 kDa) was used as constitutively expressed housekeeping protein. Data are 







Figure 5.10 Inhibition of P38 and JNK reduces the expression of IL10 and CXCL2 induced by 
MG132. 
(A) ELISA analysis of IL10 and CXCL2 in supernatants of WT BMDMs pre-treated with 10µM 
AMG548 (Inhibitor of p38, iP38) and/or 10µM AEG3482 (Inhibitor of JNK, iJNK) for one hour, and 
then treated with 20µM MG132 for 24 hours. (B) Immunoblot analysis of phosphorylated (p-) 
and total P38 (43 kDa), JNK (46-54 kDa) and CREB (43 kDa) in cell lysates from WT BMDMs pre-
treated with 10µM AMG548 or 10µM AEG3482 for one hour, and then treated with 20µM 
MG132 for 2 hours. β-actin (42 kDa) was used as constitutively expressed housekeeping protein. 
Data are presented as the mean ± SEM of three independent experiments and were subjected 

































































































the inhibitor of P38 was used alone or in combination to JNK inhibitor, and a more modest 
decrease in the presence of the JNK inhibitor alone. In order to relate the suppressive effects of 
AM548 and AEG3482 on IL10 expression to regulation of p38 and JNK respectively, levels of total 
and phosphorylated P38, JNK and CREB were measured in cell lysates of BMDMs previously 
treated for 1 h with the corresponding inhibitor and for two hours with MG132 (Figure 5.10B). 
Proteasomal inhibition with MG132 induced the phosphorylation of P38, JNK and CREB. When 
the inhibitor AM548 was used combined with MG132, phosphorylation of P38 and JNK was again 
observed. It is to notice that phosphorylation of JNK was stronger in this case compared to 
phosphorylated JNK in cells treated with MG132 alone. However, phosphorylation of CREB was 
lost with AMG548 and MG132. These data are consistent with a role for p38 in mediating 
phosphorylation of CREB. AMG does not affect phosphorylation of p38 and this is an expected 
result considering it inhibits p38  kinase activity by competing with ATP (Zhang, Shen and Lin, 
2007). The JNK inhibitor AEG3482 does not affect the ability of MG132 to promote 
phosphorylation of CREB. These results clearly prove that the proteasome inhibitor MG132 
induces production of IL10 and CXCL2 in a P38 dependant manner that is likely mediated by the 




5.2.3 Bortezomib induces IL10 expression 
Considering Bortezomib is the proteasome inhibitor used in clinical treatments for cancer and 
autoimmunity, its effect on the expression of IL10 and CXCL2 was also assessed to compare its 
efficacy with MG132. This may be of relevance to MM since IL10 is a growth factor for the 
myeloma and any macrophage expression of IL10 in response to Bortezomib may underlie the 
resistance of patients with MM to Bortezomib. To assess this, BMDMs were treated with 
different concentrations of Bortezomib for 24 hours and IL10 and CXCL2 expression at protein 
level were determined. IL10 expression was induced in the macrophages at concentrations as 
low as 0,5 µM and a clear dose-dependent increase was observed with concentrations up to 10 
µM (Figure 5.11A). Since Bortezomib promotes cell death in myeloma cells, its cytotoxic effects 
on macrophages was also measured over the same concentration range as above. The 
percentage of cytotoxicity in BMDMs treated with Bortezomib was determined by means of 
analysis of LDH release (Figure 5.11B). Bortezomib caused 10% cytotoxicity at its lowest 
concentration and this increased to a maximum of 45% at highest concentrations. These results 
showed that Bortezomib can trigger the production of IL10 and this is also coincident with its 
induction of cell death.  
Studies next addressed the signalling cascades being activated by Bortezomib. 
Phosphorylation status of P38, JNK and ERK (P44/42) MAPKs, and the transcription factor CREB 
were evaluated in response to  Bortezomib (Chi et al., 2006; Ananieva et al., 2008; Saraiva et al., 
2009; Wen, Sakamoto and Miller, 2010). Activation was determined using phospho specific 
antibodies in cell lysates from BMDMs treated with 10µM Bortezomib treatment at different 
time points. Phosphorylated P38 and CREB were induced in response to Bortezomib at 30 
minutes, reached their highest expression between 1 and 2 hours, and showed a moderately 
decrease after 3 hours of treatment. Whereas phosphorylation of ERK (also known as P44/42) 
was evident in untreated cells but progressively lost with time exposure to the same proteasome 
inhibitor (Figure 5.12). The reduction on phosphorylated P38 and CREB after 3 hours treatment 
with Bortezomib is most likely due to the reversible binding effect of this inhibitor to the 
proteasome (Teicher and Tomaszewski, 2015). Interestingly, JNK activation was not induced as 
strongly as with MG132, with Bortezomib only inducing a moderate phosphorylation of JNK after 
6 hours.  
Aiming to corroborate these observations, the selective inhibitors for P38 and JNK 
pathways were used to block their activation in response to Bortezomib. As previously 
described, BMDMs were pre-treated with either AMG548 (inhibitor for P38) or AEG3482 
151 
 
(inhibitors for JNK) for 1 h and later stimulated with Bortezomib for 24 hours. The expression of 
IL10 was then determined in the supernatant of the cells. Bortezomib-induction of IL10 was 
depleted completely by P38 inhibitor AMG548 when used individually or combined with 
AEG3482 (Figure 5.13). However, the JNK inhibitor AEG3482 failed to inhibit IL10 expression in 
response to Bortezomib. Evidently, proteasome inhibitor Bortezomib induces IL10 production in 







Figure 5.11 Bortezomib induces the expression of IL10 and increases cytotoxicity in BMDMs. 
(A) ELISA analysis of IL10 and (B) cytotoxicity analysis by LDH release in supernatants of WT 
BMDMs treated with different concentrations of Bortezomib for 24 hours. Data are presented 









































Figure 5.12 Proteasome inhibitor Bortezomib induces phosphorylation of P38 and JNK. 
Immunoblot analysis of phosphorylated (p-) and total P38 (43 kDa), JNK (46-54 kDa), P44/42 (42-
44 kDa) and CREB (43 kDa) in cell lysates from WT BMDMs treated at different times with 10 μM 
Bostezomib. β-actin (42 kDa) was used as constitutively expressed housekeeping protein. Data 







Figure 5.13 Inhibition of P38 reduces the expression of IL10 induced by Bortezomib. 
(A) ELISA analysis of IL10 in supernatants of WT BMDMs pre-treated with 10µM AMG548 
(Inhibitor of p38, iP38) and/or 10µM AEG3482 (Inhibitor of JNK, iJNK) for one hour, and then 
treated with 10µM Bortezomib for 24 hours. Data are presented as the mean ± SEM of three 
independent experiments and were subjected to two-tailed Student’s t-test. *p < 0.05, **p < 
























































5.2.4 Cell death and IL10 expression 
Considering Bortezomib is inducing cell death in macrophages at concentrations that also induce 
IL10 the next studies investigated if the expression of IL10 was a key signature of macrophage 
cell death. Three forms of cell death were evaluated. The first one, pyroptosis is generally 
associated with cellular membrane rupture and release of Damage-associated molecular pattern 
(DAMPs) signals, such as IL-1, that triggers a robust inflammatory response.  Caspase-1 is the 
key mediator of this type of cell death and facilitates the activation of IL-1β and Gasdermin D, 
the main effector molecules (Broz & Dixit, 2016; Kolb, Iii, Oberst, & Martinez, 2017). The model 
of two signals for the activation of the inflammasome previously used in our lab was applied 
(Humphries et al., 2018). IL10 and CXCL2 expression was assessed in BMDMs treated with LPS 
alone for 3 hours or LPS plus ATP for one additional hour. Both IL10 and CXCL2 were induced to 
the same levels by LPS alone or in combination with ATP (Figure 5.14). However, since pyroptosis 
requires both signals with LPS being insufficient, these results suggest that pyroptosis does not 
promote IL10 expression or secretion.  
In addition, apoptosis and necroptosis were also studied in the context of IL10 
expression following the conceptual and technical approaches described in chapter three of cell 
death from this thesis. Necroptosis, like pyroptosis, is usually described as a pro-inflammatory 
type of cell death while apoptosis is in general terms associated with immunotolerance. As 
described before, the pancaspase inhibitor Z-VAD and IAP inhibitor (LCL161) were used to drive 
the activation of these two types of cell death in the context of TNFα and TLR signalling. The 
combined treatment of LCL161 and TNFα or TLR ligands will promote apoptosis whereas the 
addition of Z-VAD to this dual treatment will favour necroptosis. The expression of IL10 was 
evaluated in supernatant of BMDMs in response to either TNFα, LPS or Poly(I:C) (Figure 5.15A). 
TNFα was unable to induce IL10 expression in the presence of Z-VAD, LCL161 or both, meaning 
this ligand does not promote expression of the anti-inflammatory cytokine in either apoptosis 
or necroptosis.  Meanwhile, stimulation of the cells with LPS and either Z-VAD or LCL161 induces 
a moderate increase of the cytokine compare to LPS treatment alone, but it was significantly 
reduced with both inhibitors and the TLR4-ligand. These means IL10 can be induced in apoptosis 
but it is inhibited in necroptosis in response to bacterial infections. In the case of TLR3 activation, 
IL10 expression was induced by Poly(I:C) but this was lost when combined with inhibitors. 
As for the expression of the chemokine CXCL2 in apoptosis and necroptosis, interestingly 
it was considerably induced by the combination of Z-VAD and LCL161 without ligands (Figure 





Figure 5.14 IL10 expression is not integral part of pyroptosis.  
ELISA analysis of IL10 and CXCL2 in supernatants of WT BMDMs treated with 100 ng/mL LPS for 
3 hours followed by 2,5mM ATP for 1 hour. Data are presented as the mean ± SEM of four 
independent experiments and were subjected to two-tailed Student’s t-test. ns, not significant. 
  


































Figure 5.15 Expression of IL10 under conditions of apoptosis and necroptosis. 
ELISA analysis of (A) IL10 and (B) CXCL2 in supernatants of WT BMDMs treated with 20 μM Z-
VAD and 10 μM LCL161 for an hour and then stimulated with 100 ng/mL LPS, 25 μg/mL Poly(I:C) 
or 40 ng/mL TNFα for 24 hrs. Data are presented as the mean ± SEM of three independent 
experiments and were subjected to two-tailed Student’s t-test. ns: not significant, *p < 0.05, **p 










































































































































































































































































was used with either Z-VAD and LCL161 or their combination, indicating that pro-apoptotic or 
pro-necrotic signals activate CXCL2. This chemokine was greatly induced by LPS stimulation. In 
contrast, Poly(I:C), Z-VAD or LCL161 individual treatments had minor effects in inducing the 
expression of CXCL2 but significant levels of CXCL2 were detected in response to co-treatment 
of all 3 ligands. Taken together these results indicate necroptosis favours the expression of this 
chemokine and may contribute to the pro-inflammatory effects of necroptosis whilst also 







The use of proteasome inhibitors is one of the main approaches to treatment for diseases like 
MM. Bortezomib is one of these drugs, and it has been used for the past fifteen years. However, 
many patients do not respond to it or develop resistance to treatment. As part of this thesis, an 
increased expression of anti-inflammatory cytokine IL10 was observed when murine 
macrophages were treated with MG132, another proteasome inhibitor. IL10 expression and/or 
its polymorphisms have been broadly discussed and correlated to disease progression and poor 
prognosis in MM patients, both before and after treatment (Pappa et al., 2007; Alexandrakis et 
al., 2015; Freire-de-Lima et al., 2017; Haydaroglu et al., 2017; Kasamatsu et al., 2017; Nielsen et 
al., 2017). Some studies suggest IL10 acts as a growth factor for MM, and it has been shown 
before that this anti-inflammatory cytokine enhances monocytes differentiation when 
combined with macrophage colony-stimulating factor (M-CSF) in vitro (Hashimoto et al., 1997; 
Pappa et al., 2007; Kovacs, 2010; Deng et al., 2012; Alexandrakis et al., 2015). Therefore, an 
increase in this cytokine triggered by a proteasome inhibitor might suggest an unwanted 
secondary effect being induced by clinical treatment with proteasome inhibitors. Interestingly, 
our results showed an increase in IL10 expression induced by MG132 alone, comparable to the 
expression of this cytokine induced by LPS alone. It was expected that LPS would increase the 
expression of IL6, IL10, CXCL1 and CXCL2 due to its capacity to activate MyD88 and TRIF signalling 
pathways through TLR4 (Boonstra et al., 2006; Iyer, Ghaffari and Cheng, 2010; Saraiva and 
O’Garra, 2010). The reduction in the expression of both cytokines and chemokines seen in 
presence of MG132 and LPS confirms that their induction was mediated by NF-B, because 
blocking proteasome activity would interfere with degradation of its inhibitory protein IκBα and 
consequently the translocation of this transcription factor to the nucleus (Akira and Takeda, 
2004). Interestingly, LPS induced expression of IL6 expression is completely abrogated with 
MG132 while IL10 expression remains at significant levels under the same conditions. In 
addition, activation of TLR4 has been shown to protect IL10 mRNA from degradation via TRIF 
and p38 signalling (Teixeira-Coelho et al., 2014). The high expression of IL10 and considerably 
lower expression of IL6 in macrophages stimulated with TLR3 ligand Poly(I:C) (approximately 
1000pg/mL and 400pg/mL respectively) could also be explained by type I IFNs signalling. These 
are consistent with findings suggesting macrophages are essential in regulating chronical viral 
infections through production of IL10 (Richter et al., 2013).  
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In line with the results for cytokine expression by LPS, the chemokines CXCL1 and CXCL2 
were also expected to be strongly increased considering their crucial role in inflammation 
(Wolpe et al., 1989; Iida and Grotendorst, 1990; Schumacher et al., 1992; Graham and Locati, 
2013). The reduction of both chemokines with MG132 and LPS treatment was also anticipated, 
and it could be explained by the inhibition of IκBα degradation, as previously mentioned for IL6 
and IL10. Considerable differences in the expression of both cytokines when comparing the 
effects of TLR4-ligand LPS or TLR3-ligand Poly(I:C) were also foreseen, given that bacterial-
derived signals induce more robust inflammatory responses than the viral-derived ones (Akira 
& Takeda, 2004; O’Neill, Golenbock, & Bowie, 2013). Notably, we saw an increase in CXCL2 
expression of approximately 2000pg/mL when macrophages were treated with MG132 alone. 
This was not seen for CXCL1. The differential effects of MG132 on the 2 chemokines are 
interesting considering CXCL2 shares approximately 90% homology with CXCL1 sequence (Iida 
and Grotendorst, 1990). However, CXCL2 has  the capacity to attract polymorphonuclear 
leukocytes and hematopoietic stem cells, in addition to neutrophils (Wolpe et al., 1989; Iida and 
Grotendorst, 1990). Interestingly, IL10 has been shown to downregulate CXCL2 in models of 
bacterial infection, viral infection, autoimmune disease and acute lung injury (Greenberger et 
al., 1995; Kasama et al., 1995; Tumpey et al., 1998; Shanley, Vasi and Denenberg, 2000). 
Expression of CXCL8, another inflammatory chemokine closely related to CXCL2, was also 
reduced by IL10 in eosinophils stimulated with LPS (Takanaski et al., 1994). Based on this 
evidence, IL10 and CXCL2 expression induced by MG132 seems to be independent of each other 
and it is more likely to be the result of signalling directly activated by the proteasome inhibitor. 
We evaluated the kinetics of upregulation of IL10 and found a considerable increase in IL10 at 
both mRNA and protein levels between 4 and 8 hours treatment with MG132. These data 
support MG132 directly triggering a signalling pathway which leads to the production of the 
anti-inflammatory cytokine. Furthermore, after 8 hours treatment with MG132, the 
upregulation of IL10 seems is much more marked. This could be explained by an autocrine 
response mediated by STAT3 signalling (Staples et al., 2007).  
Interestingly the positive effects of MG132 on IL10 expression appears to be specific to 
macrophages because MG132 failed to affect IL10 expression in dendritic cells or monocytes 
(THP-1). This may reflect findings in the literature that highlight macrophages and different 
subtypes of Th cells as the main sources of IL10 (Saraiva and O’Garra, 2010). Myeloid dendritic 
cells also produce IL10, but the present studies also show they are not responsive to MG132. It 
would be interesting to evaluate the production of IL10 induced by proteasome inhibition in the 
context of Th cells, and on MM cell lines. It could be also informative to evaluate co-cultures of 
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MM cells with macrophages to determine how IL10 production by the latter could alter 
proliferation of MM cells or if immunotolerance of macrophages can be induced by MM cells 
after treatment with proteasome inhibitors. An easy approach to study such interaction could 
be to culture MM cells in supernatants of macrophages treated with the different proteasome 
inhibitors, or vice versa, and subsequently assess changes in their proliferation, induction of cell 
death or functional activation. This may be of major relevance in a pathophysiological scenario 
and may have important consequences in the development of strategies to reverse resistance 
to treatment with proteasome inhibitors like Bortezomib in MM.  
When looking at potential signalling pathways triggered by MG132 and capable of 
inducing IL10, the phosphorylation of P38, JNK and CREB in response to MG132 was especially 
noteworthy. MAPK P38  and CREB, have been shown to be crucial in induction of IL10 (Chi et al., 
2006; Kaiser et al., 2009; Saraiva et al., 2009; Wen, Sakamoto and Miller, 2010). Interestingly, 
ERK was dephosphorylated (also known as P44/42) and JNK was phosphorylated in macrophages 
treated with MG132 (Kaiser et al., 2009; Saraiva and O’Garra, 2010). Moreover, when inhibitors 
for P38 and JNK were used, expression of both IL10 and CXCL2 was reduced almost to the level 
of non-treated cells. Considering P38 and JNK are usually described as the main MAP kinases 
involved in stress responses (Kyriakis and Avruch, 2012; Johnson and Lapadat, 2013), it is 
reasonable to expect their activation in response to accumulation of misfolded or damaged 
proteins in the cytoplasm as a result of proteasome inhibition. Also, as mentioned before, P38 
is known to be important in IL10 production. Given the essential role of P38 and JNK pathways 
in central cellular processes like apoptosis, inflammation and cell proliferation and 
differentiation, they have also been strongly associated with proliferation of malignant cells 
where most of these pathways are usually altered (Wagner & Nebreda, 2009). P38 and JNK 
signalling pathways are key regulators keeping the balance between autophagy and apoptosis 
in response to genotoxic stress. For this reason, understanding and regulating their activation 
has recently been discussed as an approach for sensitizing cancer cells to chemotherapeutic 
agents (Sui et al., 2014). In that sense, in a previous chapter of this thesis, it was shown that 
MG132 induces activation of apoptosis when in presence of LPS but not by itself (Figure 4.15B). 
Although, a slight increase in cleaved PARP is seen at 6 hours treatment with MG132 alone, the 
results suggest apoptosis is not triggered by the proteasome inhibitor alone. Experimental 
evidence with Bortezomib describes the phosphorylation of JNK and Bcl-2 as the pathways 
mediating autophagy in head and neck squamous cell carcinoma (HNSCC) cells (Li and Johnson, 
2012). Furthermore, MG132 has been proven to sensitize TRAIL-resistant prostate cancer cells 
by activating c-Fos and c-Jun (Li, Zhang and Olumi, 2007). It is to note that both c-Fos and c-Jun 
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are part of the AP1 family, an important transcription factor in IL10 signalling (Ananieva et al., 
2008; Wen, Sakamoto and Miller, 2010). Based on these reports, proteasome inhibition by 
MG132 seems to have a strong effect on activation of multiple cascades related to IL10, but the 
main mechanism seems to be phosphorylation of MAPK P38.  
 The next step was to determine the effects of Bortezomib on IL10 expression. A clear 
increase in IL10 was apparent in macrophages treated with the clinically used proteasome 
inhibitor. Interestingly, our results contrast with a recent report by Chang and collaborators 
(2015) describing a decrease in immunosuppressive cytokines like IL10 and TGF-β1 in cutaneous 
T cell lymphoma (CTCL) cells treated with Bortezomib in vitro. The authors of the study 
suggested that the Bortezomib-dependant reduction of IL10 is independent of IBα and 
connected to NF-B non-canonical activation. They also showed inhibition of the chemokine 
receptor CXCR4 (a receptor from the CXC family like CXCL2) in CTCL cells as a result of 
Bortezomib treatment (Chang, Poltoratsky and Vancurova, 2015). In the same line, reduced 
expression of IL6 and IL10, as well as reduction in STAT3 phosphorylation was seen in mantle 
cell lymphoma cell lines after treatment with Bortezomib (Baran-Marszak et al., 2010). In both 
of those cases, the effect of Bortezomib was characterised in cancer cells. However, Beyar-Kats 
and collaborators (2016) showed more recently that Bortezomib not only increases migration 
and proliferation of MM cells in vitro but also promotes pro-inflammatory macrophages and 
therefore disease progression. The same study found an increase in IL6 and IL10 in plasma 
samples of mice treated with Bortezomib (Beyar-Katz et al., 2016). Interestingly a recent report 
has described a correlation between chemokine CCL27, its receptor CCR10 and IL10 expression 
as a potential mechanism mediating drug resistance to proteasome inhibition in MM. The 
researchers described this effect to be dependent on the interaction between myeloma cells 
and stromal cells, and they succeeded in reversing drug resistance by blocking CCR10, IL10 or 
IL10R (Thangavadivel et al., 2016). Our results suggest that IL10 expression induced by 
Bortezomib is also dependant on P38 and CREB activation but independent of ERK, as previously 
seen with MG132 treatment. However, the phosphorylation state of JNK seems to be 
differentially induced by the two proteasomal inhibitor evaluated. While MG132 induced 
phosphorylation of JNK, this effect was not as obvious with Bortezomib. Such observations were 
confirmed with the inhibitors for P38 and JNK, where inhibition of P38 depleted Bortezomib-
induced expression of IL10 but inhibition of JNK did not affect it. The present evidence clearly 
indicates an association between IL10 expression in macrophages and the use of proteasome 
inhibitors. This may be of particular relevance to the treatment of MM since whereas 
Bortezomib may be able to suppress IL10 in tumour cells it may have the opposite effect in 
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stromal cells such as macrophages, as demonstrated in the present study. This may lead to 
patients becoming refractory to treatment with Bortezomib.  
The expression of IL10 in different types of cell death was also evaluated since its 
expression was coincident with cytotoxicity and the main mechanism of action of Bortezomib is 
to induce or sensitize malignant cells to cell death. Bortezomib caused cytotoxicity in 
macrophages as revealed by the release of LDH into cell supernatants. However, LDH is not a 
specific signature of a particular form of cell death. Therefore, three types of program cell death 
were evaluated as potential triggers of IL10 expression/secretion. The results suggest the anti-
inflammatory cytokine is not being induced by pyroptosis or necroptosis. These results are 
consistent with the well described pro-inflammatory nature of both types of cell death (Galluzzi 
et al., 2014; Kolb et al., 2017). As for apoptosis, our results show a modest increase in IL10 
expression in response to cell death activated by TLR4 signalling and a significant reduction in 
the case of TLR3 signalling. These seems to be in line with the anti-inflammatory nature of 
apoptosis (Kolb et al., 2017). In that sense, multiple studies report reduction or prevention of 
apoptosis correlated to increase on IL10 expression or treatment with the cytokine in many 
different models, but mainly in Treg and endothelial cells (Pan et al., 2013; Yin et al., 2013; Li et 
al., 2014; Lao et al., 2015; Behrendt et al., 2016). In the specific case of treatment with 
Bortezomib, apoptosis has been shown to increase while IL10 is reduced (Baran-Marszak et al., 
2010).  
Clearly, genetic variability and polymorphisms of IL10 have an important role in MMs 
poor prognosis and progression, but also the effect of treatment on specific cells and their 
interaction in the context of cancer microenvironment needs to be discussed. In that sense, 
macrophages have been shown to change their phenotypes in cancer development leaning 
towards an immunosuppressive type, and more likely to sustain malignant progression and 
metastasis (Biswas, Sica and Lewis, 2008). Another point to be considered in our approach is the 
specific mechanism by which MG132 and Bortezomib exert their function and the effect it has 
on subsequent changes in the cells. MG132 has been described as a weaker inhibitor of 
hydrolytic caspase and chymotrypsin-like catalytic activity compared to Bortezomib. However, 
both were reported to sensitize MM cells to apoptosis in vitro (Crawford et al., 2006). It would 
also be of interest to assess the effect on IL10 production of irreversible binding proteasome 
inhibitors such as Carfilzomib, Marizomib or Oprozomib in the macrophages, considering the 
reduction in phosphorylation of P38 and CREB seen with the reversible binding proteasome 
inhibitor Bortezomib after 3 hours treatment (Teicher and Tomaszewski, 2015). 
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In summary, the results of this Chapter describe the induction of IL10 expression in 
macrophages by the proteasome inhibitor MG1323 and the clinically used Bortezomib. It is 
possible that IL10 expression is induced by stress signals that are triggered by protein 
accumulation in the cytosol. Phosphorylation of P38 and JNK, two well-known MAPKs activated 
by stress signals, seems to be the proximal mechanisms being activated under these conditions 
(Figure 5.16). Increase phosphorylation of P38 mediates the activation of transcription factor 
CREB, which in turn induces expression of IL10 and CXCL2. These two MAPKs can then act as 
growth factors or promotors of tumoural progression and IL10 at the same time could be 
inhibiting the immune response against the malignant cells. It was also shown that inhibition of 
P38 kinase activity by means of AMG548 stops MG132 and Bortezomib-induced IL10 (Figure 
5.16). Furthermore, IL10 induction is not an intrinsic feature of pyroptosis, necroptosis or 
apoptosis. It is important to note that although the effects of the two proteasome inhibitors 
described in this thesis (MG132 and Bortezomib) were mostly similar in terms of inducing 
expression of IL10 and activation of P38 and CREB signalling, their impact in early signalling 
activation were to some extent different. Therefore, the efficiency and specificity of their 
responses needs to be considered in further experiments. Despite the strong correlation 
between the two mentioned proteasome inhibitors and the induction of anti-inflammatory 
cytokine IL10, further studies are required to determine the specificity of this response and to 
fully understand the underlying mechanism. It would be interesting to evaluate if similar 
observations are seen in MM cells or tumour-associated macrophages (TAM), or if other types 
of cells in the bone marrow microenvironment are also involved. A more comprehensive study 
on the effect of proteasome inhibition in cellular interactions and induction of soluble factors 
like IL10 and CXCL2 would be extremely useful to increase the efficiency of this type of 
treatment. This is especially relevant and timely in the light of the new generation of proteasome 





Figure 5.16 Model of IL10 production induced by proteasome inhibitors MG132 and 
Bortezomib.  
Proteasome inhibition with MG1323 or Bortezomib induces the phosphorylation of P38 and to 
some extend JNK (specifically for treatment with MG132), two well-known MAPKs activated by 
stress signals. P38 in turn activates transcription factor CREB that will mediate the production of 
IL and CXCL2. When released in the tumoural microenvironment, IL10 can promote tumoural 
progression acting as a growth factor and inhibit further immune response against the malignant 
cells. Inhibition of P38 signalling cascade with AMG548 was showed to block the expression of 














6.1 Concluding remarks 
 
The present work aimed to explore elements of the ubiquitination and proteasome pathways in 
the context of cell death and innate immune signalling, especially in macrophages. Initial studies 
evaluated whether Pellino 2 and Pellino 3 E3 ubiquitin ligases play a role in the regulation of 
necroptosis by virtue of their close molecular and functional relationships with RIP kinases. The 
data show that neither E3 ligase regulates necroptosis. This contrasts with emerging roles for 
the remaining family member Pellino 1 in regulating necroptosis. However, this is complicated 
by two recent reports describing opposite roles for Pellino 1 in necroptosis with its definitive 
function in this pathway remaining to be clarified (Wang et al., 2017; Choi et al., 2018). It is also 
interesting to note that overexpression of Pellino drives tumour formation, especially 
lymphomogenesis and raising the possibility that necroptosis may be a novel mechanism to 
control tumour cells (Park et al., 2014). The results also highlight the functional variability 
between the members of the Pellino family and promotes further investigation into their 
molecular and functional roles. 
Another pathway that is strongly regulated by the ubiquitination / proteasome system 
is the transcription factor HIF-1α and the present studies show that all tested TLRs can promote 
stabilisation of HIF-1α. This is consistent with previous reports on the close functional 
relationship of HIF-1α with other transcription factors like NF-B that are also activated by TLRs. 
Thus, whilst HIF-1α has been traditionally studied in the context of responding to hypoxia, it is 
also likely to play a key role in innate immunity. Furthermore, the findings also highlight that 
whilst HIF-1α is known to upregulate the enzymes in the glycolytic pathway, blockade of 
glycolysis suppresses the levels of HIF-1α suggesting a positive regulatory loop system that 
would facilitate amplification of signals in a short time frame. Furthermore, whilst both TLRs and 
hypoxia stabilise HIF-1α, TLRs appears capable of also stabilising a uniquely smaller form of HIF-
1α. It was not possible to functionally characterise this latter form, but mass spectrometry 
analysis may be useful in determining its identity. This would provide important insight into its 
genesis and may offer clues to its functional relevance. In hypothesising that it may represent a 
processed form of full length HIF-1α, we explored the role of the proteasome as a mediator of 
this putative processing event. In doing so, the studies serendipitously highlighted that 
proteasome blockade strongly induced IL10 in macrophages. Whilst these conditions are also 
associated with cell death, the expression of IL-10 appears to be functionally separate from 
various forms of cell death. The importance of IL-10 expression in response to treatment of 
macrophages with proteasome inhibitors is discussed in the context of Bortezomib as a 
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therapeutic strategy in the treatment of multiple myeloma. The induction of IL-10 in 
macrophages may represent a valuable insight into the refractory nature of MM in the context 
of Bortezomib treatment. It would be fascinating to examine IL-10 in the different cell 
populations of bone marrow aspirates from MM patients undergoing Bortezomib treatment to 
evaluate if it displays opposing roles on IL-10 expression in lymphoma cells and resident stromal 
macrophages.  
Overall this work emphasises the importance of the ubiquitination and proteasome 
system for cell death and innate immunity. It offers some new insights into these relationships 
and prompts further studies that may have applications that extend from understanding 










Akira, S. and Takeda, K. (2004) ‘Toll-like receptor signalling’, Nature Reviews Immunology, 4(7), 
pp. 499–511. doi: 10.1038/nri1391. 
Alexandrakis, M. G. et al. (2015) ‘Interleukin-10 Induces Both Plasma Cell Proliferation and 
Angiogenesis in Multiple Myeloma’, Pathology and Oncology Research, 21(4), pp. 929–934. doi: 
10.1007/s12253-015-9921-z. 
Alfranca, A. et al. (2002) ‘c-Jun and Hypoxia-Inducible Factor 1 Functionally Cooperate in 
Hypoxia-Induced Gene Transcription’, Molecular and Cellular Biology, 22(1), pp. 12–22. doi: 
10.1128/MCB.22.1.12-22.2002. 
Almagro, M. C. De and Vucic, D. (2015) ‘Necroptosis : Pathway diversity and characteristics’, 
Seminars in Cell & Developmental Biology, 39, pp. 56–62. 
Alturki, N. A. et al. (2018) ‘Triad3a induces the degradation of early necrosome to limit RipK1-
dependent cytokine production and necroptosis article’, Cell Death and Disease, 9(6). doi: 
10.1038/s41419-018-0672-0. 
Ananieva, O. et al. (2008) ‘The kinases MSK1 and MSK2 act as negative regulators of Toll-like 
receptor signaling’, Nature Immunology, 9(9), pp. 1028–1036. doi: 10.1038/ni.1644. 
Anderson, K. C. (2016) ‘Progress and Paradigms in Multiple Myeloma’, Anal Chem., 22(22), pp. 
5419–5427. doi: 10.1016/j.cogdev.2010.08.003.Personal. 
Arany, Z. et al. (1996) ‘An essential role for p300/CBP in the cellular response to hypoxia.’, 
Proceedings of the National Academy of Sciences of the United States of America, 93(23), pp. 
12969–73. doi: 10.1073/pnas.93.23.12969. 
Argyriou, A. A. et al. (2008) ‘Bortezomib-induced peripheral neuropathy in multiple myeloma: a 
comprehensive review of the literature’, Blood, 112(5), pp. 1593–1599. doi: 10.1182/blood-
2008-04-149385. 
Baader, E. et al. (1994) ‘Inhibition of Prolyl 4-Hydroxylase by Oxalyl Amino-Acid Derivatives in-
Vitro, in Isolated Microsomes and in Embryonic Chicken Tissues’, Biochemical Journal, 300, pp. 
525–530. 
Balamurugan, K. (2016) ‘HIF-1 at the crossroads of hypoxia, inflammation, and cancer’, 
International Journal of Cancer, 138(5), pp. 1058–1066. doi: 10.1002/ijc.29519. 
Balkwill, F. R., Capasso, M. and Hagemann, T. (2012) ‘The tumor microenvironment at a glance’, 
Journal of Cell Science, 125(23), pp. 5591–5596. doi: 10.1242/jcs.116392. 
Baran-Marszak, F. et al. (2010) ‘Constitutive and B-cell receptor-induced activation of STAT3 are 
important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma’, 
Haematologica, 95(11), pp. 1865–1872. doi: 10.3324/haematol.2009.019745. 
Barnes, B. J., Field, A. E. and Pitha-Rowe, P. M. (2003) ‘Virus-induced heterodimer formation 
between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and 
transcriptional activity of IFNA genes’, Journal of Biological Chemistry, 278(19), pp. 16630–
16641. doi: 10.1074/jbc.M212609200. 
Basith, S. et al. (2012) ‘Roles of toll-like receptors in cancer: A double-edged sword for defense 




Beck, G. and Habicht, G. S. (1996) ‘Immunity and the invertebrates.’, Scientific American, 275(5). 
doi: 10.1038/scientificamerican1196-60. 
Behrendt, P. et al. (2016) ‘IL-10 Reduces Apoptosis And Extracellular Matrix Degeneration After 
Injurious Compression Of Bovine Articular Cartilage’, Osteoarthritis and Cartilage, 24, pp. 0–2. 
Vanden Berghe, T. et al. (2014) ‘Regulated necrosis: the expanding network of non-apoptotic 
cell death pathways.’, Nature reviews. Molecular cell biology. Nature Publishing Group, 15(2), 
pp. 135–47. doi: 10.1038/nrm3737. 
Bertrand, M. J. M. et al. (2008) ‘cIAP1 and cIAP2 Facilitate Cancer Cell Survival by Functioning as 
E3 Ligases that Promote RIP1 Ubiquitination’, Molecular Cell, 30(6), pp. 689–700. doi: 
10.1016/j.molcel.2008.05.014. 
Beyar-Katz, O. et al. (2016) ‘Bortezomib-induced pro-inflammatory macrophages as a potential 
factor limiting anti-tumour efficacy’, Journal of Pathology, 239(3), pp. 262–273. doi: 
10.1002/path.4723. 
Biswas, S. K., Sica, A. and Lewis, C. E. (2008) ‘Plasticity of Macrophage Function during Tumor 
Progression: Regulation by Distinct Molecular Mechanisms’, The Journal of Immunology, 180(4), 
pp. 2011–2017. doi: 10.4049/jimmunol.180.4.2011. 
Boatright, K. M. et al. (2003) ‘A unified model for apical caspase activation’, Molecular Cell, 11(2), 
pp. 529–541. doi: 10.1016/S1097-2765(03)00051-0. 
Boonstra, A. et al. (2006) ‘Macrophages and Myeloid Dendritic Cells, but Not Plasmacytoid 
Dendritic Cells, Produce IL-10 in Response to MyD88- and TRIF-Dependent TLR Signals, and TLR-
Independent Signals’, The Journal of Immunology, 177(11), pp. 7551–7558. doi: 
10.4049/jimmunol.177.11.7551. 
Bracken, C. P., Whitelaw, M. L. and Peet, D. J. (2003) ‘The hypoxia-inducible factors: Key 
transcriptional regulators of hypoxic responses’, Cellular and Molecular Life Sciences, 60(7), pp. 
1376–1393. doi: 10.1007/s00018-003-2370-y. 
Brasier, A. R. (2006) ‘The NF- κ B Regulatory Network’, Cardiovascular Toxicology, 6(2), pp. 111–
130. 
Broz, P. and Dixit, V. M. (2016) ‘Inflammasomes: Mechanism of assembly, regulation and 
signalling’, Nature Reviews Immunology, 16(7), pp. 407–420. doi: 10.1038/nri.2016.58. 
Bruning, U. et al. (2012) ‘NFkB and HIF display synergistic behaviour during hypoxic 
inflammation’, Cellular and Molecular Life Sciences, 69(8), pp. 1319–1329. doi: 10.1007/s00018-
011-0876-2. 
Buac, D. et al. (2013) ‘From Bortezomib to other Inhibitors of the Proteasome and Beyond’, Curr 
Pharm Des, 19(22), pp. 4025–4038. doi: 10.1111/j.1743-6109.2008.01122.x.Endothelial. 
Butcher, S. K. et al. (2018) ‘Toll-like receptors drive specific patterns of tolerance and training on 
restimulation of macrophages’, Frontiers in Immunology, 9(MAY). doi: 
10.3389/fimmu.2018.00933. 
Butler, M. P., Hanly, J. A. and Moynagh, P. N. (2005) ‘Pellino3 is a novel upstream regulator of 
p38 MAPK and activates CREB in a p38-dependent manner’, Journal of Biological Chemistry, 
280(30), pp. 27759–27768. doi: 10.1074/jbc.M500756200. 
172 
 
Butler, M. P., Hanly, J. A. and Moynagh, P. N. (2007) ‘Kinase-active interleukin-1 receptor-
associated kinases promote polyubiquitination and degradation of the Pellino family: Direct 
evidence for Pellino proteins being ubiquitin-protein isopeptide ligases’, Journal of Biological 
Chemistry, 282(41), pp. 29729–29737. doi: 10.1074/jbc.M704558200. 
Campbell, E. L. et al. (2014) ‘Transmigrating neutrophils shape the mucosal microenvironment 
through localized oxygen depletion to influence resolution of inflammation’, Immunity, 40(1), 
pp. 66–77. doi: 10.1016/j.immuni.2013.11.020. 
Campbell, E. L. and Colgan, S. P. (2015) ‘Neutrophils and inflammatory metabolism in 
antimicrobial functions of the mucosa’, Journal of Leukocyte Biology, 98(4), pp. 517–522. doi: 
10.1189/jlb.3MR1114-556R. 
Cargnello, M. and Roux, P. P. (2011) ‘Activation and Function of the MAPKs and Their Substrates, 
the MAPK-Activated Protein Kinases’, Microbiology and Molecular Biology Reviews, 75(1), pp. 
50–83. doi: 10.1128/MMBR.00031-10. 
Chan, F. K. M. et al. (2003) ‘A Role for Tumor Necrosis Factor Receptor-2 and Receptor-
interacting Protein in Programmed Necrosis and Antiviral Responses’, Journal of Biological 
Chemistry, 278(51), pp. 51613–51621. doi: 10.1074/jbc.M305633200. 
Chang, M., Jin, W. and Sun, S. C. (2009) ‘Peli1 facilitates TRIF-dependent Toll-like receptor 
signaling and proinflammatory cytokine production’, Nature Immunology, 10(10), pp. 1089–
1095. doi: 10.1038/ni.1777. 
Chang, T.-P., Poltoratsky, V. and Vancurova, I. (2015) ‘Bortezomib Inhibits Expression of TGF-β1, 
IL-10, and CXCR4, Resulting in Decreased Survival and Migration of Cutaneous T Cell Lymphoma 
Cells’, The Journal of Immunology, 194(6), pp. 2942–2953. doi: 10.4049/jimmunol.1402610. 
Chapman-Smith, A. and Whitelaw, M. L. (2006) ‘Novel DNA binding by a basic helix-loop-helix 
protein: The role of the Dioxin Receptor PAS domain’, Journal of Biological Chemistry, 281(18), 
pp. 12535–12545. doi: 10.1074/jbc.M512145200. 
Chen, G. and Goeddel, D. V (2002) ‘TNF-R1 signalling: A beautiful pathway’, Science, 296(5573), 
pp. 1634–1635. 
Chen, Z. J. (2005) ‘Ubiquitin signalling in the NF-kappaB pathway.’, Nature cell biology, 7(8), pp. 
758–65. doi: 10.1038/ncb0805-758. 
Chesi, M. et al. (2014) ‘Molecular pathogenesis of multiple myeloma: basic and clinical updates’, 
International journal of hematology, 97(3), pp. 313–323. doi: 10.1007/s12185-013-1291-
2.Molecular. 
Chi, H. et al. (2006) ‘Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK 
phosphatase 1 (MKP-1) in innate immune responses’, Proc Natl Acad Sci U S A, 103(7), pp. 2274–
2279. doi: 10.1073/pnas.0510965103. 
Cho, Y. et al. (2009) ‘Phosphorylation-Driven Assembly of RIP1-RIP3 Complex Regulates 
Programmed Necrosis and Virus-Induced Inflammation’, Cell, 137(6), pp. 1112–1123. doi: 
10.1016/j.cell.2009.05.037.Phosphorylation-Driven. 
Choi, S. W. et al. (2018) ‘PELI1 Selectively Targets Kinase-Active RIP3 for Ubiquitylation-




Colgan, S. P. and Taylor, C. T. (2010) ‘Hypoxia: An alarm signal during intestinal inflammation’, 
Nature Reviews Gastroenterology and Hepatology, 7(5), pp. 281–287. doi: 
10.1038/nrgastro.2010.39. 
Condon, S. M. et al. (2014) ‘Birinapant, a smac-mimetic with improved tolerability for the 
treatment of solid tumors and hematological malignancies’, Journal of Medicinal Chemistry, 
57(9), pp. 3666–3677. doi: 10.1021/jm500176w. 
Cramer, T. et al. (2003) ‘HIF-1 alpha is essential for myeloid cell-mediated inflammation’, Cell, 
113(3), p. 419. 
Crawford, L. J. A. et al. (2006) ‘Comparative selectivity and specificity of the proteasome 
inhibitors BzLLLCOCHO, PS-341, and MG-132’, Cancer Research, 66(12), pp. 6379–6386. doi: 
10.1158/0008-5472.CAN-06-0605. 
Creagh, E. M. (2014) ‘Caspase crosstalk: Integration of apoptotic and innate immune signalling 
pathways’, Trends in Immunology, 35(12), pp. 631–640. doi: 10.1016/j.it.2014.10.004. 
Cummins, E. P. et al. (2016) ‘The role of HIF in immunity and inflammation’, Molecular Aspects 
of Medicine, 47–48, pp. 24–34. doi: 10.1016/j.mam.2015.12.004. 
Cusson-Hermance, N. et al. (2005) ‘Rip1 mediates the trif-dependent Toll-like receptor 3- and 4-
induced NF-??B activation but does not contribute to interferon regulatory factor 3 activation’, 
Journal of Biological Chemistry, 280(44), pp. 36560–36566. doi: 10.1074/jbc.M506831200. 
Dang, E. V. et al. (2011) ‘Control of TH17/Tregbalance by hypoxia-inducible factor 1’, Cell, 146(5), 
pp. 772–784. doi: 10.1016/j.cell.2011.07.033. 
Dayan, F. et al. (2006) ‘The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls 
expression of distinct genes through the bifunctional transcriptional character of hypoxia-
inducible factor-1α’, Cancer Research, 66(7), pp. 3688–3698. doi: 10.1158/0008-5472.CAN-05-
4564. 
Declercq, W., Vanden Berghe, T. and Vandenabeele, P. (2009) ‘RIP Kinases at the Crossroads of 
Cell Death and Survival’, Cell, 138, pp. 229–232. doi: 10.1016/j.cell.2009.07.006. 
Deng, B. et al. (2012) ‘IL-10 Triggers Changes in Macrophage Phenotype That Promote Muscle 
Growth and Regeneration’, The Journal of Immunology, 189(7), pp. 3669–3680. doi: 
10.4049/jimmunol.1103180. 
Dengler, V., Galbraith, M. and Espinosa, J. (2014) ‘Transcriptional Regulation by Hypoxia 
Inducible Factors’, Crit Rev Biochem Mol Biol, 49(1), pp. 1–15. doi: 
10.3109/10409238.2013.838205.Transcriptional. 
Deshaies, R. J. (2014) ‘Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy’, 
BMC Biology, 12, pp. 1–14. doi: 10.1186/s12915-014-0094-0. 
Deshaies, R. J. and Joazeiro, C. A. P. (2009) ‘RING Domain E3 Ubiquitin Ligases’, Annual Review 
of Biochemistry, 78(1), pp. 399–434. doi: 10.1146/annurev.biochem.78.101807.093809. 
Devin, A. et al. (2000) ‘The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 
recruits IKK to TNF-R1 while RIP mediates IKK activation’, Immunity, 12(4), pp. 419–429. doi: 
10.1016/S1074-7613(00)80194-6. 
Dillon, C. P. et al. (2014) ‘RIPK1 blocks early postnatal lethality mediated by caspase-8 and 
174 
 
RIPK3’, Cell, 157(5), pp. 1189–1202. doi: 10.1016/j.cell.2014.04.018. 
Dondelinger, Y. et al. (2014) ‘MLKL compromises plasma membrane integrity upon binding to 
phosphatidyl inositol phosphates’, Cell Reports. Elsevier, 7(4), pp. 1–11. doi: 
10.1016/j.celrep.2014.04.026. 
Elmore, S. (2007) ‘Apoptosis: A Review of Programmed Cell Death’, Toxicologic Pathology, 35(4), 
pp. 495–516. doi: 10.1080/01926230701320337. 
Ema, M. et al. (1999) ‘Molecular mechanisms of transcription activation by HLF and HIF1alpha 
in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300’, 
The EMBO Journal, 18(7), pp. 1905–1914. doi: 10.1093/emboj/18.7.1905. 
Ernst, A. et al. (2013) ‘A Strategy for Modulation of Enzymes in the Ubiquitin System’, Science, 
209(February), pp. 590–595. doi: 10.1126/science.1230161. 
Feng, S. et al. (2007) ‘Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway 
by removal of kinase domain’, Cellular Signalling, 19(10), pp. 2056–2067. doi: 
10.1016/j.cellsig.2007.05.016. 
Feoktistova, M. et al. (2011) ‘CIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing 
Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforms’, Molecular Cell, 
43(3), pp. 449–463. doi: 10.1016/j.molcel.2011.06.011. 
Fitzgerald, K. A. et al. (2003) ‘IKKE and TBKI are essential components of the IRF3 signalling 
pathway’, Nature Immunology, 4(5), pp. 491–496. doi: 10.1038/ni921. 
Freire-de-Lima, L. et al. (2017) ‘Multiple Myeloma Cells Express Key Immunoregulatory 
Cytokines and Modulate the Monocyte Migratory Response’, Frontiers in Medicine, 4(June). doi: 
10.3389/fmed.2017.00092. 
Fulda, S. (2015) ‘Targeting extrinsic apoptosis in cancer : Challenges and opportunities’, 
Seminars in Cell and Developmental Biology, 39, pp. 20–25. doi: 10.1016/j.semcdb.2015.01.006. 
Gaczynska, M. et al. (1994) ‘Peptidase activities of proteasomes are differentially regulated by 
the major histocompatibility complex-encoded genes for LMP2 and LMP7.’, Proceedings of the 
National Academy of Sciences, 91(20), pp. 9213–9217. doi: 10.1073/pnas.91.20.9213. 
Galluzzi, L. et al. (2014) ‘Essential versus accessory aspects of cell death: recommendations of 
the NCCD 2015’, Cell Death and Differentiation, 22(2014), pp. 58–73. doi: 
10.1038/cdd.2014.137. 
Galluzzi, L. and Kroemer, G. (2008) ‘Necroptosis: A Specialized Pathway of Programmed 
Necrosis’, Cell, 135(7), pp. 1161–1163. doi: 10.1016/j.cell.2008.12.004. 
Gilmore, T. D. (2006) ‘Introduction to NF-κB: Players, pathways, perspectives’, Oncogene, 25(51), 
pp. 6680–6684. doi: 10.1038/sj.onc.1209954. 
Glatz, G. et al. (2013) ‘Structural mechanism for the specific assembly and activation of the 
extracellular signal regulated kinase 5 (ERK5) module’, Journal of Biological Chemistry, 288(12), 
pp. 8596–8609. doi: 10.1074/jbc.M113.452235. 
Goh, E. et al. (2012) Identification of the protein kinases that activate the E3 ubiquitin ligase 
Pellino 1 in the innate immune system, The Biochemical journal. doi: 10.1042/BJ20111415. 
Graham, G. J. and Locati, M. (2013) ‘Regulation of the immune and inflammatory responses by 
175 
 
the “atypical” chemokine receptor D6’, Journal of Pathology, 229(2), pp. 168–175. doi: 
10.1002/path.4123. 
Greenberger, M. et al. (1995) ‘Neutralization of IL-10 increases survival in a murine model of 
Klebsiella pneumonia.’, The Journal of Immunology, 2, pp. 772–729. Available at: 
http://www.jimmunol.org/content/155/2/722.short. 
Griffin, T. A. et al. (1998) ‘Immunoproteasome assembly: cooperative incorporation of 
interferon gamma (IFN-gamma)-inducible subunits.’, The Journal of experimental medicine, 
187(1), pp. 97–104. doi: 10.1084/jem.187.1.97. 
Gu, Y. Z. et al. (1998) ‘Molecular characterization and chromosomal localization of a third alpha-
class hypoxia inducible factor subunit, HIF3alpha.’, Gene expression. United States, 7(3), pp. 
205–213. 
Gyrd-Hansen, M. and Meier, P. (2010) ‘IAPs: From caspase inhibitors to modulators of NF-κB, 
inflammation and cancer’, Nature Reviews Cancer, 10(8), pp. 561–574. doi: 10.1038/nrc2889. 
Haas, T. L. et al. (2009) ‘Recruitment of the Linear Ubiquitin Chain Assembly Complex Stabilizes 
the TNF-R1 Signaling Complex and Is Required for TNF-Mediated Gene Induction’, Molecular 
Cell, 36(5), pp. 831–844. doi: 10.1016/j.molcel.2009.10.013. 
Hammer, M. et al. (2005) ‘Control of dual-specificity phosphatase-1 expression in activated 
macrophages by IL-10’, European Journal of Immunology, 35(10), pp. 2991–3001. doi: 
10.1002/eji.200526192. 
Hasegawa, M. et al. (2008) ‘A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kB 
activation’, EMBO Journal, 27(2), pp. 373–383. doi: 10.1038/sj.emboj.7601962. 
Hashimoto, S. et al. (1997) ‘Enhancement of macrophage colony-stimulating factor-induced 
growth and differentiation of human monocytes by interleukin-10.’, Blood, 89(1), pp. 315–21. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/8978307. 
Hayashi, M. et al. (2005) ‘Hypoxia up-regulates hypoxia-inducible factor-1alpha expression 
through RhoA activation in trophoblast cells.’, The Journal of clinical endocrinology and 
metabolism. United States, 90(3), pp. 1712–1719. doi: 10.1210/jc.2004-1547. 
Haydaroglu, H. et al. (2017) ‘Effect of Cytokine Genes in the Pathogenesis and on the Clinical 
Parameters for the Treatment of Multiple Myeloma’, Immunological Investigations, 46(1), pp. 
10–21. doi: 10.1080/08820139.2016.1208219. 
He, S. et al. (2009) ‘Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response 
to TNF-α’, Cell, 137(6), pp. 1100–1111. doi: 10.1016/j.cell.2009.05.021. 
He, S. et al. (2011) ‘Toll-like receptors activate programmed necrosis in macrophages through a 
receptor-interacting kinase-3-mediated pathway’, Proceedings of the National Academy of 
Sciences, 108(50), pp. 20054–20059. doi: 10.1073/pnas.1116302108. 
Heaton, S. M., Borg, N. A. and Dixit, V. M. (2016) ‘Ubiquitin in the activation and attenuation of 
innate antiviral immunity’, The Journal of Experimental Medicine, 213(1), pp. 1–13. doi: 
10.1084/jem.20151531. 
Hewitson, K. S. et al. (2002) ‘Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical 
to factor inhibiting HIF (FIH) and is related to the cupin structural family’, Journal of Biological 
Chemistry, 277(29), pp. 26351–26355. doi: 10.1074/jbc.C200273200. 
176 
 
Hewitson, K. S. et al. (2003) ‘The role of iron and 2-oxoglutarate oxygenases in signalling.’, 
Biochemical Society transactions. England, 31(Pt 3), pp. 510–515. doi: 10.1042/. 
Hideshima, T. et al. (2001) ‘The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, 
and overcomes drug resistance in human multiple myeloma cells.’, Cancer research, 61(7), pp. 
3071–6. doi: 10.1054/drup.1999.0095. 
Higashiyama, M. et al. (2012) ‘HIF-1 in T cells ameliorated dextran sodium sulfate-induced 
murine colitis’, Journal of Leukocyte Biology, 91(6), pp. 901–909. doi: 10.1189/jlb.1011518. 
Hitomi, J. et al. (2008) ‘Identification of a Molecular Signaling Network that Regulates a Cellular 
Necrotic Cell Death Pathway’, Cell, 135(7), pp. 1311–1323. doi: 10.1016/j.cell.2008.10.044. 
Hoesel, B. and Schmid, J. A. (2013) ‘The complexity of NF- κ B signaling in inflammation and 
cancer’, Molecular Cancer, 12:86, pp. 1–15. doi: 10.1186/1476-4598-12-86. 
Honda, K., Takaoka, A. and Taniguchi, T. (2006) ‘Type I Inteferon Gene Induction by the 
Interferon Regulatory Factor Family of Transcription Factors’, Immunity, 25(3), pp. 349–360. doi: 
10.1016/j.immuni.2006.08.009. 
Hsu, H. et al. (1996) ‘TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-
1 signaling complex’, Immunity, 4(4), pp. 387–396. doi: 10.1016/S1074-7613(00)80252-6. 
Hu, C. et al. (2007) ‘The N-Terminal Transactivation Domain Confers Target Gene Specificity of 
Hypoxia-inducible Factors HIF-1α and HIF-2α’, Molecular biology of the cell, 18(December), pp. 
4528–42. doi: 10.1091/mbc.E06. 
Hu, F. et al. (2014) ‘Hypoxia and hypoxia-inducible factor-1α provoke toll-like receptor signalling-
induced inflammation in rheumatoid arthritis’, Annals of the Rheumatic Diseases, 73(5), pp. 
928–936. doi: 10.1136/annrheumdis-2012-202444. 
Hu, X. et al. (2006) ‘IFN-γ Suppresses IL-10 Production and Synergizes with TLR2 by Regulating 
GSK3 and CREB/AP-1 Proteins’, Immunity, 24(5), pp. 563–574. doi: 
10.1016/j.immuni.2006.02.014. 
Huang, B. et al. (2005) ‘Toll-like receptors on tumor cells facilitate evasion of immune 
surveillance’, Cancer Research, 65(12), pp. 5009–5014. doi: 10.1158/0008-5472.CAN-05-0784. 
Huang, J. et al. (2015) ‘Structural basis of cell apoptosis and necrosis in TNFR signaling’, 
Apoptosis, 20(2), pp. 210–215. doi: 10.1007/s10495-014-1061-5. 
Huang, L. E. et al. (1996) ‘Activation of hypoxia-inducible transcription factor depends primarily 
upon redox-sensitive stabilization of its α subunit’, Journal of Biological Chemistry, 271(50), pp. 
32253–32259. doi: 10.1074/jbc.271.50.32253. 
Humphries, F. (2012) ‘Investigating the regulation and enzymatic function of human ecsit in 
innate immune signalling’, Maynooth University, 21(November), p. 39. doi: 
10.1002/ejoc.201200111. 
Humphries, F. et al. (2014) ‘RIP kinases: key decision makers in cell death and innate immunity’, 
Cell Death and Differentiation. Nature Publishing Group, 22, pp. 225–236. doi: 
10.1038/cdd.2014.126. 
Humphries, F. et al. (2018) ‘The E3 ubiquitin ligase Pellino2 mediates priming of the NLRP3 
inflammasome’, Nature Communications, 9(1). doi: 10.1038/s41467-018-03669-z. 
177 
 
Iida, N. and Grotendorst, G. (1990) ‘Cloning and Sequencing of a New gro Transcript from 
Activated Human Monocytes: Expression in Leukocytes and Wound Tissue’, Molecular and 
cellular biology, 10(10), pp. 5596–5599. 
Imtiyaz, H. Z. et al. (2010) ‘Hypoxia-inducible factor 2 α regulates macrophage function in mouse 
models of acute and tumor inflammation’, The journal of clinical investigation, 120(8), pp. 2699–
2714. doi: 10.1172/JCI39506.phages. 
Inobe, T. and Matouschek, A. (2014) ‘Paradigms of protein degradation by the proteasome’, 
Current Opinion in Structural Biology, 24(1), pp. 156–164. doi: 10.1016/j.sbi.2014.02.002. 
Iwasaki, A. and Medzhitov, R. (2010) ‘Regulation of adaptive immunity by the innate immune 
system’, Science, 327(5963), pp. 291–295. doi: 10.1126/science.1183021. 
Iyer, N. V, Leung, S. W. and Semenza, G. L. (1998) ‘The human hypoxia-inducible factor 1alpha 
gene: HIF1A structure and evolutionary conservation.’, Genomics, 52, pp. 159–165. doi: 
10.1006/geno.1998.5416. 
Iyer, S. S., Ghaffari, A. A. and Cheng, G. (2010) ‘Lipopolysaccharide-Mediated IL-10 
Transcriptional Regulation Requires Sequential Induction of Type I IFNs and IL-27 in 
Macrophages’, The Journal of Immunology, 185(11), pp. 6599–6607. doi: 
10.4049/jimmunol.1002041. 
Jantsch, J. et al. (2008) ‘Hypoxia and Hypoxia-Inducible Factor-1  Modulate Lipopolysaccharide-
Induced Dendritic Cell Activation and Function’, The Journal of Immunology, 180(7), pp. 4697–
4705. doi: 10.4049/jimmunol.180.7.4697. 
Jensen, L. E. and Whitehead, A. S. (2003) ‘Pellino2 activates the mitogen activated protein kinase 
pathway’, FEBS Letters, 545(2–3), pp. 199–202. doi: 10.1016/S0014-5793(03)00533-7. 
Jensen, L. E. and Whitehead, A. S. (2003) ‘Pellino3, a Novel Member of the Pellino Protein Family, 
Promotes Activation of c-Jun and Elk-1 and May Act as a Scaffolding Protein’, The Journal of 
Immunology, 171(3), pp. 1500–1506. doi: 10.4049/jimmunol.171.3.1500. 
Jiang, B. H., Rue, E., et al. (1996) ‘Dimerization, DNA binding, and transactivation properties of 
hypoxia-inducible factor 1.’, The Journal of biological chemistry, 271(30), pp. 17771–8. doi: 
10.1074/JBC.271.30.17771. 
Jiang, B. H., Semenza, G. L., et al. (1996) ‘Hypoxia-inducible factor 1 levels vary exponentially 
over a physiologically relevant range of O2 tension.’, The American journal of physiology. United 
States, 271(4 Pt 1), pp. C1172-80. doi: 10.1152/ajpcell.1996.271.4.C1172. 
Jiang, B. H. et al. (1997) ‘Transactivation and inhibitory domains of hypoxia-inducible factor 
1alpha. Modulation of transcriptional activity by oxygen tension.’, The Journal of biological 
chemistry, 272(31), pp. 19253–19260. doi: 10.1074/jbc.272.31.19253. 
Jiang, Z. et al. (2003) ‘Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through its 
interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAK-tumor necrosis factor 
receptor-associated factor 6 (TRAF6) complex’, Journal of Biological Chemistry, 278(13), pp. 
10952–10956. doi: 10.1074/jbc.M212112200. 
Johnson, G. L. and Lapadat, R. (2013) ‘Mitogen-Activated Protein Kinase Pathways Mediated by 
ERK , JNK , and p38 Protein Kinases Author ( s ): Gary L . Johnson and Razvan Lapadat Published 
by : American Association for the Advancement of Science Stable URL : 





Jung, J. E. et al. (2005) ‘STAT3 is a potential modulator of HIF-1-mediated VEGF expression in 
human renal carcinoma cells.’, FASEB journal : official publication of the Federation of American 
Societies for  Experimental Biology. United States, 19(10), pp. 1296–1298. doi: 10.1096/fj.04-
3099fje. 
Jung, J. H. et al. (2016) ‘Association of Interleukin 10 Gene Polymorphisms with Autoimmune 
Thyroid Disease: Meta-Analysis’, Scandinavian Journal of Immunology, 84(5), pp. 272–277. doi: 
10.1111/sji.12470. 
Kaczmarek, A., Vandenabeele, P. and Krysko, D. (2013) ‘Necroptosis: the release of damage-
associated molecular patterns and its physiological relevance’, Immunity, 38, pp. 209–223. 
Kaiser, F. et al. (2009) ‘TPL-2 negatively regulates interferon-β production in macrophages and 
myeloid dendritic cells’, The Journal of Experimental Medicine, 206(9), pp. 1863–1871. doi: 
10.1084/jem.20091059. 
Kaiser, W. J. et al. (2013) ‘Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL’, 
Journal of Biological Chemistry, 288(43), pp. 31268–31279. doi: 10.1074/jbc.M113.462341. 
Kaiser, W. J., Upton, J. W. and Mocarski, E. S. (2008) ‘Receptor-Interacting Protein Homotypic 
Interaction Motif-Dependent Control of NF- B Activation via the DNA-Dependent Activator of 
IFN Regulatory Factors’, The Journal of Immunology, 181(9), pp. 6427–6434. doi: 
10.4049/jimmunol.181.9.6427. 
Karin, M. and Ben-neriah, Y. (2000) ‘Phosphorylation meets ubiquitination: The Control of NF-
kB Activity’, Annual Review of Immunology, 18, pp. 621–663. doi: DOI: 
10.1146/annurev.immunol.18.1.621. 
Kasama, T. et al. (1995) ‘Interleukin-10 expression and chemokine regulation during the 
evolution of murine type II collagen-induced arthritis’, Journal of Clinical Investigation, 95(6), pp. 
2868–2876. doi: 10.1172/JCI117993. 
Kasamatsu, T. et al. (2017) ‘Polymorphism of IL-10 receptor β affects the prognosis of multiple 
myeloma patients treated with thalidomide and/or bortezomib’, Hematological Oncology, 
35(4), pp. 711–718. doi: 10.1002/hon.2322. 
Kawai, T. and Akira, S. (2011) ‘Toll-like Receptors and Their Crosstalk with Other Innate 
Receptors in Infection and Immunity’, Immunity. Elsevier Inc., 34(5), pp. 637–650. doi: 
10.1016/j.immuni.2011.05.006. 
Kearney, C. J. et al. (2014) ‘RIPK1 can function as an inhibitor rather than an initiator of RIPK3-
dependent necroptosis’, FEBS Journal, 281, pp. 4921–4934. doi: 10.1111/febs.13034. 
Kearney, C. J. et al. (2015) ‘Necroptosis suppresses inflammation via termination of TNF-or LPS-
induced cytokine and chemokine production’, Cell Death and Differentiation, 22(8), pp. 1313–
1327. doi: 10.1038/cdd.2014.222. 
Khan, S. et al. (2001) ‘Immunoproteasomes Largely Replace Constitutive Proteasomes During an 
Antiviral and Antibacterial Immune Response in the Liver’, The Journal of Immunology, 167(12), 
pp. 6859–6868. doi: 10.4049/jimmunol.167.12.6859. 
Khandelwal, P. et al. (2014) ‘Bortezomib for refractory autoimmunity in pediatrics’, Biology of 
179 
 
Blood and Marrow Transplantation, 20(10), pp. 1641–1665. doi: 10.1016/j.bbmt.2014.06.032. 
Kimura, H. et al. (2001) ‘Identification of hypoxia-inducible factor 1 ancillary sequence and its 
function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide’, 
Journal of Biological Chemistry, 276(3), pp. 2292–2298. doi: 10.1074/jbc.M008398200. 
Kish-Trier, E. and Hill, C. P. (2013) ‘Structural Biology of the Proteasome’, Annual Review of 
Biophysics, 42(1), pp. 29–49. doi: 10.1146/annurev-biophys-083012-130417. 
Kolb, J. P. et al. (2017) ‘Programmed Cell Death and In fl ammation : Winter Is Coming’, Trends 
in Immunology, 38(10), pp. 705–718. doi: 10.1016/j.it.2017.06.009. 
Komander, D. and Rape, M. (2012) ‘The Ubiquitin Code’, Annual Review of Biochemistry, 81(1), 
pp. 203–229. doi: 10.1146/annurev-biochem-060310-170328. 
Kouroukis, C. T. et al. (2014) ‘Bortezomib in Multiple Myeloma: A Practice Guideline’, CLinical 
Oncology, 26(2), pp. 110–119. doi: 10.3747/co.20.1252. 
Kovacs, E. (2010) ‘Interleukin-6 leads to interleukin-10 production in several human multiple 
myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?’, Leukemia 
Research, 34(7), pp. 912–916. doi: 10.1016/j.leukres.2009.08.012. 
Kubiczkova, L. et al. (2014) ‘Proteasome inhibitors - molecular basis and current perspectives in 
multiple myeloma’, Journal of Cellular and Molecular Medicine, 18(6), pp. 947–961. doi: 
10.1111/jcmm.12279. 
Kumar, H., Kawai, T. and Akira, S. (2011) ‘Pathogen recognition by the innate immune system’, 
International Reviews of Immunology, 30(1), pp. 16–34. doi: 10.3109/08830185.2010.529976. 
Kurosaki, T., Kometani, K. and Ise, W. (2015) ‘Memory B cells’, Nature Reviews Immunology, 
15(3), pp. 149–159. doi: 10.1038/nri3802. 
Kyriakis, J. M. and Avruch, J. (2012) ‘Mammalian MAPK Signal Transduction Pathways Activated 
by Stress and Inflammation: A 10-Year Update’, Physiological Reviews, 92(2), pp. 689–737. doi: 
10.1152/physrev.00028.2011. 
Lando, D. et al. (2002) ‘Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic 
Switch’, Science, 295(5556), pp. 858–861. doi: 10.1126/science.1068592. 
Lando, D. et al. (2002) ‘FIH-1 is an asparaginyl hydroxylase enzyme that regulates the 
transcriptional activity of hypoxia-inducible factor service FIH-1 is an asparaginyl hydroxylase 
enzyme that regulates the transcriptional activity of hypoxia-inducible factor’, Genes and 
Development, (214), pp. 1466–1471. doi: 10.1101/gad.991402. 
Lang, R. et al. (2002) ‘Shaping Gene Expression in Activated and Resting Primary Macrophages 
by IL-10’, The Journal of Immunology, 169(5), pp. 2253–2263. doi: 
10.4049/jimmunol.169.5.2253. 
Lao, K. et al. (2015) ‘IL-10 regulate decidual Tregs apoptosis contributing to the abnormal 
pregnancy with Toxoplasma gondii infection’, Microbial Pathogenesis, 89, pp. 210–216. doi: 
10.1016/j.micpath.2015.10.002. 
Lawlor, K. E. et al. (2015) ‘RIPK3 promotes cell death and NLRP3 inflammasome activation in the 
absence of MLKL’, Nature Communications, 6, p. 6282. doi: 10.1038/ncomms7282. 
Lee, B. L. and Barton, G. M. (2014) ‘Trafficking of endosomal Toll-like receptors’, Trends in Cell 
180 
 
Biology, 24(6), pp. 360–369. doi: 10.1016/j.tcb.2013.12.002. 
Lee, T. H. et al. (2004) ‘The kinase activity of Rip1 is not required for tumor necrosis factor-??-
induced I??B kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2’, 
Journal of Biological Chemistry, 279(32), pp. 33185–33191. doi: 10.1074/jbc.M404206200. 
Lee, Y. S. et al. (2014) ‘Increased adipocyte O2 consumption triggers HIF-1alpha, causing 
inflammation and insulin resistance in obesity’, Cell, 157(6), pp. 1339–1352. doi: 
10.1016/j.cell.2014.05.012. 
Li, C. and Johnson, D. E. (2012) ‘Bortezomib induces autophagy in head and neck squamous cell 
carcinoma cells via JNK activation’, Cancer Letters, 314(1), pp. 102–107. doi: 
10.1016/j.canlet.2011.09.020. 
Li, J. et al. (2012) ‘The RIP1/RIP3 necrosome forms a functional amyloid signaling complex 
required for programmed necrosis’, Cell, 150, pp. 339–350. doi: 10.1016/j.cell.2012.06.019. 
Li, N. et al. (2014) ‘Increased apoptosis induction in CD4+ CD25+ Foxp3+ T cells contributes to 
enhanced disease activity in patients with rheumatoid arthritis through IL-10 regulation.’, 
European Review for Medical and Pharmacological Sciences, pp. 78–85. 
Li, W., Zhang, X. and Olumi, A. F. (2007) ‘MG-132 sensitizes TRAIL-resistant prostate cancer cells 
by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L)’, Cancer Research, 67(5), pp. 
2247–2255. doi: 10.1158/0008-5472.CAN-06-3793. 
Li, X., Jiang, S. and Tapping, R. I. (2010) ‘Toll-like receptor signaling in cell proliferation and 
survival’, Cytokine. Elsevier Ltd, 49(1), pp. 1–9. doi: 10.1016/j.cyto.2009.08.010. 
Lin, C. C. et al. (2008) ‘Pellino Proteins Contain a Cryptic FHA Domain that Mediates Interaction 
with Phosphorylated IRAK1’, Structure, 16(12), pp. 1806–1816. doi: 10.1016/j.str.2008.09.011. 
Lin, Y. et al. (1999) ‘Cleavage of the death domain kinase RIP by Caspase-8 prompts TNF-induced 
apoptosis’, Genes and Development, 13(19), pp. 2514–2526. doi: 10.1101/gad.13.19.2514. 
Lisy, K. and Peet, D. J. (2008) ‘Turn me on: Regulating HIF transcriptional activity’, Cell Death and 
Differentiation, 15(4), pp. 642–649. doi: 10.1038/sj.cdd.4402315. 
Litman, G. W., Cannon, J. P. and Dishaw, L. J. (2005) ‘Reconstructring immune phylogeny: new 
perspectives’, Nature Reviews Immunology, 5(11), pp. 866–879. doi: 
10.1038/nri1712.RECONSTRUCTING. 
Liu, J., Qian, C. and Cao, X. (2016) ‘Post-Translational Modification Control of Innate Immunity’, 
Immunity, 45(1), pp. 15–30. doi: 10.1016/j.immuni.2016.06.020. 
Liu, W. et al. (2012) ‘Targeted genes and interacting proteins of HIF-1’, Int J Biochem Mol Biol, 
3(2), pp. 165–178. 
Liu, Y. V. and Semenza, G. L. (2007) ‘RACK1 vs. HSP90: Competition for HIF-1α degradation vs. 
stabilization’, Cell Cycle, 6(6), pp. 656–659. doi: 10.4161/cc.6.6.3981. 
Lukashev, D. et al. (2001) ‘Differential Regulation of Two Alternatively Spliced Isoforms of 
Hypoxia-inducible Factor-1?? in Activated T Lymphocytes’, Journal of Biological Chemistry, 
276(52), pp. 48754–48763. doi: 10.1074/jbc.M104782200. 
Ma, M. H. et al. (2003) ‘The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of 
Multiple Myeloma Tumor Cells to Chemotherapeutic Agents The Proteasome Inhibitor PS-341 
181 
 
Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents 
1’, Clin Cancer Res, 9(March), pp. 1136–1144. doi: 10.1158/1078-0432.ccr-12-2118. 
Mahoney, D. J. et al. (2008) ‘Both cIAP1 and cIAP2 regulate TNF -mediated NF- B activation’, 
Proceedings of the National Academy of Sciences, 105(33), pp. 11778–11783. doi: 
10.1073/pnas.0711122105. 
Makino, Y. et al. (2001) ‘Inhibitory PAS domain protein is a negative regulator of hypoxia- 
inducible gene expression’, Nature, 414(6863), p. 550–554. Available at: 
http://www.ncbi.nlm.nih.gov/htbin-
post/Entrez/query?db=m&form=6&dopt=r&uid=11734856. 
Malefyt, R. D. W. et al. (1991) ‘Interleukin 10 (IL-10) Inhibits Cytokine Synthesis by Human 
Monocytes: An Autoregulatory Role of IL-10 Produced by monocytes’, Journal of Experimental 
Medicine, 174(November), pp. 1209–1220. 
Mamane, Y. et al. (1999) ‘Interferon regulatory factors: the next generation.’, Gene, 237, pp. 1–
14. doi: 10.1016/S0378-1119(99)00262-0. 
Mamlouk, S. and Wielockx, B. (2013) ‘Hypoxia-inducible factors as key regulators of tumor 
inflammation’, International Journal of Cancer, 132(12), pp. 2721–2729. doi: 10.1002/ijc.27901. 
Manasanch, E. E. et al. (2014) ‘The proteasome: Mechanisms of biology and markers of activity 
and response to treatment in multiple myeloma’, Leukemia and Lymphoma, 55(8), pp. 1707–
1714. doi: 10.3109/10428194.2013.828351. 
Manicassamy, S. and Pulendran, B. (2009) ‘Modulation of adaptive immunity with Toll-like 
receptors’, Seminars in Immunology, 21(4), pp. 185–193. doi: 10.1016/j.smim.2009.05.005. 
Mannino, M. H. et al. (2015) ‘The paradoxical role of IL - 10 in immunity and cancer’, Cancer 
Letters, 367, pp. 103–107. doi: 10.1016/j.canlet.2015.07.009. 
Mantovani, A. et al. (2008) ‘Cancer-related inflammation’, Nature, 454(7203), pp. 436–444. doi: 
10.1038/nature07205. 
Matijevic Glavan, T. et al. (2017) ‘Toll-like receptor 3 stimulation triggers metabolic 
reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF’, Molecular 
Carcinogenesis, 56(4), pp. 1214–1226. doi: 10.1002/mc.22584. 
Matzinger, P. (2002) ‘The Danger Model : A Renewed Sense of Self’, Science, 296(April), pp. 301–
305. 
Maxwell, P. H. et al. (1999) ‘The Tumour Suppressor Protein VHL Targets Hypoxia Inducible 
Factors for Oxygen Dependent Proteolysis’, Nature, 399(6733), pp. 271–275. 
Maxwell, P. J. et al. (2007) ‘HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 
expression promotes cell survival in hypoxic prostate cancer cells’, Oncogene, 26(52), pp. 7333–
7345. doi: 10.1038/sj.onc.1210536. 
Medzhitov, R. (2007) ‘Recognition of microorganisms and activation of the immune response’, 
Nature, 449(7164), pp. 819–826. doi: 10.1038/nature06246. 
Mellett, M. et al. (2011) ‘Mal Mediates TLR-Induced Activation of CREB and Expression of IL-10’, 
The Journal of Immunology, 186(8), pp. 4925–4935. doi: 10.4049/jimmunol.1002739. 
Mercurio, F. et al. (2018) ‘IKK-1 and IKK-2 : Cytokine-Activated IκB Kinases Essential for NF- κB 
182 
 
Activation and Anjana Rao Published by : American Association for the Advancement of Science 
Stable URL : https://www.jstor.org/stable/2894457 REFERENCES Linked references are 
available’, Science, 278(5339), pp. 860–866. 
Metzger, M. B. et al. (2014) ‘RING-type E3 ligases: Master manipulators of E2 ubiquitin-
conjugating enzymes and ubiquitination’, Biochimica et Biophysica Acta - Molecular Cell 
Research, 1843(1), pp. 47–60. doi: 10.1016/j.bbamcr.2013.05.026. 
Meylan, E. et al. (2004) ‘RIP1 is an essential mediator of Toll-like receptor 3-induced NF κB 
activation’, Nature Immunology, 5(5), pp. 503–507. doi: 10.1038/ni1061. 
Meylan, E. and Tschopp, J. (2005) ‘The RIP kinases: Crucial integrators of cellular stress’, Trends 
in Biochemical Sciences, 30(3), pp. 151–159. doi: 10.1016/j.tibs.2005.01.003. 
Micheau, O. and Tschopp, J. (2003) ‘Induction of TNF Receptor I- Mediated Apoptosis via Two 
Sequential Signaling Complexes’, Cell, 114, pp. 181–190. 
Moreau, P. et al. (2015) ‘Review article Proteasome inhibitors in multiple myeloma: 10 years 
later’, Blood, 120(5), pp. 947–960. doi: 10.1182/blood-2012-04-403733. 
Moriwaki, K. and Chan, F. K. M. (2013) ‘RIP3: A molecular switch for necrosis and inflammation’, 
Genes and Development, 27, pp. 1640–1649. doi: 10.1101/gad.223321.113. 
Moynagh, P. N. (2005) ‘TLR signalling and activation of IRFs: Revisiting old friends from the NF-
κB pathway’, Trends in Immunology, 26(9), pp. 469–476. doi: 10.1016/j.it.2005.06.009. 
Moynagh, P. N. (2014) ‘The roles of Pellino E3 ubiquitin ligases in immunity.’, Nature reviews. 
Immunology, 14(February), pp. 122–31. doi: 10.1038/nri3599. 
Müller-Sienerth, N. et al. (2011) ‘SMAC Mimetic BV6 induces cell death in monocytes and 
maturation of monocyte-derived dendritic cells’, PLoS ONE, 6(6), pp. 13–15. doi: 
10.1371/journal.pone.0021556. 
Multhoff, G., Molls, M. and Radons, J. (2012) ‘Chronic inflammation in cancer development’, 
Frontiers in Immunology, 2(JAN), pp. 1–17. doi: 10.3389/fimmu.2011.00098. 
Murata, S., Yashiroda, H. and Tanaka, K. (2009) ‘Molecular mechanisms of proteasome 
assembly’, Nature Reviews Molecular Cell Biology, 10(2), pp. 104–115. doi: 10.1038/nrm2630. 
Murphy, J. M. et al. (2013) ‘The pseudokinase MLKL mediates necroptosis via a molecular switch 
mechanism’, Immunity, 39(3), pp. 443–453. doi: 10.1016/j.immuni.2013.06.018. 
Murray, M. Y. et al. (2015) ‘Ibrutinib inhibits BTK-driven NF-κ B p65 activity to overcome 
bortezomib-resistance in multiple myeloma’, Cell Cycle, 14(14), pp. 2367–2375. doi: 
10.1080/15384101.2014.998067. 
Murray, P. J. (2006) ‘Understanding and exploiting the endogenous interleukin-10/STAT3-
mediated anti-inflammatory response’, Current Opinion in Pharmacology, 6(4), pp. 379–386. 
doi: 10.1016/j.coph.2006.01.010. 
NCCN Foundation (2018) ‘Multiple Myeloma’, NCCN, pp. 1–18. doi: 10.1056/NEJMra041875. 
Newton, K. et al. (2014) ‘Activity of protein kinase RIPK3 determines whether cells die by 
necroptosis or apoptosis’, Science, 343(6177), pp. 1357–1360. doi: 10.1126/science.1249361. 
Nielsen, K. R. et al. (2017) ‘Interactions between SNPs affecting inflammatory response genes 
183 
 
are associated with multiple myeloma disease risk and survival’, Leukemia & Lymphoma, 58(11), 
pp. 2695–2704. doi: 10.1080/10428194.2017.1306643. 
Noman, M. Z. et al. (2009) ‘The Cooperative Induction of Hypoxia-Inducible Factor-1  and STAT3 
during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis’, The 
Journal of Immunology, 182(6), pp. 3510–3521. doi: 10.4049/jimmunol.0800854. 
O’Neill, L. A. J., Golenbock, D. and Bowie, A. G. (2013) ‘Redefining Innate Immunity’, Nature 
Publishing Group, 13(6), pp. 453–460. doi: 10.1038/nri3446. 
Oblak, A. and Jerala, R. (2011) ‘Toll-like receptor 4 activation in cancer progression and therapy’, 
Clinical and Developmental Immunology, 2011. doi: 10.1155/2011/609579. 
Ordureau, A. et al. (2008) ‘The IRAK-catalysed activation of the E3 ligase function of Pellino 
isoforms induces the Lys 63 -linked polyubiquitination of IRAK1’, Biochemical Journal, 409(1), pp. 
43–52. doi: 10.1042/BJ20071365. 
Orozco, S. et al. (2014) ‘RIPK1 both positively and negatively regulates RIPK3 oligomerization 
and necroptosis.’, Cell death and differentiation. Nature Publishing Group, 21(10), pp. 1–11. doi: 
10.1038/cdd.2014.76. 
Palazon-Riquelme, P. and Lopez-Castejon, G. (2018) ‘The inflammasomes, immune guardians at 
defence barriers.’, Immunology. England. doi: 10.1111/imm.12989. 
Palazon, A. et al. (2014) ‘Review HIF transcription factors , inflammation , and immunity’, 
Immunity, 41(4), pp. 518–528. doi: 10.1016/j.immuni.2014.09.008. 
Paludan, S. and Bowie, A. (2013) ‘Immune Sensing of DNA’, Immunity, 38(5), pp. 870–880. doi: 
10.1016/j.immuni.2013.05.004. 
Palumbo, A. and Rajkumar, S. (2009) ‘Treatment of newly diagnosed myeloma’, Leukemia, 23(3), 
pp. 449–456. doi: 10.1111/j.1743-6109.2008.01122.x.Endothelial. 
Pan, D. et al. (2013) ‘Interleukin-10 prevents epithelial cell apoptosis by regulating IFNγ and 
TNFα expression in rhesus macaque colon explants’, Cytokine, 64(1), pp. 30–34. doi: 
10.1016/j.cyto.2013.06.312. 
Paone, A. et al. (2010) ‘Toll-like Receptor 3 Regulates Angiogenesis and Apoptosis in Prostate 
Cancer Cell Lines through Hypoxia-Inducible Factor 1α’, Neoplasia, 12(7), pp. 539–549. doi: 
10.1593/neo.92106. 
Pappa, C. et al. (2007) ‘Serum levels of Interleukin-15 and Interleukin-10 and their correlation 
with proliferating cell nuclear antigen in multiple myeloma’, Cytokine, 37(2), pp. 171–175. doi: 
10.1016/j.cyto.2007.02.022. 
Parameswaran, N. and Patial, S. (2010) ‘Tumor Necrosis Factor-α Signaling in Macrophages’, Crit 
Rev Eukaryot Gene Expr., 20(2), pp. 87–103. doi: 10.1021/nl061786n.Core-Shell. 
Park, H. Y. et al. (2014) ‘Pellino promotes lymphomagenesis by deregulating BCL 
polyubiquitination’, Journal of Clinical Investigation, 124(11), pp. 4976–4988. doi: 
10.1172/JCI75667. 
Park, S. M., Yoon, J. B. and Lee, T. H. (2004) ‘Receptor interacting protein is ubiquitinated by 
cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro’, FEBS Letters, 566(1–3), pp. 
151–156. doi: 10.1016/j.febslet.2004.04.021. 
184 
 
Pasparakis, M. and Vandenabeele, P. (2015) ‘Necroptosis and its role in inflammation’, Nature, 
517, pp. 311–320. doi: 10.1038/nature14191. 
Pawlus, M., Wang, L. and Hu, C. (2014) ‘STAT3 and HIF1α cooperatively activate HIF1 target 
genes in MDA-MB-231 and RCC4 cells’, Oncogene, 33(13), pp. 1670–1679. doi: 
10.1021/nl061786n.Core-Shell. 
Pelzer, C. et al. (2007) ‘UBE1L2, a novel E1 enzyme specific for ubiquitin’, Journal of Biological 
Chemistry, 282(32), pp. 23010–23014. doi: 10.1074/jbc.C700111200. 
Peyssonnaux, C. et al. (2007) ‘Essential Role of Hypoxia Inducible Factor-1 in Development of 
Lipopolysaccharide-Induced Sepsis’, The Journal of Immunology, 178(12), pp. 7516–7519. doi: 
10.4049/jimmunol.178.12.7516. 
Ping Dou, Q. and Zonder, J. A. (2014) ‘Overview of Proteasome Inhibitor-Based Anti-cancer 
Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus 
Future Generation Inhibitors of Ubiquitin- Proteasome System’, Current cancer drug targets, 
14(6), pp. 517–536. doi: 10.1111/j.1743-6109.2008.01122.x.Endothelial. 
Pitcher, D. S. et al. (2015) ‘Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing 
Proteasome Structure’, EBioMedicine, 2(7), pp. 642–648. doi: 10.1016/j.ebiom.2015.05.016. 
Pohar, J. et al. (2014) ‘The ectodomain of TLR3 receptor is required for its plasma membrane 
translocation’, PLoS ONE, 9(3), pp. 1–11. doi: 10.1371/journal.pone.0092391. 
Pugh, C. W. et al. (1997) ‘Activation of Hypoxia-inducible Factor-1; Definition of Regulatory 
Domains within the alpha Subunit’, J. Biol. Chem, 272(17), pp. 11205–11214. doi: 
10.1074/jbc.272.17.11205. 
Rajkumar, S. V. (2016) ‘Multiple Myeloma: 2016 update on Diagnosis, Risk-stratification and 
Management’, American Journal of Hematology, 91(7), pp. 719–734. doi: 
10.1002/ajh.24402.Multiple. 
Ravid, T. and Hochstrasser, M. (2008) ‘Diversity of degradation signals in the ubiquitin-
proteasome system’, Nature Reviews Molecular Cell Biology, 9(9), pp. 679–689. doi: 
10.1038/nrm2468. 
Regan, C. P. et al. (2002) ‘Erk5 null mice display multiple extraembryonic vascular and embryonic 
cardiovascular defects’, Proceedings of the National Academy of Sciences, 99(14), pp. 9248–
9253. doi: 10.1073/pnas.142293999. 
Restifo, N. and Gattinoni, L. (2013) ‘Lineage relationship of effector and memory T cells’, Current 
Opinion in Immunology, 25(5), pp. 1385–1395. doi: 10.2217/nnm.12.167.Gene. 
Richardson, P. G. et al. (2014) ‘A phase 2 trial of lenalidomide , bortezomib , and dexamethasone 
in patients with relapsed and relapsed / refractory myeloma’, Blood, 123(10), pp. 1461–1469. 
doi: 10.1182/blood-2013-07-517276.The. 
Richter, K. et al. (2013) ‘Macrophage and T Cell Produced IL-10 Promotes Viral Chronicity’, PLoS 
Pathogens, 9(11). doi: 10.1371/journal.ppat.1003735. 
Rius, J. et al. (2008) ‘NF-κB links innate immunity to the hypoxic response through transcriptional 
regulation of HIF-1α’, Nature, 453(7196), pp. 807–811. doi: 10.1038/nature06905. 
Roberson, S. M. and Walker, W. S. (1988) ‘Immortalization of cloned mouse splenic macrophages 
185 
 
with a retrovirus containing  the v-raf/mil and v-myc oncogenes.’, Cellular immunology. 
Netherlands, 116(2), pp. 341–351. 
Rodriguez, D. A. et al. (2016) ‘Characterization of RIPK3-mediated phosphorylation of the 
activation loop of MLKL during necroptosis’, Cell Death and Differentiation, 23(1), pp. 76–88. 
doi: 10.1038/cdd.2015.70. 
Sabat, R. et al. (2010) ‘Biology of interleukin-10’, Cytokine and Growth Factor Reviews, 21(5), pp. 
331–344. doi: 10.1016/j.cytogfr.2010.09.002. 
Saha, S. and Cheng, G. (2006) ‘TRAF3: A New Regulator of Type I Interferons Supriya’, Cell Cycle, 
5(8), pp. 804–807. doi: 10.4161/cc.6.11.4315. 
Salaun, B. et al. (2006) ‘TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells’, The Journal 
of Immunology, 176(8), pp. 4894–4901. doi: 10.4049/jimmunol.176.8.4894. 
Salnikow, K. et al. (2002) ‘The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which 
cooperates with hypoxia-inducible factor 1 in response to hypoxia’, Mol Cell Biol, 22(6), pp. 
1734–1741. doi: 10.1128/MCB.22.6.1734. 
Sánchez-Elsner, T. et al. (2001) ‘Synergistic Cooperation between Hypoxia and Transforming 
Growth Factor-β Pathways on Human Vascular Endothelial Growth Factor Gene Expression’, 
Journal of Biological Chemistry, 276(42), pp. 38527–38535. doi: 10.1074/jbc.M104536200. 
Saraiva, M. et al. (2009) ‘Interleukin-10 Production by Th1 Cells Requires Interleukin-12-Induced 
STAT4 Transcription Factor and ERK MAP Kinase Activation by High Antigen Dose’, Immunity, 
31(2), pp. 209–219. doi: 10.1016/j.immuni.2009.05.012. 
Saraiva, M. and O’Garra, A. (2010) ‘The regulation of IL-10 production by immune cells’, Nature 
Reviews Immunology, 10(3), pp. 170–181. doi: 10.1038/nri2711. 
Sato, S. et al. (2003) ‘Toll/IL-1 Receptor Domain-Containing Adaptor Inducing IFN-  (TRIF) 
Associates with TNF Receptor-Associated Factor 6 and TANK-Binding Kinase 1, and Activates Two 
Distinct Transcription Factors, NF- B and IFN-Regulatory Factor-3, in the Toll-Like Receptor S’, 
The Journal of Immunology, 171(8), pp. 4304–4310. doi: 10.4049/jimmunol.171.8.4304. 
Sato, Y. et al. (2009) ‘Cancer cells expressing toll-like receptors and the tumor 
microenvironment’, Cancer Microenvironment, 2(SUPPL. 1). doi: 10.1007/s12307-009-0022-y. 
Schauvliege, R., Janssens, S. and Beyaert, R. (2006) ‘Pellino proteins are more than scaffold 
proteins in TLR/IL-1R signalling: A role as novel RING E3-ubiquitin-ligases’, FEBS Letters, 580(19), 
pp. 4697–4702. doi: 10.1016/j.febslet.2006.07.046. 
Scholz, C. C. and Taylor, C. T. (2013) ‘Targeting the HIF pathway in inflammation and immunity’, 
Current Opinion in Pharmacology, 13(4), pp. 646–653. doi: 10.1016/j.coph.2013.04.009. 
Schumacher, C. et al. (1992) ‘High- and low-affinity binding of GRO alpha and neutrophil-
activating peptide 2 to interleukin 8 receptors on human neutrophils.’, Proceedings of the 
National Academy of Sciences of the United States of America, 89(21), pp. 10542–6. doi: 
10.1073/pnas.89.21.10542. 
Sedger, L. M. and McDermott, M. F. (2014) ‘TNF and TNF-receptors: From mediators of cell death 
and inflammation to therapeutic giants - past, present and future’, Cytokine and Growth Factor 
Reviews, 25(4), pp. 453–472. doi: 10.1016/j.cytogfr.2014.07.016. 
186 
 
Semenza, G. L. (1999) ‘Regulation of mammalian O2 homeostasis by Hypoxia-inducible factor 1’, 
Annu. Rev. Cell Dev. Biol., 15, pp. 551–78. 
Semenza, G. L. (2004) ‘Hydroxylation of HIF-1 : Oxygen Sensing Control of Oxygen-Regulated 
Gene’, Physiology, pp. 176–182. doi: 10.1152/physiol.00001.2004. 
Semenza, G. L. and Wang, G. L. (1992) ‘A nuclear factor induced by hypoxia via de novo protein 
synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional 
activation.’, Molecular and Cellular Biology, 12(12), pp. 5447–5454. doi: 
10.1128/MCB.12.12.5447. 
Shah, Y. et al. (2009) ‘Hypoxia-Inducible Factor Augments Experimental Colitis Through a MIF-
Dependent Inflammatory Signaling Cascade’, 134(7), pp. 2036–48. doi: 
10.1021/ja064902x.Brilliant. 
Shalini, S. et al. (2015) ‘Old, new and emerging functions of caspases’, Cell Death and 
Differentiation, 22(4), pp. 526–539. doi: 10.1038/cdd.2014.216. 
Shanley, T. P., Vasi, N. and Denenberg, A. (2000) ‘Regulation of chemokine expression by IL-10 
in lung inflammation’, Cytokine, 12(7), pp. 1054–1064. doi: 10.1006/cyto.1999.0655. 
Shekarriz, R., Janbabaei, G. and Kenari, S. A. (2018) ‘Prognostic Value of IL-10 and Its Relationship 
with Disease Stage in Iranian Patients with Multiple Myeloma’, Asian Pacific Journal of Cancer 
Prevention, 19, pp. 27–32. doi: 10.22034/APJCP.2018.19.1.27. 
Shin, E. C. et al. (2006) ‘Virus-induced type I IFN stimulates generation of immunoproteasomes 
at the site of infection’, Journal of Clinical Investigation, 116(11), pp. 3006–3014. doi: 
10.1172/JCI29832. 
Shiozaki, E. N., Chai, J. and Shi, Y. (2002) ‘Oligomerization and activation of caspase-9, induced 
by Apaf-1 CARD’, Proceedings of the National Academy of Sciences, 99(7), pp. 4197–4202. doi: 
10.1073/pnas.072544399. 
Siddiqui, W. A., Ahad, A. and Ahsan, H. (2015) ‘The mystery of BCL2 family: Bcl-2 proteins and 
apoptosis: an update’, Archives of Toxicology, 89(3), pp. 289–317. doi: 10.1007/s00204-014-
1448-7. 
Siednienko, J. et al. (2012) ‘Pellino3 targets the IRF7 pathway and facilitates autoregulation of 
TLR3- and viral-induced expression of type I interferons’, Nature Immunology, 13(c), pp. 1055–
1062. doi: 10.1038/ni.2429. 
Siegel, M. B. et al. (2015) ‘Small molecule inhibitor screen identifies synergistic activity of the 
bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma’, Oncotarget, 6(22), 
pp. 18921–18932. doi: 10.18632/oncotarget.4214. 
Silke, J., Rickard, J. A. and Gerlic, M. (2015) ‘The diverse role of RIP kinases in necroptosis and 
inflammation’, Nature Immunology, 16(7), pp. 689–697. doi: 10.1038/ni.3206. 
Škrott, Z. and Cvek, B. (2014) ‘Linking the activity of bortezomib in multiple myeloma and 
autoimmune diseases’, Critical Reviews in Oncology/Hematology, 92(2), pp. 61–70. doi: 
10.1016/j.critrevonc.2014.05.003. 
Stanger BZ et al. (1995) ‘RIP: a novel protein containing a death domain that interacts with 
Fas/Apo (CD95) in yeast and cause cell death’, Cell, 81, pp. 513–523. 
187 
 
Staples, K. J. et al. (2007) ‘IL-10 Induces IL-10 in Primary Human Monocyte-Derived Macrophages 
via the Transcription Factor Stat3’, The Journal of Immunology, 178(8), pp. 4779–4785. doi: 
10.4049/jimmunol.178.8.4779. 
Steinman, R. M. et al. (1983) ‘Endocytosis and the recycling of plasma membrane’, Journal of 
Cell Biology, 96(1), pp. 1–27. doi: 10.1083/jcb.96.1.1. 
Stewart, M. D. et al. (2016) ‘E2 enzymes: More than just middle men’, Cell Research, 26(4), pp. 
423–440. doi: 10.1038/cr.2016.35. 
Strelow, A., Kollewe, C. and Wesche, H. (2003) ‘Characterization of Pellino2, a substrate of IRAK1 
and IRAK4’, FEBS Letters, 547(1–3), pp. 157–161. doi: 10.1016/S0014-5793(03)00697-5. 
Sui, X. et al. (2014) ‘P38 and JNK MAPK pathways control the balance of apoptosis and autophagy 
in response to chemotherapeutic agents’, Cancer Letters, 344(2), pp. 174–179. doi: 
10.1016/j.canlet.2013.11.019. 
Sun, L. et al. (2012) ‘Mixed lineage kinase domain-like protein mediates necrosis signaling 
downstream of RIP3 kinase’, Cell, 148(1–2), pp. 213–227. doi: 10.1016/j.cell.2011.11.031. 
Swatek, K. N. and Komander, D. (2016) ‘Ubiquitin modifications’, Cell Research, 26(4), pp. 399–
422. doi: 10.1038/cr.2016.39. 
Tait, S. W. G. and Green, D. R. (2010) ‘Mitochondria and cell death: outer membrane 
permeabilization and beyond’, Nature Reviews Molecular Cell Biology, 11(9), pp. 621–632. doi: 
10.1038/nrm2952. 
Takanaski, S. et al. (1994) ‘Interleukin 10 inhibits lipopolysaccharide-induced survival and 
cytokine production by human peripheral blood eosinophils.’, The Journal of experimental 
medicine, 180(2), pp. 711–5. doi: 10.1084/jem.180.2.711. 
Taylor, R. C., Cullen, S. P. and Martin, S. J. (2008) ‘Apoptosis: Controlled demolition at the cellular 
level’, Nature Reviews Molecular Cell Biology, 9(3), pp. 231–241. doi: 10.1038/nrm2312. 
Teicher, B. A. and Tomaszewski, J. E. (2015) ‘Proteasome inhibitors’, Biochemical Pharmacology, 
96(1), pp. 1–9. doi: 10.1016/j.bcp.2015.04.008. 
Teixeira-Coelho, M. et al. (2014) ‘Differential post-transcriptional regulation of IL-10 by TLR2 and 
TLR4-activated macrophages’, European Journal of Immunology, 44(3), pp. 856–866. doi: 
10.1002/eji.201343734. 
Tenev, T. et al. (2011) ‘The Ripoptosome, a Signaling Platform that Assembles in Response to 
Genotoxic Stress and Loss of IAPs’, Molecular Cell, 43(3), pp. 432–448. doi: 
10.1016/j.molcel.2011.06.006. 
Tewari, R. et al. (2012) ‘Involvement of TNFα-induced TLR4-NF-κB and TLR4-HIF-1α feed-forward 
loops in the regulation of inflammatory responses in glioma’, Journal of Molecular Medicine, 
90(1), pp. 67–80. doi: 10.1007/s00109-011-0807-6. 
Thangavadivel, S. et al. (2016) ‘CCR10/CCL27 crosstalk contributes to failure of proteasome- 
inhibitors in multiple myeloma’, Oncotarget, 7(48). doi: 10.18632/oncotarget.12522. 
Thapa, R. J. et al. (2013) ‘Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is 
licensed by FADD and caspases’, Proceedings of the National Academy of Sciences, 110(33), pp. 
E3109–E3118. doi: 10.1073/pnas.1301218110. 
188 
 
Toes, R. E. M. et al. (2001) ‘Discrete cleavage motifs of constitutive and immunoproteasomes 
revealed by quantitative analysis of cleavage products’, J Exp Med, 194(1), p. 1–12. doi: 
10.1084/jem.194.1.1. 
Torres, E. M. et al. (2007) ‘Effects of Aneuploidy on Cellular Physiology and Cell Division in 
Haploid Yeast’, Science, 317(2007), pp. 916–924. doi: 10.1126/science.1142210. 
Tsubuki, S. et al. (1996) ‘Differential Inhibition of Calpain Peptidyl Aldehydes of Di-Leucine and 
Proteasome and Tri-Leucine Activities by’, J Biol Chem., pp. 572–576. 
Tumpey, T. M. et al. (1998) ‘Chemokine synthesis in the HSV-1-infected cornea and its 
suppression by interleukin-10’, Journal of Leukocyte Biology, 63(4), pp. 486–492. doi: 
10.1002/jlb.63.4.486. 
Upton, J. W., Kaiser, W. J. and Mocarski, E. S. (2010) ‘Virus inhibition of RIP3-dependent 
necrosis’, Cell Host and Microbe, 7(4), pp. 302–313. doi: 10.1016/j.chom.2010.03.006. 
Upton, J. W., Kaiser, W. J. and Mocarski, E. S. (2012) ‘DAI/ZBP1/DLM-1 complexes with RIP3 to 
mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA’, 
Cell Host and Microbe, 11(3), pp. 290–297. doi: 10.1016/j.chom.2012.01.016. 
van Uden, P., Kenneth, N. S. and Rocha, S. (2008) ‘Regulation of hypoxia-inducible factor-1α by 
NF-κB’, Biochemical Journal, 412(3), pp. 477–484. doi: 10.1042/BJ20080476. 
Varfolomeev, E. et al. (2008) ‘c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α 
(TNFα)-induced NF-κB activation’, Journal of Biological Chemistry, 283(36), pp. 24295–24299. 
doi: 10.1074/jbc.C800128200. 
Varfolomeev, E. and Vucic, D. (2018) ‘Intracellular regulation of TNF activity in health and 
disease’, Cytokine, 101, pp. 26–32. doi: 10.1016/j.cyto.2016.08.035. 
Vasudevan, D. and Ryoo, H. D. (2015) ‘Regulation of Cell Death by IAPs and their Antagonists’, 
Curr Top Dev Biol., 114, pp. 185–208. doi: 10.1016/j.cogdev.2010.08.003.Personal. 
Veyrat, M. et al. (2016) ‘Stimulation of the toll-like receptor 3 promotes metabolic 
reprogramming in head and neck carcinoma cells.’, Oncotarget, 7(50), pp. 82580–82593. doi: 
10.18632/oncotarget.12892. 
Wagner, E. F. and Nebreda, Á. R. (2009) ‘Signal integration by JNK and p38 MAPK pathways in 
cancer development’, Nature Reviews Cancer, 9(8), pp. 537–549. doi: 10.1038/nrc2694. 
Walczak, H. (2011) ‘TNF and ubiquitin at the crossroads of gene activation, cell death, 
inflammation, and cancer’, Immunological Reviews, pp. 9–28. Available at: 
https://mail.google.com/mail/u/0/%7B#%7Dsearch/anselm/148c31b8dd384d69?projector=1. 
Walmsley, S. R. et al. (2005) ‘Hypoxia-induced neutrophil survival is mediated by HIF-1α–
dependent NF-κB activity’, The Journal of Experimental Medicine, 201(1), pp. 105–115. doi: 
10.1084/jem.20040624. 
Wang, C. et al. (2001) ‘TAK1 is a ubiquitin-dependent kinase of MKK and IKK’, Nature, 412(6844), 
pp. 346–351. doi: 10.1038/35085597. 
Wang, G. L. et al. (1995) ‘Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer 
regulated by cellular O2 tension.’, Proceedings of the National Academy of Sciences, 92(12), pp. 
5510–5514. doi: 10.1073/pnas.92.12.5510. 
189 
 
Wang, G. and Semenza, G. (1995) ‘Purification and characterization of Hypoxia-inducible Factor 
1’, The Journal of biological chemistry, 270(20), pp. 1230–1237. 
Wang, H. et al. (2014) ‘Mixed Lineage Kinase Domain-like Protein MLKL Causes Necrotic 
Membrane Disruption upon Phosphorylation by RIP3’, Molecular Cell. Elsevier Inc., 54(1), pp. 
133–146. doi: 10.1016/j.molcel.2014.03.003. 
Wang, H. et al. (2017) ‘PELI1 functions as a dual modulator of necroptosis and apoptosis by 
regulating ubiquitination of RIPK1 and mRNA levels of c-FLIP’, Proceedings of the National 
Academy of Sciences, 114(45), pp. 11944–11949. doi: 10.1073/pnas.1715742114. 
Wang, L., Du, F. and Wang, X. (2008) ‘TNF-α Induces Two Distinct Caspase-8 Activation 
Pathways’, Cell, 133(4), pp. 693–703. doi: 10.1016/j.cell.2008.03.036. 
Wells, P. G., Parman, T. and Wiley, M. J. (1999) ‘Free radical-mediated oxidative DNA damage in 
the mechanism of thalidomide\nteratogenicity’, Nature Medicine, 5(5), pp. 582–585. doi: 
10.1038/8466. 
Wen, A. Y., Sakamoto, K. M. and Miller, L. S. (2010) ‘The Role of the Transcription Factor CREB in 
Immune Function’, The Journal of Immunology, 185(11), pp. 6413–6419. doi: 
10.4049/jimmunol.1001829. 
Wenger, R. H. et al. (1998) ‘Mouse hypoxia-inducible factor-1alpha is encoded by two different 
mRNA isoforms: expression from a tissue-specific and a housekeeping-type promoter.’, Blood, 
91(9), pp. 3471–80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9558407. 
Wick, A. et al. (1957) ‘Localization of the primary block produced by 2-Deoxyglucose’, J Biol 
Chem., 224(2), pp. 963–9. 
Wilson, N. S., Dixit, V. and Ashkenazi, A. (2009) ‘Death receptor signal transducers: Nodes of 
coordination in immune signaling networks’, Nature Immunology, 10(4), pp. 348–355. doi: 
10.1038/ni.1714. 
Wolpe, S. D. et al. (1989) ‘Identification and characterization of macrophage inflammatory 
protein 2.’, Proceedings of the National Academy of Sciences of the United States of America, 
86(2), pp. 612–6. doi: 10.1073/pnas.86.2.612. 
Wu, C. et al. (2018) ‘ARNT /HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to 
drug resistance and poor prognosis in multiple myeloma’, Cancer Medicine, (March), pp. 1–13. 
doi: 10.1002/cam4.1596. 
Wu, D. et al. (2015) ‘Structural integration in hypoxia-inducible factors’, Nature, 524(7565), pp. 
303–308. doi: 10.1038/nature14883. 
Wu, J. et al. (2013) ‘Mlkl knockout mice demonstrate the indispensable role of Mlkl in 
necroptosis’, Cell Research, 23(8), pp. 994–1006. doi: 10.1038/cr.2013.91. 
Wu, X.-N. et al. (2014) ‘Distinct roles of RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in 
mediating necroptosis.’, Cell death and differentiation, pp. 1–12. doi: 10.1038/cdd.2014.77. 
Xiao, H. et al. (2008) ‘Pellino 3b negatively regulates interleukin-1-induced TAK1-dependent 
NFκB activation’, Journal of Biological Chemistry, 283(21), pp. 14654–14664. doi: 
10.1074/jbc.M706931200. 
Yabal, M. et al. (2014) ‘XIAP restricts TNF-and RIP3-dependent cell death and inflammasome 
190 
 
activation’, Cell reports, 7(6), pp. 1796–1808. 
Yamamoto, M. et al. (2002) ‘Cutting Edge: A Novel Toll/IL-1 Receptor Domain-Containing 
Adapter That Preferentially Activates the IFN-  Promoter in the Toll-Like Receptor Signaling’, The 
Journal of Immunology, 169(12), pp. 6668–6672. doi: 10.4049/jimmunol.169.12.6668. 
Yang, S.-H., Sharrocks, A. D. and Whitmarsh, A. J. (2013) ‘MAP kinase signalling cascades and 
transcriptional regulation’, Gene, 513(1), pp. 1–13. doi: 
http://dx.doi.org/10.1016/j.gene.2012.10.033. 
Yang, S., Wang, B., Tang, L. S., et al. (2013) ‘Pellino3 targets RIP1 and regulates the pro-apoptotic 
effects of TNF-α.’, Nature communications. Nature Publishing Group, 4, p. 2583. doi: 
10.1038/ncomms3583. 
Yang, S., Wang, B., Humphries, F., et al. (2013) ‘Pellino3 ubiquitinates RIP2 and mediates Nod2-
induced signaling and protective effects in colitis.’, Nature immunology, 14(9), pp. 927–36. doi: 
10.1038/ni.2669. 
Yang, S. et al. (2014) ‘The E3 Ubiquitin Ligase Pellino3 Protects against Obesity - Induced 
Inflammation and Insulin Resistance’, Immunity, 41(6), pp. 973–987. 
Yang, Y. et al. (2007) ‘NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection 
involves the stable polyubiquitination of Rip2’, Journal of Biological Chemistry, 282(50), pp. 
36223–36229. doi: 10.1074/jbc.M703079200. 
Yin, Y. et al. (2013) ‘The essential role of p38 MAPK in mediating the interplay of oxLDL and IL-
10 in regulating endothelial cell apoptosis’, European Journal of Cell Biology, 92(4–5), pp. 150–
159. doi: 10.1016/j.ejcb.2013.01.001. 
Yu, A. Y. et al. (1998) ‘Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible 
factor-1  in the lung.’, The American journal of physiology. United States, 275(4 Pt 1), pp. L818-
26. 
Zdanov, A. et al. (1995) ‘Crystal structure of interleukin-10 reveals the functional dimer with an 
unexpected topological similarity to interferon γ’, Structure, 3(6), pp. 591–601. doi: 
10.1016/S0969-2126(01)00193-9. 
Zhang, D.-W. et al. (2009) ‘RIP3, an Energy Metabolism Regulator That Switched TNF-Induced 
Cell Death from Apoptosis to Necrosis’, Science, 325(July), pp. 332–336. Available at: 
http://science.sciencemag.org/content/sci/325/5938/332.full.pdf. 
Zhang, D., Lin, J. and Han, J. (2010) ‘Receptor-interacting protein (RIP) kinase family’, Cellular 
and Molecular Immunology, 7(4), pp. 243–249. doi: 10.1038/cmi.2010.10. 
Zhang, J. J. et al. (2010) ‘Expression and significance of TLR4 and HIF-1α in pancreatic ductal 
adenocarcinoma’, World Journal of Gastroenterology, 16(23), pp. 2881–2888. doi: 
10.3748/wjg.v16.i23.2881. 
Zhang, J., Shen, B. and Lin, A. (2007) ‘Novel strategies for inhibition of the p38 MAPK pathway’, 
Trends in Pharmacological Sciences, 28(6), pp. 286–295. doi: 10.1016/j.tips.2007.04.008. 
 
